CN115052478A - Trpv4受体配体 - Google Patents
Trpv4受体配体 Download PDFInfo
- Publication number
- CN115052478A CN115052478A CN202080080479.8A CN202080080479A CN115052478A CN 115052478 A CN115052478 A CN 115052478A CN 202080080479 A CN202080080479 A CN 202080080479A CN 115052478 A CN115052478 A CN 115052478A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- compound
- sulfonyl
- methyl
- azetidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101150098315 TRPV4 gene Proteins 0.000 title abstract description 4
- 239000003446 ligand Substances 0.000 title abstract description 4
- 102000003567 TRPV4 Human genes 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 238
- 238000000034 method Methods 0.000 claims abstract description 48
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 12
- 102000005962 receptors Human genes 0.000 claims abstract description 8
- 108020003175 receptors Proteins 0.000 claims abstract description 8
- 102100029611 Transient receptor potential cation channel subfamily V member 4 Human genes 0.000 claims abstract description 4
- 108700039205 Transient receptor potential cation channel subfamily V member 4 Proteins 0.000 claims abstract description 4
- -1 Cycloalkyl radical Chemical class 0.000 claims description 224
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 44
- 150000003839 salts Chemical class 0.000 claims description 38
- 125000000217 alkyl group Chemical group 0.000 claims description 33
- 125000003118 aryl group Chemical group 0.000 claims description 32
- 125000001072 heteroaryl group Chemical group 0.000 claims description 31
- 208000035475 disorder Diseases 0.000 claims description 28
- 229910052739 hydrogen Inorganic materials 0.000 claims description 27
- 125000000623 heterocyclic group Chemical group 0.000 claims description 26
- 239000001257 hydrogen Substances 0.000 claims description 26
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 19
- 230000000694 effects Effects 0.000 claims description 17
- 125000001424 substituent group Chemical group 0.000 claims description 16
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims description 15
- 229910052736 halogen Inorganic materials 0.000 claims description 15
- 150000002367 halogens Chemical class 0.000 claims description 15
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 15
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 15
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 13
- 230000009885 systemic effect Effects 0.000 claims description 13
- 206010030043 Ocular hypertension Diseases 0.000 claims description 12
- 229910019142 PO4 Inorganic materials 0.000 claims description 12
- 102000003563 TRPV Human genes 0.000 claims description 12
- 108060008564 TRPV Proteins 0.000 claims description 12
- 125000002947 alkylene group Chemical group 0.000 claims description 12
- 229910052760 oxygen Inorganic materials 0.000 claims description 12
- 239000010452 phosphate Substances 0.000 claims description 12
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 11
- 125000004429 atom Chemical group 0.000 claims description 10
- 125000001188 haloalkyl group Chemical group 0.000 claims description 10
- BLORRZQTHNGFTI-ZZMNMWMASA-L calcium-L-ascorbate Chemical compound [Ca+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] BLORRZQTHNGFTI-ZZMNMWMASA-L 0.000 claims description 8
- 230000004064 dysfunction Effects 0.000 claims description 8
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 8
- 206010020772 Hypertension Diseases 0.000 claims description 6
- 206010030113 Oedema Diseases 0.000 claims description 6
- 208000002193 Pain Diseases 0.000 claims description 6
- 208000019693 Lung disease Diseases 0.000 claims description 5
- 230000001684 chronic effect Effects 0.000 claims description 5
- 230000036407 pain Effects 0.000 claims description 5
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims description 4
- 206010019280 Heart failures Diseases 0.000 claims description 4
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 4
- 201000006370 kidney failure Diseases 0.000 claims description 4
- 150000003014 phosphoric acid esters Chemical class 0.000 claims description 4
- 201000001320 Atherosclerosis Diseases 0.000 claims description 3
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 3
- 206010012735 Diarrhoea Diseases 0.000 claims description 3
- 206010016807 Fluid retention Diseases 0.000 claims description 3
- 206010058061 Gastrointestinal oedema Diseases 0.000 claims description 3
- 206010020853 Hypertonic bladder Diseases 0.000 claims description 3
- 206010061218 Inflammation Diseases 0.000 claims description 3
- 208000009722 Overactive Urinary Bladder Diseases 0.000 claims description 3
- 206010037423 Pulmonary oedema Diseases 0.000 claims description 3
- 206010040047 Sepsis Diseases 0.000 claims description 3
- 150000005840 aryl radicals Chemical class 0.000 claims description 3
- 210000000988 bone and bone Anatomy 0.000 claims description 3
- 230000004054 inflammatory process Effects 0.000 claims description 3
- 230000000968 intestinal effect Effects 0.000 claims description 3
- 208000005264 motor neuron disease Diseases 0.000 claims description 3
- 230000000414 obstructive effect Effects 0.000 claims description 3
- 201000008482 osteoarthritis Diseases 0.000 claims description 3
- 208000020629 overactive bladder Diseases 0.000 claims description 3
- 208000005333 pulmonary edema Diseases 0.000 claims description 3
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 3
- 238000006467 substitution reaction Methods 0.000 claims description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 2
- XTFIVUDBNACUBN-UHFFFAOYSA-N 1,3,5-trinitro-1,3,5-triazinane Chemical compound [O-][N+](=O)N1CN([N+]([O-])=O)CN([N+]([O-])=O)C1 XTFIVUDBNACUBN-UHFFFAOYSA-N 0.000 claims description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 2
- 208000015943 Coeliac disease Diseases 0.000 claims description 2
- 206010010774 Constipation Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 208000034347 Faecal incontinence Diseases 0.000 claims description 2
- 201000010538 Lactose Intolerance Diseases 0.000 claims description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 2
- 208000010285 Ventilator-Induced Lung Injury Diseases 0.000 claims description 2
- 230000003187 abdominal effect Effects 0.000 claims description 2
- 206010069351 acute lung injury Diseases 0.000 claims description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 206010009887 colitis Diseases 0.000 claims description 2
- 206010016766 flatulence Diseases 0.000 claims description 2
- 230000002980 postoperative effect Effects 0.000 claims description 2
- 230000002685 pulmonary effect Effects 0.000 claims description 2
- 230000009257 reactivity Effects 0.000 claims description 2
- 206010039083 rhinitis Diseases 0.000 claims description 2
- 201000009890 sinusitis Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 208000005392 Spasm Diseases 0.000 claims 1
- 230000002068 genetic effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 166
- 238000011282 treatment Methods 0.000 abstract description 24
- 208000022873 Ocular disease Diseases 0.000 abstract description 5
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 261
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 159
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 159
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 98
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 81
- 235000019439 ethyl acetate Nutrition 0.000 description 79
- 239000011541 reaction mixture Substances 0.000 description 69
- 239000000243 solution Substances 0.000 description 58
- 239000011734 sodium Substances 0.000 description 56
- 230000004410 intraocular pressure Effects 0.000 description 52
- 238000003818 flash chromatography Methods 0.000 description 48
- 210000004027 cell Anatomy 0.000 description 47
- 229920006395 saturated elastomer Polymers 0.000 description 44
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 43
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 39
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 38
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 34
- 239000012267 brine Substances 0.000 description 34
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 34
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 33
- 239000003153 chemical reaction reagent Substances 0.000 description 33
- 239000007787 solid Substances 0.000 description 33
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 31
- ZLRXNPKDNDPTTB-UHFFFAOYSA-N C1C(C[NH2+]1)(CO)COC2=CC(=C(C=C2)C#N)F.C(=O)(C(F)(F)F)[O-] Chemical compound C1C(C[NH2+]1)(CO)COC2=CC(=C(C=C2)C#N)F.C(=O)(C(F)(F)F)[O-] ZLRXNPKDNDPTTB-UHFFFAOYSA-N 0.000 description 29
- 230000000699 topical effect Effects 0.000 description 29
- 210000001508 eye Anatomy 0.000 description 28
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 27
- 238000003756 stirring Methods 0.000 description 27
- XMMOTYWNEJXADT-UHFFFAOYSA-N ClC1=C(C=CC(=C1)Cl)S(=O)(=O)N1CC(C1)(C=O)COC1=CC(=C(C#N)C=C1)F Chemical compound ClC1=C(C=CC(=C1)Cl)S(=O)(=O)N1CC(C1)(C=O)COC1=CC(=C(C#N)C=C1)F XMMOTYWNEJXADT-UHFFFAOYSA-N 0.000 description 25
- 239000007864 aqueous solution Substances 0.000 description 25
- 208000010412 Glaucoma Diseases 0.000 description 23
- 239000012230 colorless oil Substances 0.000 description 23
- 239000005557 antagonist Substances 0.000 description 22
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 20
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 19
- 239000011575 calcium Substances 0.000 description 19
- 229910052799 carbon Inorganic materials 0.000 description 19
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 19
- 239000003921 oil Substances 0.000 description 18
- 235000019198 oils Nutrition 0.000 description 18
- 229910002027 silica gel Inorganic materials 0.000 description 18
- 239000000741 silica gel Substances 0.000 description 18
- 239000012141 concentrate Substances 0.000 description 17
- 235000008504 concentrate Nutrition 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 201000010099 disease Diseases 0.000 description 16
- 210000001585 trabecular meshwork Anatomy 0.000 description 16
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 15
- 239000002904 solvent Substances 0.000 description 15
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 14
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 14
- 210000003994 retinal ganglion cell Anatomy 0.000 description 14
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 12
- 108091006146 Channels Proteins 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 229910010082 LiAlH Inorganic materials 0.000 description 12
- 229910052791 calcium Inorganic materials 0.000 description 12
- 125000004432 carbon atom Chemical group C* 0.000 description 12
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 12
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 12
- FDTPBIKNYWQLAE-UHFFFAOYSA-N 2,4-dichlorobenzenesulfonyl chloride Chemical compound ClC1=CC=C(S(Cl)(=O)=O)C(Cl)=C1 FDTPBIKNYWQLAE-UHFFFAOYSA-N 0.000 description 11
- 239000000460 chlorine Substances 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 10
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 10
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 10
- 150000001335 aliphatic alkanes Chemical class 0.000 description 10
- 239000003086 colorant Substances 0.000 description 10
- 239000003085 diluting agent Substances 0.000 description 10
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 10
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 10
- 210000004498 neuroglial cell Anatomy 0.000 description 10
- 210000001525 retina Anatomy 0.000 description 10
- 230000002207 retinal effect Effects 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 229960004605 timolol Drugs 0.000 description 10
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 9
- 239000007821 HATU Substances 0.000 description 9
- 239000000796 flavoring agent Substances 0.000 description 9
- 239000012458 free base Substances 0.000 description 9
- 125000005842 heteroatom Chemical group 0.000 description 9
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 9
- 229910052717 sulfur Inorganic materials 0.000 description 9
- 239000003765 sweetening agent Substances 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- 241000282472 Canis lupus familiaris Species 0.000 description 8
- HJWWKNMCEBJPKU-UHFFFAOYSA-N ClC1=C(C=CC(=C1)Cl)S(=O)(=O)N1CC(C1)(CO)COC1=CC(=C(C#N)C=C1)F Chemical compound ClC1=C(C=CC(=C1)Cl)S(=O)(=O)N1CC(C1)(CO)COC1=CC(=C(C#N)C=C1)F HJWWKNMCEBJPKU-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000000556 agonist Substances 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 239000002552 dosage form Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 8
- 239000006260 foam Substances 0.000 description 8
- 235000003599 food sweetener Nutrition 0.000 description 8
- 125000004404 heteroalkyl group Chemical group 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 7
- QXSANAHCTLNSTC-UHFFFAOYSA-N C(#N)C1=C(C=C(OCC2(CN(C2)S(=O)(=O)C2=C(C=C(C=C2)Cl)Cl)C(=O)O)C=C1)F Chemical compound C(#N)C1=C(C=C(OCC2(CN(C2)S(=O)(=O)C2=C(C=C(C=C2)Cl)Cl)C(=O)O)C=C1)F QXSANAHCTLNSTC-UHFFFAOYSA-N 0.000 description 7
- BDHCGJXWOKSQAN-UHFFFAOYSA-N C(#N)C1=C(C=CC=C1)S(=O)(=O)N1CC(C1)(CO)COC1=CC(=C(C#N)C=C1)F Chemical compound C(#N)C1=C(C=CC=C1)S(=O)(=O)N1CC(C1)(CO)COC1=CC(=C(C#N)C=C1)F BDHCGJXWOKSQAN-UHFFFAOYSA-N 0.000 description 7
- MXJJYAUBEPIMHS-UHFFFAOYSA-N NCC1(CN(C1)S(=O)(=O)C1=C(C=C(C=C1)Cl)Cl)COC1=CC(=C(C#N)C=C1)F Chemical compound NCC1(CN(C1)S(=O)(=O)C1=C(C=C(C=C1)Cl)Cl)COC1=CC(=C(C#N)C=C1)F MXJJYAUBEPIMHS-UHFFFAOYSA-N 0.000 description 7
- 102000003566 TRPV1 Human genes 0.000 description 7
- 101150016206 Trpv1 gene Proteins 0.000 description 7
- 125000003277 amino group Chemical group 0.000 description 7
- 210000001742 aqueous humor Anatomy 0.000 description 7
- GFZWHAAOIVMHOI-UHFFFAOYSA-N azetidine-3-carboxylic acid Chemical compound OC(=O)C1CNC1 GFZWHAAOIVMHOI-UHFFFAOYSA-N 0.000 description 7
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 7
- 239000000314 lubricant Substances 0.000 description 7
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 7
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 6
- REIVHYDACHXPNH-UHFFFAOYSA-N 2-fluoro-4-hydroxybenzonitrile Chemical compound OC1=CC=C(C#N)C(F)=C1 REIVHYDACHXPNH-UHFFFAOYSA-N 0.000 description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- 108010010803 Gelatin Proteins 0.000 description 6
- 101000764872 Homo sapiens Transient receptor potential cation channel subfamily A member 1 Proteins 0.000 description 6
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 6
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 6
- 102000003568 TRPV3 Human genes 0.000 description 6
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 6
- 101150043371 Trpv3 gene Proteins 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 150000001298 alcohols Chemical class 0.000 description 6
- 125000003342 alkenyl group Chemical group 0.000 description 6
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 6
- 239000011230 binding agent Substances 0.000 description 6
- 230000033228 biological regulation Effects 0.000 description 6
- 235000013355 food flavoring agent Nutrition 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000008273 gelatin Substances 0.000 description 6
- 229920000159 gelatin Polymers 0.000 description 6
- 235000019322 gelatine Nutrition 0.000 description 6
- 235000011852 gelatine desserts Nutrition 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000011325 microbead Substances 0.000 description 6
- 125000002950 monocyclic group Chemical group 0.000 description 6
- 238000010172 mouse model Methods 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- GFAKQSWJCMKEGE-UHFFFAOYSA-N 1-o-tert-butyl 3-o-ethyl azetidine-1,3-dicarboxylate Chemical compound CCOC(=O)C1CN(C(=O)OC(C)(C)C)C1 GFAKQSWJCMKEGE-UHFFFAOYSA-N 0.000 description 5
- OFJKGNQMVDKSFQ-UHFFFAOYSA-N C1C(CN1S(=O)(=O)C2=C(C=C(C=C2)Cl)Cl)(COC3=CC(=C(C=C3)C#N)F)N.Cl Chemical compound C1C(CN1S(=O)(=O)C2=C(C=C(C=C2)Cl)Cl)(COC3=CC(=C(C=C3)C#N)F)N.Cl OFJKGNQMVDKSFQ-UHFFFAOYSA-N 0.000 description 5
- 102000003610 TRPM8 Human genes 0.000 description 5
- 102100026186 Transient receptor potential cation channel subfamily A member 1 Human genes 0.000 description 5
- 101150111302 Trpm8 gene Proteins 0.000 description 5
- 125000003545 alkoxy group Chemical group 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 125000004567 azetidin-3-yl group Chemical group N1CC(C1)* 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 125000002619 bicyclic group Chemical group 0.000 description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 208000037765 diseases and disorders Diseases 0.000 description 5
- 239000006196 drop Substances 0.000 description 5
- 230000004406 elevated intraocular pressure Effects 0.000 description 5
- 229910052731 fluorine Inorganic materials 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 229960004063 propylene glycol Drugs 0.000 description 5
- 235000013772 propylene glycol Nutrition 0.000 description 5
- 230000035882 stress Effects 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 238000011200 topical administration Methods 0.000 description 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- VRPJIFMKZZEXLR-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]acetic acid Chemical compound CC(C)(C)OC(=O)NCC(O)=O VRPJIFMKZZEXLR-UHFFFAOYSA-N 0.000 description 4
- CVNOWLNNPYYEOH-UHFFFAOYSA-N 4-cyanophenol Chemical compound OC1=CC=C(C#N)C=C1 CVNOWLNNPYYEOH-UHFFFAOYSA-N 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 206010030348 Open-Angle Glaucoma Diseases 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 235000010443 alginic acid Nutrition 0.000 description 4
- 229920000615 alginic acid Polymers 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 125000004103 aminoalkyl group Chemical group 0.000 description 4
- 125000003710 aryl alkyl group Chemical group 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000004359 castor oil Substances 0.000 description 4
- 235000019438 castor oil Nutrition 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 210000004081 cilia Anatomy 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 125000000392 cycloalkenyl group Chemical group 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 239000007884 disintegrant Substances 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 239000003974 emollient agent Substances 0.000 description 4
- 239000003889 eye drop Substances 0.000 description 4
- 229940012356 eye drops Drugs 0.000 description 4
- 239000011737 fluorine Substances 0.000 description 4
- 125000003709 fluoroalkyl group Chemical group 0.000 description 4
- 230000004907 flux Effects 0.000 description 4
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 4
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 4
- 239000003906 humectant Substances 0.000 description 4
- 239000007943 implant Substances 0.000 description 4
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- 210000004925 microvascular endothelial cell Anatomy 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- 208000020911 optic nerve disease Diseases 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000007634 remodeling Methods 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 4
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- 125000000169 tricyclic heterocycle group Chemical group 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 3
- SECFRXGVLMVUPD-UHFFFAOYSA-N 1-o-tert-butyl 3-o-methyl azetidine-1,3-dicarboxylate Chemical compound COC(=O)C1CN(C(=O)OC(C)(C)C)C1 SECFRXGVLMVUPD-UHFFFAOYSA-N 0.000 description 3
- IMLXLGZJLAOKJN-UHFFFAOYSA-N 4-aminocyclohexan-1-ol Chemical compound NC1CCC(O)CC1 IMLXLGZJLAOKJN-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 201000004569 Blindness Diseases 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- QTKKZDKWTRPJJH-UHFFFAOYSA-N ClC1=C(C=CC(=C1)Cl)S(=O)(=O)N1CC(C1)(CO)COC1=CC(=C(C#N)C=C1)OCC Chemical compound ClC1=C(C=CC(=C1)Cl)S(=O)(=O)N1CC(C1)(CO)COC1=CC(=C(C#N)C=C1)OCC QTKKZDKWTRPJJH-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 206010012689 Diabetic retinopathy Diseases 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 3
- 239000001856 Ethyl cellulose Substances 0.000 description 3
- IVYQPSHHYIAUFO-VXKWHMMOSA-N GSK1016790A Chemical compound N([C@@H](CO)C(=O)N1CCN(CC1)C(=O)[C@@H](NC(=O)C=1SC2=CC=CC=C2C=1)CC(C)C)S(=O)(=O)C1=CC=C(Cl)C=C1Cl IVYQPSHHYIAUFO-VXKWHMMOSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 108090000862 Ion Channels Proteins 0.000 description 3
- 102000004310 Ion Channels Human genes 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- 208000035023 Oculocerebrorenal syndrome of Lowe Diseases 0.000 description 3
- 206010061323 Optic neuropathy Diseases 0.000 description 3
- 235000019483 Peanut oil Nutrition 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 3
- 239000012346 acetyl chloride Substances 0.000 description 3
- QOMNQGZXFYNBNG-UHFFFAOYSA-N acetyloxymethyl 2-[2-[2-[5-[3-(acetyloxymethoxy)-2,7-difluoro-6-oxoxanthen-9-yl]-2-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]phenoxy]ethoxy]-n-[2-(acetyloxymethoxy)-2-oxoethyl]-4-methylanilino]acetate Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=C(C)C=C1OCCOC1=CC(C2=C3C=C(F)C(=O)C=C3OC3=CC(OCOC(C)=O)=C(F)C=C32)=CC=C1N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O QOMNQGZXFYNBNG-UHFFFAOYSA-N 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 239000000783 alginic acid Substances 0.000 description 3
- 229960001126 alginic acid Drugs 0.000 description 3
- 150000004781 alginic acids Chemical class 0.000 description 3
- 125000003282 alkyl amino group Chemical group 0.000 description 3
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 3
- 125000000304 alkynyl group Chemical group 0.000 description 3
- 210000002159 anterior chamber Anatomy 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000004094 calcium homeostasis Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 229940126142 compound 16 Drugs 0.000 description 3
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 230000003412 degenerative effect Effects 0.000 description 3
- SGZSDHYCUBSYKQ-UHFFFAOYSA-N diethyl azetidine-3,3-dicarboxylate hydrochloride Chemical compound Cl.N1CC(C1)(C(=O)OCC)C(=O)OCC SGZSDHYCUBSYKQ-UHFFFAOYSA-N 0.000 description 3
- CMXMEUUHZBOBGZ-UHFFFAOYSA-N ethyl azetidine-3-carboxylate Chemical compound CCOC(=O)C1CNC1 CMXMEUUHZBOBGZ-UHFFFAOYSA-N 0.000 description 3
- 235000019325 ethyl cellulose Nutrition 0.000 description 3
- 229920001249 ethyl cellulose Polymers 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 3
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 208000002780 macular degeneration Diseases 0.000 description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- MBABOKRGFJTBAE-UHFFFAOYSA-N methyl methanesulfonate Chemical compound COS(C)(=O)=O MBABOKRGFJTBAE-UHFFFAOYSA-N 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- OKDQKPLMQBXTNH-UHFFFAOYSA-N n,n-dimethyl-2h-pyridin-1-amine Chemical compound CN(C)N1CC=CC=C1 OKDQKPLMQBXTNH-UHFFFAOYSA-N 0.000 description 3
- 230000000324 neuroprotective effect Effects 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 201000006352 oculocerebrorenal syndrome Diseases 0.000 description 3
- 239000000312 peanut oil Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 201000006366 primary open angle glaucoma Diseases 0.000 description 3
- 239000003380 propellant Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000008159 sesame oil Substances 0.000 description 3
- 235000011803 sesame oil Nutrition 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 238000012384 transportation and delivery Methods 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- 238000001665 trituration Methods 0.000 description 3
- 229940002639 xalatan Drugs 0.000 description 3
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 2
- HXKKHQJGJAFBHI-VKHMYHEASA-N (2s)-1-aminopropan-2-ol Chemical compound C[C@H](O)CN HXKKHQJGJAFBHI-VKHMYHEASA-N 0.000 description 2
- MEJYDZQQVZJMPP-ULAWRXDQSA-N (3s,3ar,6r,6ar)-3,6-dimethoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan Chemical compound CO[C@H]1CO[C@@H]2[C@H](OC)CO[C@@H]21 MEJYDZQQVZJMPP-ULAWRXDQSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- FOZVXADQAHVUSV-UHFFFAOYSA-N 1-bromo-2-(2-bromoethoxy)ethane Chemical compound BrCCOCCBr FOZVXADQAHVUSV-UHFFFAOYSA-N 0.000 description 2
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- LGWJASCXAUGZHB-UHFFFAOYSA-N 1-o-tert-butyl 3-o-ethyl 3-(hydroxymethyl)azetidine-1,3-dicarboxylate Chemical compound CCOC(=O)C1(CO)CN(C(=O)OC(C)(C)C)C1 LGWJASCXAUGZHB-UHFFFAOYSA-N 0.000 description 2
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 2
- ICKWICRCANNIBI-UHFFFAOYSA-N 2,4-di-tert-butylphenol Chemical compound CC(C)(C)C1=CC=C(O)C(C(C)(C)C)=C1 ICKWICRCANNIBI-UHFFFAOYSA-N 0.000 description 2
- KMVZDSQHLDGKGV-UHFFFAOYSA-N 2-chlorobenzenesulfonyl chloride Chemical compound ClC1=CC=CC=C1S(Cl)(=O)=O KMVZDSQHLDGKGV-UHFFFAOYSA-N 0.000 description 2
- QBINCWCUKSGTNZ-UHFFFAOYSA-N 2-cyano-4-methylbenzenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C(C#N)=C1 QBINCWCUKSGTNZ-UHFFFAOYSA-N 0.000 description 2
- NQAYCMBZPAARNO-UHFFFAOYSA-N 2-cyanobenzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1C#N NQAYCMBZPAARNO-UHFFFAOYSA-N 0.000 description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- BNPWVUJOPCGHIK-UHFFFAOYSA-N 3,4-difluorophenol Chemical compound OC1=CC=C(F)C(F)=C1 BNPWVUJOPCGHIK-UHFFFAOYSA-N 0.000 description 2
- AGDFIODDRZMYBT-UHFFFAOYSA-N 3-(hydroxymethyl)azetidine-1,3-dicarboxylic acid Chemical compound OCC1(C(O)=O)CN(C(O)=O)C1 AGDFIODDRZMYBT-UHFFFAOYSA-N 0.000 description 2
- JLUZCHOYSPEHES-UHFFFAOYSA-N 3-aminocyclobutan-1-ol Chemical compound NC1CC(O)C1 JLUZCHOYSPEHES-UHFFFAOYSA-N 0.000 description 2
- KQIGMPWTAHJUMN-UHFFFAOYSA-N 3-aminopropane-1,2-diol Chemical compound NCC(O)CO KQIGMPWTAHJUMN-UHFFFAOYSA-N 0.000 description 2
- GRFNBEZIAWKNCO-UHFFFAOYSA-N 3-pyridinol Chemical compound OC1=CC=CN=C1 GRFNBEZIAWKNCO-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- FDUGOYTWYJZNNP-UHFFFAOYSA-N 4-amino-2-fluorobenzonitrile Chemical compound NC1=CC=C(C#N)C(F)=C1 FDUGOYTWYJZNNP-UHFFFAOYSA-N 0.000 description 2
- DENKGPBHLYFNGK-UHFFFAOYSA-N 4-bromobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(Br)C=C1 DENKGPBHLYFNGK-UHFFFAOYSA-N 0.000 description 2
- QJRWLNLUIAJTAD-UHFFFAOYSA-N 4-hydroxy-3-methoxybenzonitrile Chemical compound COC1=CC(C#N)=CC=C1O QJRWLNLUIAJTAD-UHFFFAOYSA-N 0.000 description 2
- QXSAKPUBHTZHKW-UHFFFAOYSA-N 4-hydroxybenzamide Chemical compound NC(=O)C1=CC=C(O)C=C1 QXSAKPUBHTZHKW-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 2
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 2
- 108010036280 Aquaporin 4 Proteins 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- YEOYCUYGHQBJEZ-UHFFFAOYSA-N C(#N)C1=CC=C(OCC2(CN(C2)S(=O)(=O)C2=C(C=C(C=C2)Cl)Cl)C(=O)O)C=C1 Chemical compound C(#N)C1=CC=C(OCC2(CN(C2)S(=O)(=O)C2=C(C=C(C=C2)Cl)Cl)C(=O)O)C=C1 YEOYCUYGHQBJEZ-UHFFFAOYSA-N 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- MVYJGMOAYWRAMG-UHFFFAOYSA-N ClC1=C(C=CC(=C1)Cl)S(=O)(=O)N1CC(C1)(CNCCO)COC1=CC(=C(C#N)C=C1)F Chemical compound ClC1=C(C=CC(=C1)Cl)S(=O)(=O)N1CC(C1)(CNCCO)COC1=CC(=C(C#N)C=C1)F MVYJGMOAYWRAMG-UHFFFAOYSA-N 0.000 description 2
- 229940126657 Compound 17 Drugs 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 2
- YNQLUTRBYVCPMQ-UHFFFAOYSA-N Ethylbenzene Chemical compound CCC1=CC=CC=C1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 description 2
- 206010018341 Gliosis Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000633097 Homo sapiens Transient receptor potential cation channel subfamily V member 4 Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 229930194542 Keto Natural products 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 244000246386 Mentha pulegium Species 0.000 description 2
- 235000016257 Mentha pulegium Nutrition 0.000 description 2
- 235000004357 Mentha x piperita Nutrition 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
- 235000019502 Orange oil Nutrition 0.000 description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 2
- 241000282320 Panthera leo Species 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 206010047513 Vision blurred Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 125000004442 acylamino group Chemical group 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 2
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 2
- 239000001099 ammonium carbonate Substances 0.000 description 2
- 125000001769 aryl amino group Chemical group 0.000 description 2
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 229910000085 borane Inorganic materials 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 230000003185 calcium uptake Effects 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000013375 chromatographic separation Methods 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 238000003271 compound fluorescence assay Methods 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 239000008406 cosmetic ingredient Substances 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 239000002385 cottonseed oil Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 230000003436 cytoskeletal effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 210000001787 dendrite Anatomy 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 150000002066 eicosanoids Chemical class 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 2
- 229940093471 ethyl oleate Drugs 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 125000004428 fluoroalkoxy group Chemical group 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000002518 glial effect Effects 0.000 description 2
- 230000007387 gliosis Effects 0.000 description 2
- 150000002334 glycols Chemical class 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 125000004438 haloalkoxy group Chemical group 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 230000003284 homeostatic effect Effects 0.000 description 2
- 235000001050 hortel pimenta Nutrition 0.000 description 2
- 102000052948 human TRPV4 Human genes 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000005462 in vivo assay Methods 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- 125000000468 ketone group Chemical group 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- 229940039717 lanolin Drugs 0.000 description 2
- 229960001160 latanoprost Drugs 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229940041616 menthol Drugs 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 230000004112 neuroprotection Effects 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 210000003733 optic disk Anatomy 0.000 description 2
- 210000001328 optic nerve Anatomy 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000010502 orange oil Substances 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- AHVQYHFYQWKUKB-UHFFFAOYSA-N oxan-4-amine Chemical compound NC1CCOCC1 AHVQYHFYQWKUKB-UHFFFAOYSA-N 0.000 description 2
- OJEOJUQOECNDND-UHFFFAOYSA-N oxetan-3-amine Chemical compound NC1COC1 OJEOJUQOECNDND-UHFFFAOYSA-N 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- IWDCLRJOBJJRNH-UHFFFAOYSA-N p-cresol Chemical compound CC1=CC=C(O)C=C1 IWDCLRJOBJJRNH-UHFFFAOYSA-N 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 2
- 229960003081 probenecid Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 235000019204 saccharin Nutrition 0.000 description 2
- 229940081974 saccharin Drugs 0.000 description 2
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 208000002320 spinal muscular atrophy Diseases 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 229960003080 taurine Drugs 0.000 description 2
- QUERMGFVJPRMJL-UHFFFAOYSA-N tert-butyl azetidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC1 QUERMGFVJPRMJL-UHFFFAOYSA-N 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 125000005323 thioketone group Chemical group 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 238000003828 vacuum filtration Methods 0.000 description 2
- 230000004393 visual impairment Effects 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 1
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 1
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- HXKKHQJGJAFBHI-GSVOUGTGSA-N (2R)-1-aminopropan-2-ol Chemical compound C[C@@H](O)CN HXKKHQJGJAFBHI-GSVOUGTGSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- GCTFTMWXZFLTRR-GFCCVEGCSA-N (2r)-2-amino-n-[3-(difluoromethoxy)-4-(1,3-oxazol-5-yl)phenyl]-4-methylpentanamide Chemical compound FC(F)OC1=CC(NC(=O)[C@H](N)CC(C)C)=CC=C1C1=CN=CO1 GCTFTMWXZFLTRR-GFCCVEGCSA-N 0.000 description 1
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 1
- VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 description 1
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 1
- UJJLJRQIPMGXEZ-BYPYZUCNSA-N (2s)-oxolane-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCO1 UJJLJRQIPMGXEZ-BYPYZUCNSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 1
- OOKAZRDERJMRCJ-KOUAFAAESA-N (3r)-7-[(1s,2s,4ar,6s,8s)-2,6-dimethyl-8-[(2s)-2-methylbutanoyl]oxy-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]-3-hydroxy-5-oxoheptanoic acid Chemical compound C1=C[C@H](C)[C@H](CCC(=O)C[C@@H](O)CC(O)=O)C2[C@@H](OC(=O)[C@@H](C)CC)C[C@@H](C)C[C@@H]21 OOKAZRDERJMRCJ-KOUAFAAESA-N 0.000 description 1
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 1
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 1
- STPKWKPURVSAJF-LJEWAXOPSA-N (4r,5r)-5-[4-[[4-(1-aza-4-azoniabicyclo[2.2.2]octan-4-ylmethyl)phenyl]methoxy]phenyl]-3,3-dibutyl-7-(dimethylamino)-1,1-dioxo-4,5-dihydro-2h-1$l^{6}-benzothiepin-4-ol Chemical compound O[C@H]1C(CCCC)(CCCC)CS(=O)(=O)C2=CC=C(N(C)C)C=C2[C@H]1C(C=C1)=CC=C1OCC(C=C1)=CC=C1C[N+]1(CC2)CCN2CC1 STPKWKPURVSAJF-LJEWAXOPSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical class CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 description 1
- BKMMTJMQCTUHRP-VKHMYHEASA-N (S)-2-aminopropan-1-ol Chemical compound C[C@H](N)CO BKMMTJMQCTUHRP-VKHMYHEASA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- DEVSOMFAQLZNKR-RJRFIUFISA-N (z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-n'-pyrazin-2-ylprop-2-enehydrazide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C2=NN(\C=C/C(=O)NNC=3N=CC=NC=3)C=N2)=C1 DEVSOMFAQLZNKR-RJRFIUFISA-N 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
- 125000004530 1,2,4-triazinyl group Chemical group N1=NC(=NC=C1)* 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- 125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 description 1
- ZPQOPVIELGIULI-UHFFFAOYSA-N 1,3-dichlorobenzene Chemical compound ClC1=CC=CC(Cl)=C1 ZPQOPVIELGIULI-UHFFFAOYSA-N 0.000 description 1
- DJMOXMNDXFFONV-UHFFFAOYSA-N 1,3-dimethyl-7-[2-(n-methylanilino)ethyl]purine-2,6-dione Chemical compound C1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CCN(C)C1=CC=CC=C1 DJMOXMNDXFFONV-UHFFFAOYSA-N 0.000 description 1
- KKHFRAFPESRGGD-UHFFFAOYSA-N 1,3-dimethyl-7-[3-(n-methylanilino)propyl]purine-2,6-dione Chemical compound C1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CCCN(C)C1=CC=CC=C1 KKHFRAFPESRGGD-UHFFFAOYSA-N 0.000 description 1
- AFFSTQSBJFQGPY-UHFFFAOYSA-N 1,3-dimethylpyrazole-4-sulfonyl chloride Chemical compound CC1=NN(C)C=C1S(Cl)(=O)=O AFFSTQSBJFQGPY-UHFFFAOYSA-N 0.000 description 1
- IGERFAHWSHDDHX-UHFFFAOYSA-N 1,3-dioxanyl Chemical group [CH]1OCCCO1 IGERFAHWSHDDHX-UHFFFAOYSA-N 0.000 description 1
- 125000000164 1,3-thiazinyl group Chemical group S1C(N=CC=C1)* 0.000 description 1
- JOZSYOPADROCMP-UHFFFAOYSA-N 1,3-thiazol-2-ylmethanamine Chemical compound NCC1=NC=CS1 JOZSYOPADROCMP-UHFFFAOYSA-N 0.000 description 1
- FZQXMGLQANXZRP-UHFFFAOYSA-N 1-(3,4-dimethoxyphenyl)-3-(3-imidazol-1-ylpropyl)thiourea Chemical compound C1=C(OC)C(OC)=CC=C1NC(=S)NCCCN1C=NC=C1 FZQXMGLQANXZRP-UHFFFAOYSA-N 0.000 description 1
- JFEHNAOCCNHMIM-UHFFFAOYSA-N 1-O-tert-butyl 3-O-methyl 3-(hydroxymethyl)azetidine-1,3-dicarboxylate Chemical compound COC(=O)C1(CO)CN(C1)C(=O)OC(C)(C)C JFEHNAOCCNHMIM-UHFFFAOYSA-N 0.000 description 1
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- HXKKHQJGJAFBHI-UHFFFAOYSA-N 1-aminopropan-2-ol Chemical compound CC(O)CN HXKKHQJGJAFBHI-UHFFFAOYSA-N 0.000 description 1
- WENISBCJPGSITQ-UHFFFAOYSA-N 1-azatricyclo[3.3.1.13,7]decane Chemical compound C1C(C2)CC3CC1CN2C3 WENISBCJPGSITQ-UHFFFAOYSA-N 0.000 description 1
- QXQAPNSHUJORMC-UHFFFAOYSA-N 1-chloro-4-propylbenzene Chemical compound CCCC1=CC=C(Cl)C=C1 QXQAPNSHUJORMC-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- FYUPJGXEWFMXHW-UHFFFAOYSA-N 1-o-tert-butyl 3-o,3-o'-diethyl azetidine-1,3,3-tricarboxylate Chemical compound CCOC(=O)C1(C(=O)OCC)CN(C(=O)OC(C)(C)C)C1 FYUPJGXEWFMXHW-UHFFFAOYSA-N 0.000 description 1
- MMEIVVYGFADKTL-UHFFFAOYSA-N 1-o-tert-butyl 3-o-ethyl 3-aminoazetidine-1,3-dicarboxylate Chemical compound CCOC(=O)C1(N)CN(C(=O)OC(C)(C)C)C1 MMEIVVYGFADKTL-UHFFFAOYSA-N 0.000 description 1
- PRWCITKRUVKOEQ-UHFFFAOYSA-N 1-o-tert-butyl 3-o-methyl 3-methylazetidine-1,3-dicarboxylate Chemical compound COC(=O)C1(C)CN(C(=O)OC(C)(C)C)C1 PRWCITKRUVKOEQ-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- CNWINRVXAYPOMW-FCNJXWMTSA-N 1-stearoyl-2-arachidonoyl-sn-glycero-3-phospho-1D-myo-inositol 4,5-biphosphate Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCC)COP(O)(=O)O[C@@H]1[C@H](O)[C@H](O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H]1O CNWINRVXAYPOMW-FCNJXWMTSA-N 0.000 description 1
- LGEZTMRIZWCDLW-UHFFFAOYSA-N 14-methylpentadecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC(C)C LGEZTMRIZWCDLW-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- FZWSBCNMDDULHX-UHFFFAOYSA-N 2,3-dihydroisoquinoline Chemical compound C1=CC=CC2=CCNC=C21 FZWSBCNMDDULHX-UHFFFAOYSA-N 0.000 description 1
- HDIFHQMREAYYJW-FMIVXFBMSA-N 2,3-dihydroxypropyl (e)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C\CCCCCCCC(=O)OCC(O)CO HDIFHQMREAYYJW-FMIVXFBMSA-N 0.000 description 1
- 125000003660 2,3-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- LLSSTAFRCYCGTH-UHFFFAOYSA-N 2,4-dichloro-1-(2,4-dichlorophenyl)sulfonylbenzene Chemical compound ClC1=CC(Cl)=CC=C1S(=O)(=O)C1=CC=C(Cl)C=C1Cl LLSSTAFRCYCGTH-UHFFFAOYSA-N 0.000 description 1
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 description 1
- GFFJSTHQILQFNQ-UHFFFAOYSA-N 2,4-dimethyl-1,3-thiazole-5-sulfonyl chloride Chemical compound CC1=NC(C)=C(S(Cl)(=O)=O)S1 GFFJSTHQILQFNQ-UHFFFAOYSA-N 0.000 description 1
- FREOGXBZEAMJQN-UHFFFAOYSA-N 2,4-dimethylbenzenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C(C)=C1 FREOGXBZEAMJQN-UHFFFAOYSA-N 0.000 description 1
- WGGKQIKICKLWGN-UHFFFAOYSA-N 2,6-dichlorobenzenesulfonyl chloride Chemical compound ClC1=CC=CC(Cl)=C1S(Cl)(=O)=O WGGKQIKICKLWGN-UHFFFAOYSA-N 0.000 description 1
- WGFNXGPBPIJYLI-UHFFFAOYSA-N 2,6-difluoro-3-[(3-fluorophenyl)sulfonylamino]-n-(3-methoxy-1h-pyrazolo[3,4-b]pyridin-5-yl)benzamide Chemical compound C1=C2C(OC)=NNC2=NC=C1NC(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=CC(F)=C1 WGFNXGPBPIJYLI-UHFFFAOYSA-N 0.000 description 1
- FQMZXMVHHKXGTM-UHFFFAOYSA-N 2-(1-adamantyl)-n-[2-[2-(2-hydroxyethylamino)ethylamino]quinolin-5-yl]acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=CC=CC2=NC(NCCNCCO)=CC=C21 FQMZXMVHHKXGTM-UHFFFAOYSA-N 0.000 description 1
- VCUXVXLUOHDHKK-UHFFFAOYSA-N 2-(2-aminopyrimidin-4-yl)-4-(2-chloro-4-methoxyphenyl)-1,3-thiazole-5-carboxamide Chemical compound ClC1=CC(OC)=CC=C1C1=C(C(N)=O)SC(C=2N=C(N)N=CC=2)=N1 VCUXVXLUOHDHKK-UHFFFAOYSA-N 0.000 description 1
- BFUUJUGQJUTPAF-UHFFFAOYSA-N 2-(3-amino-4-propoxybenzoyl)oxyethyl-diethylazanium;chloride Chemical compound [Cl-].CCCOC1=CC=C(C(=O)OCC[NH+](CC)CC)C=C1N BFUUJUGQJUTPAF-UHFFFAOYSA-N 0.000 description 1
- FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 1
- DPZHKLJPVMYFCU-UHFFFAOYSA-N 2-(5-bromopyridin-2-yl)acetonitrile Chemical compound BrC1=CC=C(CC#N)N=C1 DPZHKLJPVMYFCU-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 1
- FMKGJQHNYMWDFJ-CVEARBPZSA-N 2-[[4-(2,2-difluoropropoxy)pyrimidin-5-yl]methylamino]-4-[[(1R,4S)-4-hydroxy-3,3-dimethylcyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound FC(COC1=NC=NC=C1CNC1=NC=C(C(=N1)N[C@H]1CC([C@H](CC1)O)(C)C)C#N)(C)F FMKGJQHNYMWDFJ-CVEARBPZSA-N 0.000 description 1
- FPTVUFLXTAXDDB-UHFFFAOYSA-N 2-[amino(dimethyl)silyl]-2-methylpropane Chemical compound CC(C)(C)[Si](C)(C)N FPTVUFLXTAXDDB-UHFFFAOYSA-N 0.000 description 1
- YRXIMPFOTQVOHG-UHFFFAOYSA-N 2-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]acetic acid Chemical compound OC(=O)CN(C)C(=O)OC(C)(C)C YRXIMPFOTQVOHG-UHFFFAOYSA-N 0.000 description 1
- VVCMGAUPZIKYTH-VGHSCWAPSA-N 2-acetyloxybenzoic acid;[(2s,3r)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate;1,3,7-trimethylpurine-2,6-dione Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O.CN1C(=O)N(C)C(=O)C2=C1N=CN2C.C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 VVCMGAUPZIKYTH-VGHSCWAPSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- WKNMKGVLOWGGOU-UHFFFAOYSA-N 2-aminoacetamide;hydron;chloride Chemical compound Cl.NCC(N)=O WKNMKGVLOWGGOU-UHFFFAOYSA-N 0.000 description 1
- VWWRUCDVDGRSNG-UHFFFAOYSA-N 2-bromo-4-(trifluoromethoxy)benzenesulfonyl chloride Chemical compound FC(F)(F)OC1=CC=C(S(Cl)(=O)=O)C(Br)=C1 VWWRUCDVDGRSNG-UHFFFAOYSA-N 0.000 description 1
- NRNTWMTVYWBKSM-UHFFFAOYSA-N 2-bromo-4-methoxybenzenesulfonyl chloride Chemical compound COC1=CC=C(S(Cl)(=O)=O)C(Br)=C1 NRNTWMTVYWBKSM-UHFFFAOYSA-N 0.000 description 1
- VBEHFOMFHUQAOW-UHFFFAOYSA-N 2-chloro-1h-pyridin-4-one Chemical compound OC1=CC=NC(Cl)=C1 VBEHFOMFHUQAOW-UHFFFAOYSA-N 0.000 description 1
- NJXDBSSSDPOAFI-UHFFFAOYSA-N 2-chloro-4-(trifluoromethyl)benzenesulfonyl chloride Chemical compound FC(F)(F)C1=CC=C(S(Cl)(=O)=O)C(Cl)=C1 NJXDBSSSDPOAFI-UHFFFAOYSA-N 0.000 description 1
- GNJOWOAPHOFJBW-UHFFFAOYSA-N 2-chloro-4-cyanobenzenesulfonyl chloride Chemical compound ClC1=CC(C#N)=CC=C1S(Cl)(=O)=O GNJOWOAPHOFJBW-UHFFFAOYSA-N 0.000 description 1
- KVRCCIGDMLSANW-UHFFFAOYSA-N 2-chloro-4-methoxybenzenesulfonyl chloride Chemical compound COC1=CC=C(S(Cl)(=O)=O)C(Cl)=C1 KVRCCIGDMLSANW-UHFFFAOYSA-N 0.000 description 1
- JWFLSLOCDIEDGQ-UHFFFAOYSA-N 2-chloro-4-methylbenzenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C(Cl)=C1 JWFLSLOCDIEDGQ-UHFFFAOYSA-N 0.000 description 1
- MFJSIQDQIZEVJX-UHFFFAOYSA-N 2-chloropyridine-3-sulfonyl chloride Chemical compound ClC1=NC=CC=C1S(Cl)(=O)=O MFJSIQDQIZEVJX-UHFFFAOYSA-N 0.000 description 1
- MITFCFJALKLPLC-UHFFFAOYSA-N 2-cyano-4-(trifluoromethyl)benzenesulfonyl chloride Chemical compound FC(F)(F)C1=CC=C(S(Cl)(=O)=O)C(C#N)=C1 MITFCFJALKLPLC-UHFFFAOYSA-N 0.000 description 1
- KXWBPZIFIFCHHG-UHFFFAOYSA-N 2-cyano-4-fluorobenzenesulfonyl chloride Chemical compound FC1=CC=C(S(Cl)(=O)=O)C(C#N)=C1 KXWBPZIFIFCHHG-UHFFFAOYSA-N 0.000 description 1
- UZKRLYXQSNQUCT-UHFFFAOYSA-N 2-cyano-4-methoxybenzenesulfonyl chloride Chemical compound COC1=CC=C(S(Cl)(=O)=O)C(C#N)=C1 UZKRLYXQSNQUCT-UHFFFAOYSA-N 0.000 description 1
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
- VBZLRHYLNXWZIU-UHFFFAOYSA-N 2-fluoro-5-methoxybenzonitrile Chemical compound COC1=CC=C(F)C(C#N)=C1 VBZLRHYLNXWZIU-UHFFFAOYSA-N 0.000 description 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 1
- ASUDFOJKTJLAIK-UHFFFAOYSA-N 2-methoxyethanamine Chemical compound COCCN ASUDFOJKTJLAIK-UHFFFAOYSA-N 0.000 description 1
- KZDSIZCJICMHJW-UHFFFAOYSA-N 2-methyl-1h-pyridin-4-one Chemical compound CC1=CC(O)=CC=N1 KZDSIZCJICMHJW-UHFFFAOYSA-N 0.000 description 1
- HDECRAPHCDXMIJ-UHFFFAOYSA-N 2-methylbenzenesulfonyl chloride Chemical compound CC1=CC=CC=C1S(Cl)(=O)=O HDECRAPHCDXMIJ-UHFFFAOYSA-N 0.000 description 1
- OJIBJRXMHVZPLV-UHFFFAOYSA-N 2-methylpropyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(C)C OJIBJRXMHVZPLV-UHFFFAOYSA-N 0.000 description 1
- CMRFJAMFEWYMKE-UHFFFAOYSA-N 2-oxaadamantane Chemical compound C1C(O2)CC3CC1CC2C3 CMRFJAMFEWYMKE-UHFFFAOYSA-N 0.000 description 1
- XSDLSEOIVCVTQZ-UHFFFAOYSA-N 2h-cyclopenta[b]furan Chemical compound C1=CC2=CCOC2=C1 XSDLSEOIVCVTQZ-UHFFFAOYSA-N 0.000 description 1
- ONJRTQUWKRDCTA-UHFFFAOYSA-N 2h-thiochromene Chemical compound C1=CC=C2C=CCSC2=C1 ONJRTQUWKRDCTA-UHFFFAOYSA-N 0.000 description 1
- NYIBPWGZGSXURD-UHFFFAOYSA-N 3,4-dichlorobenzenesulfonyl chloride Chemical compound ClC1=CC=C(S(Cl)(=O)=O)C=C1Cl NYIBPWGZGSXURD-UHFFFAOYSA-N 0.000 description 1
- RJSQINMKOSOUGT-UHFFFAOYSA-N 3,5-dichlorobenzenesulfonyl chloride Chemical compound ClC1=CC(Cl)=CC(S(Cl)(=O)=O)=C1 RJSQINMKOSOUGT-UHFFFAOYSA-N 0.000 description 1
- RCEFMOGVOYEGJN-UHFFFAOYSA-N 3-(2-hydroxyphenyl)-6-(3-nitrophenyl)-1,4-dihydropyrimidin-2-one Chemical compound OC1=CC=CC=C1N1C(=O)NC(C=2C=C(C=CC=2)[N+]([O-])=O)=CC1 RCEFMOGVOYEGJN-UHFFFAOYSA-N 0.000 description 1
- QBUMCHMBECZQKS-UHFFFAOYSA-N 3-(hydroxymethyl)-3-methylazetidine-1-carboxylic acid Chemical compound OCC1(CN(C1)C(=O)O)C QBUMCHMBECZQKS-UHFFFAOYSA-N 0.000 description 1
- ONCAZCNPWWQQMW-UHFFFAOYSA-N 3-(trifluoromethyl)benzenesulfonyl chloride Chemical compound FC(F)(F)C1=CC=CC(S(Cl)(=O)=O)=C1 ONCAZCNPWWQQMW-UHFFFAOYSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- WFOVEDJTASPCIR-UHFFFAOYSA-N 3-[(4-methyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)methylamino]-n-[[2-(trifluoromethyl)phenyl]methyl]benzamide Chemical compound N=1N=C(C=2C=CN=CC=2)N(C)C=1CNC(C=1)=CC=CC=1C(=O)NCC1=CC=CC=C1C(F)(F)F WFOVEDJTASPCIR-UHFFFAOYSA-N 0.000 description 1
- FVXBTPGZQMNAEZ-UHFFFAOYSA-N 3-amino-2-methylpropan-1-ol Chemical compound NCC(C)CO FVXBTPGZQMNAEZ-UHFFFAOYSA-N 0.000 description 1
- GYOZYIRJPFGMJI-UHFFFAOYSA-N 3-aminoazetidine-1,3-dicarboxylic acid Chemical compound OC(=O)C1(N)CN(C(O)=O)C1 GYOZYIRJPFGMJI-UHFFFAOYSA-N 0.000 description 1
- XUMSHCRPQCZRGX-UHFFFAOYSA-N 3-aminocyclobutan-1-ol;hydrochloride Chemical compound Cl.NC1CC(O)C1 XUMSHCRPQCZRGX-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- DXFXNSNBZNELII-UHFFFAOYSA-N 3-chloro-4-fluorobenzenesulfonyl chloride Chemical compound FC1=CC=C(S(Cl)(=O)=O)C=C1Cl DXFXNSNBZNELII-UHFFFAOYSA-N 0.000 description 1
- CRYPJUOSZDQWJZ-UHFFFAOYSA-N 3-chloro-4-hydroxybenzonitrile Chemical compound OC1=CC=C(C#N)C=C1Cl CRYPJUOSZDQWJZ-UHFFFAOYSA-N 0.000 description 1
- SGHBRHKBCLLVCI-UHFFFAOYSA-N 3-hydroxybenzonitrile Chemical compound OC1=CC=CC(C#N)=C1 SGHBRHKBCLLVCI-UHFFFAOYSA-N 0.000 description 1
- GSBRXQPKHYLOCC-UHFFFAOYSA-N 3-methylazetidine-1,3-dicarboxylic acid Chemical compound OC(=O)C1(C)CN(C(O)=O)C1 GSBRXQPKHYLOCC-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- WYFCZWSWFGJODV-MIANJLSGSA-N 4-[[(1s)-2-[(e)-3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro-1h-isoquinoline-1-carbonyl]amino]benzoic acid Chemical compound O=C1CN(C)CCN1C1=CC=CC2=C1CCN(C(=O)\C=C\C=1C(=CC=C(Cl)C=1F)N1N=NN=C1)[C@@H]2C(=O)NC1=CC=C(C(O)=O)C=C1 WYFCZWSWFGJODV-MIANJLSGSA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- NAXUFNXWXFZVSI-UHFFFAOYSA-N 4-aminobutan-2-ol Chemical compound CC(O)CCN NAXUFNXWXFZVSI-UHFFFAOYSA-N 0.000 description 1
- RKTQEVMZBCBOSB-UHFFFAOYSA-N 4-aminocyclohexan-1-ol;hydron;chloride Chemical compound Cl.NC1CCC(O)CC1 RKTQEVMZBCBOSB-UHFFFAOYSA-N 0.000 description 1
- QISOBCMNUJQOJU-UHFFFAOYSA-N 4-bromo-1h-pyrazole-5-carboxylic acid Chemical compound OC(=O)C=1NN=CC=1Br QISOBCMNUJQOJU-UHFFFAOYSA-N 0.000 description 1
- UJNSAHMCGIKGLS-UHFFFAOYSA-N 4-chloro-2-cyanobenzenesulfonyl chloride Chemical compound ClC1=CC=C(S(Cl)(=O)=O)C(C#N)=C1 UJNSAHMCGIKGLS-UHFFFAOYSA-N 0.000 description 1
- ZFZRENUEJCOCRE-UHFFFAOYSA-N 4-chloro-2-fluorobenzenesulfonyl chloride Chemical compound FC1=CC(Cl)=CC=C1S(Cl)(=O)=O ZFZRENUEJCOCRE-UHFFFAOYSA-N 0.000 description 1
- DTMRZJATPXTPSM-UHFFFAOYSA-N 4-chloro-2-methylbenzenesulfonyl chloride Chemical compound CC1=CC(Cl)=CC=C1S(Cl)(=O)=O DTMRZJATPXTPSM-UHFFFAOYSA-N 0.000 description 1
- ZLYBFBAHAQEEQQ-UHFFFAOYSA-N 4-chlorobenzenesulfonyl chloride Chemical compound ClC1=CC=C(S(Cl)(=O)=O)C=C1 ZLYBFBAHAQEEQQ-UHFFFAOYSA-N 0.000 description 1
- VLUSOMHSAVNNLL-UHFFFAOYSA-N 4-cyano-2-methylbenzenesulfonyl chloride Chemical compound CC1=CC(C#N)=CC=C1S(Cl)(=O)=O VLUSOMHSAVNNLL-UHFFFAOYSA-N 0.000 description 1
- XLPGWKNCWMFHOD-UHFFFAOYSA-N 4-fluoro-2-methylbenzenesulfonyl chloride Chemical compound CC1=CC(F)=CC=C1S(Cl)(=O)=O XLPGWKNCWMFHOD-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 description 1
- GCNTZFIIOFTKIY-UHFFFAOYSA-N 4-hydroxypyridine Chemical compound OC1=CC=NC=C1 GCNTZFIIOFTKIY-UHFFFAOYSA-N 0.000 description 1
- TYJOQICPGZGYDT-UHFFFAOYSA-N 4-methylsulfonylbenzenesulfonyl chloride Chemical compound CS(=O)(=O)C1=CC=C(S(Cl)(=O)=O)C=C1 TYJOQICPGZGYDT-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 1
- 125000004608 5,6,7,8-tetrahydroquinolinyl group Chemical group N1=C(C=CC=2CCCCC12)* 0.000 description 1
- VKLKXFOZNHEBSW-UHFFFAOYSA-N 5-[[3-[(4-morpholin-4-ylbenzoyl)amino]phenyl]methoxy]pyridine-3-carboxamide Chemical compound O1CCN(CC1)C1=CC=C(C(=O)NC=2C=C(COC=3C=NC=C(C(=O)N)C=3)C=CC=2)C=C1 VKLKXFOZNHEBSW-UHFFFAOYSA-N 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 description 1
- RSIWALKZYXPAGW-NSHDSACASA-N 6-(3-fluorophenyl)-3-methyl-7-[(1s)-1-(7h-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)N=C2SC=C(C)N2C(=O)C=1C1=CC=CC(F)=C1 RSIWALKZYXPAGW-NSHDSACASA-N 0.000 description 1
- AMEMLELAMQEAIA-UHFFFAOYSA-N 6-(tert-butyl)thieno[3,2-d]pyrimidin-4(3H)-one Chemical compound N1C=NC(=O)C2=C1C=C(C(C)(C)C)S2 AMEMLELAMQEAIA-UHFFFAOYSA-N 0.000 description 1
- NSGLNIQAWVNZFB-UHFFFAOYSA-N 6-(trifluoromethyl)pyridine-3-sulfonyl chloride Chemical compound FC(F)(F)C1=CC=C(S(Cl)(=O)=O)C=N1 NSGLNIQAWVNZFB-UHFFFAOYSA-N 0.000 description 1
- GDUANFXPOZTYKS-UHFFFAOYSA-N 6-bromo-8-[(2,6-difluoro-4-methoxybenzoyl)amino]-4-oxochromene-2-carboxylic acid Chemical compound FC1=CC(OC)=CC(F)=C1C(=O)NC1=CC(Br)=CC2=C1OC(C(O)=O)=CC2=O GDUANFXPOZTYKS-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- XASOHFCUIQARJT-UHFFFAOYSA-N 8-methoxy-6-[7-(2-morpholin-4-ylethoxy)imidazo[1,2-a]pyridin-3-yl]-2-(2,2,2-trifluoroethyl)-3,4-dihydroisoquinolin-1-one Chemical compound C(N1C(=O)C2=C(OC)C=C(C=3N4C(=NC=3)C=C(C=C4)OCCN3CCOCC3)C=C2CC1)C(F)(F)F XASOHFCUIQARJT-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 101150096011 Adamts10 gene Proteins 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 244000144927 Aloe barbadensis Species 0.000 description 1
- 235000002961 Aloe barbadensis Nutrition 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N Aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- IYHHRZBKXXKDDY-UHFFFAOYSA-N BI-605906 Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(C(F)(F)CC)=CC=1N1CCC(S(C)(=O)=O)CC1 IYHHRZBKXXKDDY-UHFFFAOYSA-N 0.000 description 1
- KYNSBQPICQTCGU-UHFFFAOYSA-N Benzopyrane Chemical compound C1=CC=C2C=CCOC2=C1 KYNSBQPICQTCGU-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- LWTXZTGDYLUGFH-UHFFFAOYSA-N BrC1(CN(C1)C(=O)OC(C)(C)C)C(=O)OCC Chemical compound BrC1(CN(C1)C(=O)OC(C)(C)C)C(=O)OCC LWTXZTGDYLUGFH-UHFFFAOYSA-N 0.000 description 1
- ZKYCVBNXTJDMRJ-UHFFFAOYSA-N BrC1=C(C=CC(=C1)OC(F)(F)F)S(=O)(=O)N1CC(C1)(CO)COC1=CC(=C(C#N)C=C1)F Chemical compound BrC1=C(C=CC(=C1)OC(F)(F)F)S(=O)(=O)N1CC(C1)(CO)COC1=CC(=C(C#N)C=C1)F ZKYCVBNXTJDMRJ-UHFFFAOYSA-N 0.000 description 1
- YNMDVXFCQKWKQG-UHFFFAOYSA-N BrC1=C(C=CC(=C1)OC)S(=O)(=O)N1CC(C1)(CO)COC1=CC(=C(C#N)C=C1)F Chemical compound BrC1=C(C=CC(=C1)OC)S(=O)(=O)N1CC(C1)(CO)COC1=CC(=C(C#N)C=C1)F YNMDVXFCQKWKQG-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 239000004358 Butane-1, 3-diol Substances 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- JRMDVRXVBOHKMB-UHFFFAOYSA-N C(#N)C1=C(C=C(OCC2(CN(C2)S(=O)(=O)C2=C(C=C(C=C2)Cl)Cl)C(=O)OCC)C=C1)F Chemical compound C(#N)C1=C(C=C(OCC2(CN(C2)S(=O)(=O)C2=C(C=C(C=C2)Cl)Cl)C(=O)OCC)C=C1)F JRMDVRXVBOHKMB-UHFFFAOYSA-N 0.000 description 1
- MGUZENMPVRSISK-UHFFFAOYSA-N C(#N)C1=C(C=C(OCC2(CN(C2)S(=O)(=O)C2=C(C=C(C=C2)Cl)Cl)CNC(C)=O)C=C1)F Chemical compound C(#N)C1=C(C=C(OCC2(CN(C2)S(=O)(=O)C2=C(C=C(C=C2)Cl)Cl)CNC(C)=O)C=C1)F MGUZENMPVRSISK-UHFFFAOYSA-N 0.000 description 1
- VMDZUXOWSBRPDD-UHFFFAOYSA-N C(#N)C1=C(C=C(OCC2(CN(C2)S(=O)(=O)C2=C(C=C(C=C2)Cl)Cl)CNC(CO)=O)C=C1)F Chemical compound C(#N)C1=C(C=C(OCC2(CN(C2)S(=O)(=O)C2=C(C=C(C=C2)Cl)Cl)CNC(CO)=O)C=C1)F VMDZUXOWSBRPDD-UHFFFAOYSA-N 0.000 description 1
- ZEKVNNIDXCFKNW-UHFFFAOYSA-N C(#N)C1=C(C=C(OCC2(CN(C2)S(=O)(=O)C2=C(C=C(C=C2)Cl)Cl)NC(C)=O)C=C1)F Chemical compound C(#N)C1=C(C=C(OCC2(CN(C2)S(=O)(=O)C2=C(C=C(C=C2)Cl)Cl)NC(C)=O)C=C1)F ZEKVNNIDXCFKNW-UHFFFAOYSA-N 0.000 description 1
- MMHFWMWZMCBTEZ-UHFFFAOYSA-N C(#N)C1=C(C=C(OCC2(CN(C2)S(=O)(=O)C2=C(C=C(C=C2)Cl)Cl)NC(CO)=O)C=C1)F Chemical compound C(#N)C1=C(C=C(OCC2(CN(C2)S(=O)(=O)C2=C(C=C(C=C2)Cl)Cl)NC(CO)=O)C=C1)F MMHFWMWZMCBTEZ-UHFFFAOYSA-N 0.000 description 1
- PKQGLEUORKDVHX-UHFFFAOYSA-N C(#N)C1=C(C=CC(=C1)C(F)(F)F)S(=O)(=O)N1CC(C1)(CO)COC1=CC(=C(C#N)C=C1)F Chemical compound C(#N)C1=C(C=CC(=C1)C(F)(F)F)S(=O)(=O)N1CC(C1)(CO)COC1=CC(=C(C#N)C=C1)F PKQGLEUORKDVHX-UHFFFAOYSA-N 0.000 description 1
- KEVKVNUJHLIJGM-UHFFFAOYSA-N C(#N)C1=C(C=CC(=C1)C)S(=O)(=O)N1CC(C1)(CO)COC1=CC(=C(C#N)C=C1)F Chemical compound C(#N)C1=C(C=CC(=C1)C)S(=O)(=O)N1CC(C1)(CO)COC1=CC(=C(C#N)C=C1)F KEVKVNUJHLIJGM-UHFFFAOYSA-N 0.000 description 1
- KDZAOJKNQHGQES-UHFFFAOYSA-N C(#N)C1=C(C=CC(=C1)C)S(=O)(=O)N1CC(C1)(CO)COC1=CC(=C(C#N)C=C1OC)F Chemical compound C(#N)C1=C(C=CC(=C1)C)S(=O)(=O)N1CC(C1)(CO)COC1=CC(=C(C#N)C=C1OC)F KDZAOJKNQHGQES-UHFFFAOYSA-N 0.000 description 1
- FAXKUWSMBLVALG-UHFFFAOYSA-N C(#N)C1=C(C=CC(=C1)F)S(=O)(=O)N1CC(C1)(CO)COC1=CC(=C(C#N)C=C1)F Chemical compound C(#N)C1=C(C=CC(=C1)F)S(=O)(=O)N1CC(C1)(CO)COC1=CC(=C(C#N)C=C1)F FAXKUWSMBLVALG-UHFFFAOYSA-N 0.000 description 1
- PJPJWGLTKLMLKG-UHFFFAOYSA-N C(#N)C1=C(C=CC(=C1)OC(F)(F)F)S(=O)(=O)N1CC(C1)(CO)COC1=CC(=C(C#N)C=C1)F Chemical compound C(#N)C1=C(C=CC(=C1)OC(F)(F)F)S(=O)(=O)N1CC(C1)(CO)COC1=CC(=C(C#N)C=C1)F PJPJWGLTKLMLKG-UHFFFAOYSA-N 0.000 description 1
- OROQXEWMYYZRLY-UHFFFAOYSA-N C(#N)C1=C(C=CC(=C1)OC)S(=O)(=O)N1CC(C1)(CO)COC1=CC(=C(C#N)C=C1)F Chemical compound C(#N)C1=C(C=CC(=C1)OC)S(=O)(=O)N1CC(C1)(CO)COC1=CC(=C(C#N)C=C1)F OROQXEWMYYZRLY-UHFFFAOYSA-N 0.000 description 1
- IMEJSNSJEREKPR-UHFFFAOYSA-N C(#N)C1=C(C=CC=C1)S(=O)(=O)N1CC(C1)(CNC1CCOCC1)COC1=CC(=C(C#N)C=C1)F Chemical compound C(#N)C1=C(C=CC=C1)S(=O)(=O)N1CC(C1)(CNC1CCOCC1)COC1=CC(=C(C#N)C=C1)F IMEJSNSJEREKPR-UHFFFAOYSA-N 0.000 description 1
- FAZYRTBLIKHVIA-UHFFFAOYSA-N C(#N)C1=C(C=CC=C1)S(=O)(=O)N1CC(C1)(CNC1COC1)COC1=CC(=C(C#N)C=C1)F Chemical compound C(#N)C1=C(C=CC=C1)S(=O)(=O)N1CC(C1)(CNC1COC1)COC1=CC(=C(C#N)C=C1)F FAZYRTBLIKHVIA-UHFFFAOYSA-N 0.000 description 1
- NEGPHXQHEIJPOG-UHFFFAOYSA-N C(#N)C1=C(C=CC=C1)S(=O)(=O)N1CC(C1)(CNCC(CO)O)COC1=CC(=C(C#N)C=C1)F Chemical compound C(#N)C1=C(C=CC=C1)S(=O)(=O)N1CC(C1)(CNCC(CO)O)COC1=CC(=C(C#N)C=C1)F NEGPHXQHEIJPOG-UHFFFAOYSA-N 0.000 description 1
- KHDXYSJTNUECFJ-INIZCTEOSA-N C(#N)C1=C(C=CC=C1)S(=O)(=O)N1CC(C1)(CNC[C@H](C)O)COC1=CC(=C(C#N)C=C1)F Chemical compound C(#N)C1=C(C=CC=C1)S(=O)(=O)N1CC(C1)(CNC[C@H](C)O)COC1=CC(=C(C#N)C=C1)F KHDXYSJTNUECFJ-INIZCTEOSA-N 0.000 description 1
- KQXVYBLWJMQXHT-MEMLXQNLSA-N C(#N)C1=C(C=CC=C1)S(=O)(=O)N1CC(C1)(CN[C@@H]1CC[C@H](CC1)O)COC1=CC(=C(C#N)C=C1)F Chemical compound C(#N)C1=C(C=CC=C1)S(=O)(=O)N1CC(C1)(CN[C@@H]1CC[C@H](CC1)O)COC1=CC(=C(C#N)C=C1)F KQXVYBLWJMQXHT-MEMLXQNLSA-N 0.000 description 1
- ZSNKZOHUNTVBNQ-WGSAOQKQSA-N C(#N)C1=C(C=CC=C1)S(=O)(=O)N1CC(C1)(CN[C@@H]1C[C@H](C1)O)COC1=CC(=C(C#N)C=C1)F Chemical compound C(#N)C1=C(C=CC=C1)S(=O)(=O)N1CC(C1)(CN[C@@H]1C[C@H](C1)O)COC1=CC(=C(C#N)C=C1)F ZSNKZOHUNTVBNQ-WGSAOQKQSA-N 0.000 description 1
- DCNQORNZJNTSEL-UHFFFAOYSA-N C(#N)C1=C(C=CC=C1)S(=O)(=O)N1CC(C1)(CO)COC1=CC(=C(C#N)C=C1OC)F Chemical compound C(#N)C1=C(C=CC=C1)S(=O)(=O)N1CC(C1)(CO)COC1=CC(=C(C#N)C=C1OC)F DCNQORNZJNTSEL-UHFFFAOYSA-N 0.000 description 1
- KFPMHLUYVUHMGU-UHFFFAOYSA-N C(#N)C1=CC=C(OCC2(CN(C2)C(=O)OC(C)(C)C)C)C=C1 Chemical compound C(#N)C1=CC=C(OCC2(CN(C2)C(=O)OC(C)(C)C)C)C=C1 KFPMHLUYVUHMGU-UHFFFAOYSA-N 0.000 description 1
- IMBGXSXWLMJUMQ-UHFFFAOYSA-N C(#N)C1=CC=C(OCC2(CN(C2)S(=O)(=O)C2=C(C=C(C=C2)Cl)Cl)C(=O)NC)C=C1 Chemical compound C(#N)C1=CC=C(OCC2(CN(C2)S(=O)(=O)C2=C(C=C(C=C2)Cl)Cl)C(=O)NC)C=C1 IMBGXSXWLMJUMQ-UHFFFAOYSA-N 0.000 description 1
- NVPLHARYLAVQFU-UHFFFAOYSA-N C(#N)CCNCC1(CN(C1)S(=O)(=O)C1=C(C=C(C=C1)Cl)Cl)COC1=CC(=C(C#N)C=C1)F Chemical compound C(#N)CCNCC1(CN(C1)S(=O)(=O)C1=C(C=C(C=C1)Cl)Cl)COC1=CC(=C(C#N)C=C1)F NVPLHARYLAVQFU-UHFFFAOYSA-N 0.000 description 1
- JQUCWIWWWKZNCS-LESHARBVSA-N C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F Chemical compound C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F JQUCWIWWWKZNCS-LESHARBVSA-N 0.000 description 1
- KMSGNZYFAOWFQE-UHFFFAOYSA-N C(C1=CC=CC=C1)OC(=O)NC1(CN(C1)C(=O)OC(C)(C)C)COC1=CC(=C(C=C1)C#N)F Chemical compound C(C1=CC=CC=C1)OC(=O)NC1(CN(C1)C(=O)OC(C)(C)C)COC1=CC(=C(C=C1)C#N)F KMSGNZYFAOWFQE-UHFFFAOYSA-N 0.000 description 1
- TYOXQOXOYUHKCJ-UHFFFAOYSA-N C1C(CN1S(=O)(=O)C2=C(C=C(C=C2)Cl)Cl)(CNCC(CO)O)COC3=CC(=C(C=C3)C#N)F.Cl Chemical compound C1C(CN1S(=O)(=O)C2=C(C=C(C=C2)Cl)Cl)(CNCC(CO)O)COC3=CC(=C(C=C3)C#N)F.Cl TYOXQOXOYUHKCJ-UHFFFAOYSA-N 0.000 description 1
- FCZUORUBOLXDRU-UHFFFAOYSA-N C1C(CN1S(=O)(=O)C2=C(C=C(C=C2)Cl)Cl)(CNCC3=NC=CS3)COC4=CC(=C(C=C4)C#N)F.Cl Chemical compound C1C(CN1S(=O)(=O)C2=C(C=C(C=C2)Cl)Cl)(CNCC3=NC=CS3)COC4=CC(=C(C=C4)C#N)F.Cl FCZUORUBOLXDRU-UHFFFAOYSA-N 0.000 description 1
- PFKBMSIIPUXPKE-UHFFFAOYSA-N C1C(CN1S(=O)(=O)C2=C(C=C(C=C2)Cl)Cl)(CNCCCO)COC3=CC(=C(C=C3)C#N)F.Cl Chemical compound C1C(CN1S(=O)(=O)C2=C(C=C(C=C2)Cl)Cl)(CNCCCO)COC3=CC(=C(C=C3)C#N)F.Cl PFKBMSIIPUXPKE-UHFFFAOYSA-N 0.000 description 1
- ODORIXBMSPPWFL-UHFFFAOYSA-N C1COCC1CNCC2(CN(C2)S(=O)(=O)C3=C(C=C(C=C3)Cl)Cl)COC4=CC(=C(C=C4)C#N)F.Cl Chemical compound C1COCC1CNCC2(CN(C2)S(=O)(=O)C3=C(C=C(C=C3)Cl)Cl)COC4=CC(=C(C=C4)C#N)F.Cl ODORIXBMSPPWFL-UHFFFAOYSA-N 0.000 description 1
- QSQXDMIQDLBDLR-UHFFFAOYSA-N C1COCCC1CNCC2(CN(C2)S(=O)(=O)C3=C(C=C(C=C3)Cl)Cl)COC4=CC(=C(C=C4)C#N)F.Cl Chemical compound C1COCCC1CNCC2(CN(C2)S(=O)(=O)C3=C(C=C(C=C3)Cl)Cl)COC4=CC(=C(C=C4)C#N)F.Cl QSQXDMIQDLBDLR-UHFFFAOYSA-N 0.000 description 1
- NXWXTOAXZRDNOR-UHFFFAOYSA-N C1COCCN1CC2(CN(C2)S(=O)(=O)C3=C(C=C(C=C3)Cl)Cl)COC4=CC(=C(C=C4)C#N)F.Cl Chemical compound C1COCCN1CC2(CN(C2)S(=O)(=O)C3=C(C=C(C=C3)Cl)Cl)COC4=CC(=C(C=C4)C#N)F.Cl NXWXTOAXZRDNOR-UHFFFAOYSA-N 0.000 description 1
- JQZQQZKYMVEHCF-FSRHSHDFSA-N C1C[C@@H](OC1)CNCC2(CN(C2)S(=O)(=O)C3=C(C=C(C=C3)Cl)Cl)COC4=CC(=C(C=C4)C#N)F.Cl Chemical compound C1C[C@@H](OC1)CNCC2(CN(C2)S(=O)(=O)C3=C(C=C(C=C3)Cl)Cl)COC4=CC(=C(C=C4)C#N)F.Cl JQZQQZKYMVEHCF-FSRHSHDFSA-N 0.000 description 1
- JQZQQZKYMVEHCF-FYZYNONXSA-N C1C[C@H](OC1)CNCC2(CN(C2)S(=O)(=O)C3=C(C=C(C=C3)Cl)Cl)COC4=CC(=C(C=C4)C#N)F.Cl Chemical compound C1C[C@H](OC1)CNCC2(CN(C2)S(=O)(=O)C3=C(C=C(C=C3)Cl)Cl)COC4=CC(=C(C=C4)C#N)F.Cl JQZQQZKYMVEHCF-FYZYNONXSA-N 0.000 description 1
- UWAKVUYNYVRSHW-UHFFFAOYSA-N CC(CCNCC1(CN(C1)S(=O)(=O)C2=C(C=C(C=C2)Cl)Cl)COC3=CC(=C(C=C3)C#N)F)O.Cl Chemical compound CC(CCNCC1(CN(C1)S(=O)(=O)C2=C(C=C(C=C2)Cl)Cl)COC3=CC(=C(C=C3)C#N)F)O.Cl UWAKVUYNYVRSHW-UHFFFAOYSA-N 0.000 description 1
- FCXTWXKCRMQBHA-UHFFFAOYSA-N CC(CNCC1(CN(C1)S(=O)(=O)C2=C(C=C(C=C2)Cl)Cl)COC3=CC(=C(C=C3)C#N)F)CO.Cl Chemical compound CC(CNCC1(CN(C1)S(=O)(=O)C2=C(C=C(C=C2)Cl)Cl)COC3=CC(=C(C=C3)C#N)F)CO.Cl FCXTWXKCRMQBHA-UHFFFAOYSA-N 0.000 description 1
- VRVDELJFDOBYNQ-UHFFFAOYSA-N CC(CNCC1(CN(C1)S(=O)(=O)C2=C(C=C(C=C2)Cl)Cl)COC3=CC(=C(C=C3)C#N)F)O.Cl Chemical compound CC(CNCC1(CN(C1)S(=O)(=O)C2=C(C=C(C=C2)Cl)Cl)COC3=CC(=C(C=C3)C#N)F)O.Cl VRVDELJFDOBYNQ-UHFFFAOYSA-N 0.000 description 1
- ARCBQZVQSPFOTG-UHFFFAOYSA-N CC(CO)NCC1(CN(C1)S(=O)(=O)C2=C(C=C(C=C2)Cl)Cl)COC3=CC(=C(C=C3)C#N)F.Cl Chemical compound CC(CO)NCC1(CN(C1)S(=O)(=O)C2=C(C=C(C=C2)Cl)Cl)COC3=CC(=C(C=C3)C#N)F.Cl ARCBQZVQSPFOTG-UHFFFAOYSA-N 0.000 description 1
- QVDWBKNJGQDXQX-UHFFFAOYSA-N CC1(CNC1)COC1=CC=C(C#N)C=C1 Chemical compound CC1(CNC1)COC1=CC=C(C#N)C=C1 QVDWBKNJGQDXQX-UHFFFAOYSA-N 0.000 description 1
- OBRRKQKGRPXIKP-UHFFFAOYSA-N CC1=C(C=CC(=C1)C)S(=O)(=O)N1CC(C1)(CO)COC1=CC(=C(C#N)C=C1)F Chemical compound CC1=C(C=CC(=C1)C)S(=O)(=O)N1CC(C1)(CO)COC1=CC(=C(C#N)C=C1)F OBRRKQKGRPXIKP-UHFFFAOYSA-N 0.000 description 1
- LPQPPGJHKOCJAN-UHFFFAOYSA-N CC=1SC(=C(N=1)C)S(=O)(=O)N1CC(C1)(CO)COC1=CC(=C(C#N)C=C1)F Chemical compound CC=1SC(=C(N=1)C)S(=O)(=O)N1CC(C1)(CO)COC1=CC(=C(C#N)C=C1)F LPQPPGJHKOCJAN-UHFFFAOYSA-N 0.000 description 1
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 1
- ACTCJNGUVFNYMU-UHFFFAOYSA-N CN(CCO)CC1(CN(C1)S(=O)(=O)C2=C(C=C(C=C2)Cl)Cl)COC3=CC(=C(C=C3)C#N)F.Cl Chemical compound CN(CCO)CC1(CN(C1)S(=O)(=O)C2=C(C=C(C=C2)Cl)Cl)COC3=CC(=C(C=C3)C#N)F.Cl ACTCJNGUVFNYMU-UHFFFAOYSA-N 0.000 description 1
- IEXGWOUUZATITM-UHFFFAOYSA-N CN1N=C(C(=C1)S(=O)(=O)N1CC(C1)(CO)COC1=CC(=C(C#N)C=C1)F)C Chemical compound CN1N=C(C(=C1)S(=O)(=O)N1CC(C1)(CO)COC1=CC(=C(C#N)C=C1)F)C IEXGWOUUZATITM-UHFFFAOYSA-N 0.000 description 1
- KYVAICPQDAOPOE-UHFFFAOYSA-N CNCC1(CN(C1)S(=O)(=O)C2=C(C=C(C=C2)Cl)Cl)COC3=CC(=C(C=C3)C#N)F.Cl Chemical compound CNCC1(CN(C1)S(=O)(=O)C2=C(C=C(C=C2)Cl)Cl)COC3=CC(=C(C=C3)C#N)F.Cl KYVAICPQDAOPOE-UHFFFAOYSA-N 0.000 description 1
- PHYRENBFVYSBGD-UHFFFAOYSA-N COC1=C(C=C(C(=C1)C#N)F)OCC2(C[NH2+]C2)CO.C(=O)(C(F)(F)F)[O-] Chemical compound COC1=C(C=C(C(=C1)C#N)F)OCC2(C[NH2+]C2)CO.C(=O)(C(F)(F)F)[O-] PHYRENBFVYSBGD-UHFFFAOYSA-N 0.000 description 1
- VRVDELJFDOBYNQ-UQKRIMTDSA-N C[C@@H](CNCC1(CN(C1)S(=O)(=O)C2=C(C=C(C=C2)Cl)Cl)COC3=CC(=C(C=C3)C#N)F)O.Cl Chemical compound C[C@@H](CNCC1(CN(C1)S(=O)(=O)C2=C(C=C(C=C2)Cl)Cl)COC3=CC(=C(C=C3)C#N)F)O.Cl VRVDELJFDOBYNQ-UQKRIMTDSA-N 0.000 description 1
- PKMUHQIDVVOXHQ-HXUWFJFHSA-N C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O Chemical compound C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O PKMUHQIDVVOXHQ-HXUWFJFHSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229940122072 Carbonic anhydrase inhibitor Drugs 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 108091005462 Cation channels Proteins 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 description 1
- 201000008992 Charcot-Marie-Tooth disease type 1B Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- XEBKYOPRAVLSTO-UHFFFAOYSA-N ClC1=C(C(=CC=C1)Cl)S(=O)(=O)N1CC(C1)(CO)COC1=CC(=C(C#N)C=C1)F Chemical compound ClC1=C(C(=CC=C1)Cl)S(=O)(=O)N1CC(C1)(CO)COC1=CC(=C(C#N)C=C1)F XEBKYOPRAVLSTO-UHFFFAOYSA-N 0.000 description 1
- AFUNSOOOUYDCIY-UHFFFAOYSA-N ClC1=C(C=CC(=C1)C#N)S(=O)(=O)N1CC(C1)(CO)COC1=CC(=C(C#N)C=C1)F Chemical compound ClC1=C(C=CC(=C1)C#N)S(=O)(=O)N1CC(C1)(CO)COC1=CC(=C(C#N)C=C1)F AFUNSOOOUYDCIY-UHFFFAOYSA-N 0.000 description 1
- HEHKEJZAUNCQMJ-UHFFFAOYSA-N ClC1=C(C=CC(=C1)C(F)(F)F)S(=O)(=O)N1CC(C1)(CO)COC1=CC(=C(C#N)C=C1)F Chemical compound ClC1=C(C=CC(=C1)C(F)(F)F)S(=O)(=O)N1CC(C1)(CO)COC1=CC(=C(C#N)C=C1)F HEHKEJZAUNCQMJ-UHFFFAOYSA-N 0.000 description 1
- CSGRFHLVHVATBX-UHFFFAOYSA-N ClC1=C(C=CC(=C1)C)S(=O)(=O)N1CC(C1)(CO)COC1=CC(=C(C#N)C=C1)F Chemical compound ClC1=C(C=CC(=C1)C)S(=O)(=O)N1CC(C1)(CO)COC1=CC(=C(C#N)C=C1)F CSGRFHLVHVATBX-UHFFFAOYSA-N 0.000 description 1
- DXVFEGKTJBVVAP-UHFFFAOYSA-N ClC1=C(C=CC(=C1)Cl)S(=O)(=O)N1CC(C1)(C)COC1=CC=C(C#N)C=C1 Chemical compound ClC1=C(C=CC(=C1)Cl)S(=O)(=O)N1CC(C1)(C)COC1=CC=C(C#N)C=C1 DXVFEGKTJBVVAP-UHFFFAOYSA-N 0.000 description 1
- RAXLNRGJQDGZNE-UHFFFAOYSA-N ClC1=C(C=CC(=C1)Cl)S(=O)(=O)N1CC(C1)(CNC1COC1)COC1=CC(=C(C#N)C=C1)F Chemical compound ClC1=C(C=CC(=C1)Cl)S(=O)(=O)N1CC(C1)(CNC1COC1)COC1=CC(=C(C#N)C=C1)F RAXLNRGJQDGZNE-UHFFFAOYSA-N 0.000 description 1
- CYGHDPXEHUPBHJ-UHFFFAOYSA-N ClC1=C(C=CC(=C1)Cl)S(=O)(=O)N1CC(C1)(CNCC1COC1)COC1=CC(=C(C#N)C=C1)F Chemical compound ClC1=C(C=CC(=C1)Cl)S(=O)(=O)N1CC(C1)(CNCC1COC1)COC1=CC(=C(C#N)C=C1)F CYGHDPXEHUPBHJ-UHFFFAOYSA-N 0.000 description 1
- WQUZOXNMFMUCIA-UHFFFAOYSA-N ClC1=C(C=CC(=C1)Cl)S(=O)(=O)N1CC(C1)(CO)CNC1=CC(=C(C#N)C=C1)F Chemical compound ClC1=C(C=CC(=C1)Cl)S(=O)(=O)N1CC(C1)(CO)CNC1=CC(=C(C#N)C=C1)F WQUZOXNMFMUCIA-UHFFFAOYSA-N 0.000 description 1
- FLFQAZPRNYFEAK-UHFFFAOYSA-N ClC1=C(C=CC(=C1)Cl)S(=O)(=O)N1CC(C1)(CO)COC1=C(C=C(C#N)C=C1)OC Chemical compound ClC1=C(C=CC(=C1)Cl)S(=O)(=O)N1CC(C1)(CO)COC1=C(C=C(C#N)C=C1)OC FLFQAZPRNYFEAK-UHFFFAOYSA-N 0.000 description 1
- PITWXXNLKRPGLH-UHFFFAOYSA-N ClC1=C(C=CC(=C1)Cl)S(=O)(=O)N1CC(C1)(CO)COC1=CC(=C(C#N)C=C1OC)F Chemical compound ClC1=C(C=CC(=C1)Cl)S(=O)(=O)N1CC(C1)(CO)COC1=CC(=C(C#N)C=C1OC)F PITWXXNLKRPGLH-UHFFFAOYSA-N 0.000 description 1
- BXEPTESBINUIGE-UHFFFAOYSA-N ClC1=C(C=CC(=C1)Cl)S(=O)(=O)N1CC(C1)(CO)COC1=CC=C(C#N)C=C1 Chemical compound ClC1=C(C=CC(=C1)Cl)S(=O)(=O)N1CC(C1)(CO)COC1=CC=C(C#N)C=C1 BXEPTESBINUIGE-UHFFFAOYSA-N 0.000 description 1
- FCKQWZGXUHYZRT-UHFFFAOYSA-N ClC1=C(C=CC(=C1)Cl)S(=O)(=O)N1CC(C1)(CO)COC=1C=C(C#N)C=CC=1 Chemical compound ClC1=C(C=CC(=C1)Cl)S(=O)(=O)N1CC(C1)(CO)COC=1C=C(C#N)C=CC=1 FCKQWZGXUHYZRT-UHFFFAOYSA-N 0.000 description 1
- LOQVAWPBQQKQSM-UHFFFAOYSA-N ClC1=C(C=CC(=C1)Cl)S(=O)(=O)N1CC(C1)(COC)COC1=CC(=C(C#N)C=C1)F Chemical compound ClC1=C(C=CC(=C1)Cl)S(=O)(=O)N1CC(C1)(COC)COC1=CC(=C(C#N)C=C1)F LOQVAWPBQQKQSM-UHFFFAOYSA-N 0.000 description 1
- RJSDMWYMIAZSMH-UHFFFAOYSA-N ClC1=C(C=CC(=C1)Cl)S(=O)(=O)N1CC(C1)(COC1=CC(=C(C=C1)F)F)CO Chemical compound ClC1=C(C=CC(=C1)Cl)S(=O)(=O)N1CC(C1)(COC1=CC(=C(C=C1)F)F)CO RJSDMWYMIAZSMH-UHFFFAOYSA-N 0.000 description 1
- JXNAPHMAPVPAJE-UHFFFAOYSA-N ClC1=C(C=CC(=C1)Cl)S(=O)(=O)N1CC(C1)(COC1=CC(=NC=C1)C)CO Chemical compound ClC1=C(C=CC(=C1)Cl)S(=O)(=O)N1CC(C1)(COC1=CC(=NC=C1)C)CO JXNAPHMAPVPAJE-UHFFFAOYSA-N 0.000 description 1
- IWMVIYDTGDYZNY-UHFFFAOYSA-N ClC1=C(C=CC(=C1)Cl)S(=O)(=O)N1CC(C1)(COC1=CC=C(C=C1)C)CO Chemical compound ClC1=C(C=CC(=C1)Cl)S(=O)(=O)N1CC(C1)(COC1=CC=C(C=C1)C)CO IWMVIYDTGDYZNY-UHFFFAOYSA-N 0.000 description 1
- KEXHIJMEFFEDOF-UHFFFAOYSA-N ClC1=C(C=CC(=C1)Cl)S(=O)(=O)N1CC(C1)(COC1=CC=NC=C1)CO Chemical compound ClC1=C(C=CC(=C1)Cl)S(=O)(=O)N1CC(C1)(COC1=CC=NC=C1)CO KEXHIJMEFFEDOF-UHFFFAOYSA-N 0.000 description 1
- BLXYNNFRIODOHH-UHFFFAOYSA-N ClC1=C(C=CC(=C1)Cl)S(=O)(=O)N1CC(C1)(COC=1C=C(C=CC=1)C)CO Chemical compound ClC1=C(C=CC(=C1)Cl)S(=O)(=O)N1CC(C1)(COC=1C=C(C=CC=1)C)CO BLXYNNFRIODOHH-UHFFFAOYSA-N 0.000 description 1
- AWAVJLRNCZSJQN-UHFFFAOYSA-N ClC1=C(C=CC(=C1)Cl)S(=O)(=O)N1CC(C1)(COC=1C=NC=CC=1)CO Chemical compound ClC1=C(C=CC(=C1)Cl)S(=O)(=O)N1CC(C1)(COC=1C=NC=CC=1)CO AWAVJLRNCZSJQN-UHFFFAOYSA-N 0.000 description 1
- IAKXBWXEQUJRRH-UHFFFAOYSA-N ClC1=C(C=CC(=C1)Cl)S(=O)(=O)N1CC(C1)(N(C)C)COC1=CC(=C(C#N)C=C1)F Chemical compound ClC1=C(C=CC(=C1)Cl)S(=O)(=O)N1CC(C1)(N(C)C)COC1=CC(=C(C#N)C=C1)F IAKXBWXEQUJRRH-UHFFFAOYSA-N 0.000 description 1
- UFKUNMSMNAXAIA-UHFFFAOYSA-N ClC1=C(C=CC(=C1)OC)S(=O)(=O)N1CC(C1)(CO)COC1=CC(=C(C#N)C=C1)F Chemical compound ClC1=C(C=CC(=C1)OC)S(=O)(=O)N1CC(C1)(CO)COC1=CC(=C(C#N)C=C1)F UFKUNMSMNAXAIA-UHFFFAOYSA-N 0.000 description 1
- IDEBQUDYDYDXDK-UHFFFAOYSA-N ClC1=C(C=CC=C1)S(=O)(=O)N1CC(C1)(CO)COC1=CC(=C(C#N)C=C1)F Chemical compound ClC1=C(C=CC=C1)S(=O)(=O)N1CC(C1)(CO)COC1=CC(=C(C#N)C=C1)F IDEBQUDYDYDXDK-UHFFFAOYSA-N 0.000 description 1
- KCXOLJOSCKBEAU-UHFFFAOYSA-N ClC1=CC(=C(C=C1)S(=O)(=O)N1CC(C1)(CO)COC1=CC(=C(C#N)C=C1)F)C Chemical compound ClC1=CC(=C(C=C1)S(=O)(=O)N1CC(C1)(CO)COC1=CC(=C(C#N)C=C1)F)C KCXOLJOSCKBEAU-UHFFFAOYSA-N 0.000 description 1
- HBLQWRGOKJPHJT-UHFFFAOYSA-N ClC1=CC(=C(C=C1)S(=O)(=O)N1CC(C1)(CO)COC1=CC(=C(C#N)C=C1)F)C#N Chemical compound ClC1=CC(=C(C=C1)S(=O)(=O)N1CC(C1)(CO)COC1=CC(=C(C#N)C=C1)F)C#N HBLQWRGOKJPHJT-UHFFFAOYSA-N 0.000 description 1
- BXZGMZQDFJUOFC-UHFFFAOYSA-N ClC1=CC(=C(C=C1)S(=O)(=O)N1CC(C1)(CO)COC1=CC(=C(C#N)C=C1)F)F Chemical compound ClC1=CC(=C(C=C1)S(=O)(=O)N1CC(C1)(CO)COC1=CC(=C(C#N)C=C1)F)F BXZGMZQDFJUOFC-UHFFFAOYSA-N 0.000 description 1
- MOQRCVMSFXVIIA-UHFFFAOYSA-N ClC1=CC=C(C=C1)S(=O)(=O)N1CC(C1)(CO)COC1=CC(=C(C#N)C=C1)F Chemical compound ClC1=CC=C(C=C1)S(=O)(=O)N1CC(C1)(CO)COC1=CC(=C(C#N)C=C1)F MOQRCVMSFXVIIA-UHFFFAOYSA-N 0.000 description 1
- BTKWWOYVOKYTMK-UHFFFAOYSA-N ClC1=NC=CC(=C1)OCC1(CN(C1)S(=O)(=O)C1=C(C=C(C=C1)Cl)Cl)CO Chemical compound ClC1=NC=CC(=C1)OCC1(CN(C1)S(=O)(=O)C1=C(C=C(C=C1)Cl)Cl)CO BTKWWOYVOKYTMK-UHFFFAOYSA-N 0.000 description 1
- MDTAUTLSRQAHQZ-UHFFFAOYSA-N ClC1=NC=CC=C1S(=O)(=O)N1CC(C1)(CO)COC1=CC(=C(C#N)C=C1)F Chemical compound ClC1=NC=CC=C1S(=O)(=O)N1CC(C1)(CO)COC1=CC(=C(C#N)C=C1)F MDTAUTLSRQAHQZ-UHFFFAOYSA-N 0.000 description 1
- DBDRBTPAMLGHAW-UHFFFAOYSA-N ClC=1C=C(C#N)C=CC=1OCC1(CN(C1)S(=O)(=O)C1=C(C=C(C=C1)Cl)Cl)CO Chemical compound ClC=1C=C(C#N)C=CC=1OCC1(CN(C1)S(=O)(=O)C1=C(C=C(C=C1)Cl)Cl)CO DBDRBTPAMLGHAW-UHFFFAOYSA-N 0.000 description 1
- REPAEFQGPYFVIO-UHFFFAOYSA-N ClC=1C=C(C=CC=1Cl)S(=O)(=O)N1CC(C1)(CO)COC1=CC(=C(C#N)C=C1)F Chemical compound ClC=1C=C(C=CC=1Cl)S(=O)(=O)N1CC(C1)(CO)COC1=CC(=C(C#N)C=C1)F REPAEFQGPYFVIO-UHFFFAOYSA-N 0.000 description 1
- SAFKHKVAVHVEAB-UHFFFAOYSA-N ClC=1C=C(C=CC=1F)S(=O)(=O)N1CC(C1)(CO)COC1=CC(=C(C#N)C=C1)F Chemical compound ClC=1C=C(C=CC=1F)S(=O)(=O)N1CC(C1)(CO)COC1=CC(=C(C#N)C=C1)F SAFKHKVAVHVEAB-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229940126639 Compound 33 Drugs 0.000 description 1
- 229940127007 Compound 39 Drugs 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 208000026292 Cystic Kidney disease Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 206010012559 Developmental delay Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 208000014094 Dystonic disease Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- JFSBASSFMQPKBY-UHFFFAOYSA-N FC(F)(F)Oc1ccc(c(c1)C#N)S(Cl)(=O)=O Chemical compound FC(F)(F)Oc1ccc(c(c1)C#N)S(Cl)(=O)=O JFSBASSFMQPKBY-UHFFFAOYSA-N 0.000 description 1
- KIOSGKMULVXTIX-UHFFFAOYSA-N FC1=C(C#N)C=CC(=C1)OCC1(CN(C1)S(=O)(=O)C1=C(C=C(C=C1)F)C)CO Chemical compound FC1=C(C#N)C=CC(=C1)OCC1(CN(C1)S(=O)(=O)C1=C(C=C(C=C1)F)C)CO KIOSGKMULVXTIX-UHFFFAOYSA-N 0.000 description 1
- LLBXZVKTQYRBTA-UHFFFAOYSA-N FC1=C(C#N)C=CC(=C1)OCC1(CN(C1)S(=O)(=O)C1=C(C=CC=C1)C)CO Chemical compound FC1=C(C#N)C=CC(=C1)OCC1(CN(C1)S(=O)(=O)C1=C(C=CC=C1)C)CO LLBXZVKTQYRBTA-UHFFFAOYSA-N 0.000 description 1
- XRMOCNRTLBNYMW-UHFFFAOYSA-N FC1=C(C#N)C=CC(=C1)OCC1(CN(C1)S(=O)(=O)C1=CC(=CC=C1)C(F)(F)F)CO Chemical compound FC1=C(C#N)C=CC(=C1)OCC1(CN(C1)S(=O)(=O)C1=CC(=CC=C1)C(F)(F)F)CO XRMOCNRTLBNYMW-UHFFFAOYSA-N 0.000 description 1
- YPLSYJUGKHPZIG-UHFFFAOYSA-N FC1=C(C#N)C=CC(=C1)OCC1(CN(C1)S(=O)(=O)C1=CC=C(C)C=C1)CO Chemical compound FC1=C(C#N)C=CC(=C1)OCC1(CN(C1)S(=O)(=O)C1=CC=C(C)C=C1)CO YPLSYJUGKHPZIG-UHFFFAOYSA-N 0.000 description 1
- ZDUOVMKVGWVFHT-UHFFFAOYSA-N FC1=C(C#N)C=CC(=C1)OCC1(CN(C1)S(=O)(=O)C1=CC=C(C=C1)S(=O)(=O)C)CO Chemical compound FC1=C(C#N)C=CC(=C1)OCC1(CN(C1)S(=O)(=O)C1=CC=C(C=C1)S(=O)(=O)C)CO ZDUOVMKVGWVFHT-UHFFFAOYSA-N 0.000 description 1
- HVWHZFJHVFLNOD-UHFFFAOYSA-N FC1=C(C#N)C=CC(=C1)OCC1(CN(C1)S(=O)(=O)C1=CC=CC=C1)CO Chemical compound FC1=C(C#N)C=CC(=C1)OCC1(CN(C1)S(=O)(=O)C1=CC=CC=C1)CO HVWHZFJHVFLNOD-UHFFFAOYSA-N 0.000 description 1
- RMPAHLPPIRCMJL-UHFFFAOYSA-N FC1=C(C#N)C=CC(=C1)OCC1(CN(C1)S(=O)(=O)C=1C=NC(=CC=1)C(F)(F)F)CO Chemical compound FC1=C(C#N)C=CC(=C1)OCC1(CN(C1)S(=O)(=O)C=1C=NC(=CC=1)C(F)(F)F)CO RMPAHLPPIRCMJL-UHFFFAOYSA-N 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- OUVXYXNWSVIOSJ-UHFFFAOYSA-N Fluo-4 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(F)C(=O)C=C3OC3=CC(O)=C(F)C=C32)N(CC(O)=O)CC(O)=O)=C1 OUVXYXNWSVIOSJ-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- CMBYOWLFQAFZCP-UHFFFAOYSA-N Hexyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCCCCC CMBYOWLFQAFZCP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 206010023644 Lacrimation increased Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 208000001344 Macular Edema Diseases 0.000 description 1
- 206010025415 Macular oedema Diseases 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 206010027940 Mood altered Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 210000005156 Müller Glia Anatomy 0.000 description 1
- ZNECVJPGVVNIMZ-UHFFFAOYSA-N N(=[N+]=[N-])C1(CN(C1)C(=O)OC(C)(C)C)C(=O)OCC Chemical compound N(=[N+]=[N-])C1(CN(C1)C(=O)OC(C)(C)C)C(=O)OCC ZNECVJPGVVNIMZ-UHFFFAOYSA-N 0.000 description 1
- CFEXEHUPMCFDJZ-UHFFFAOYSA-N N(=[N+]=[N-])CC1(CN(C1)S(=O)(=O)C1=C(C=C(C=C1)Cl)Cl)COC1=CC(=C(C#N)C=C1)F Chemical compound N(=[N+]=[N-])CC1(CN(C1)S(=O)(=O)C1=C(C=C(C=C1)Cl)Cl)COC1=CC(=C(C#N)C=C1)F CFEXEHUPMCFDJZ-UHFFFAOYSA-N 0.000 description 1
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- AVYVHIKSFXVDBG-UHFFFAOYSA-N N-benzyl-N-hydroxy-2,2-dimethylbutanamide Chemical compound C(C1=CC=CC=C1)N(C(C(CC)(C)C)=O)O AVYVHIKSFXVDBG-UHFFFAOYSA-N 0.000 description 1
- POFVJRKJJBFPII-UHFFFAOYSA-N N-cyclopentyl-5-[2-[[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]amino]-5-fluoropyrimidin-4-yl]-4-methyl-1,3-thiazol-2-amine Chemical compound C1(CCCC1)NC=1SC(=C(N=1)C)C1=NC(=NC=C1F)NC1=NC=C(C=C1)CN1CCN(CC1)CC POFVJRKJJBFPII-UHFFFAOYSA-N 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- QOYFVEHSTTZSNY-UHFFFAOYSA-N NCC1=C(C=C(OCC2(CN(C2)S(=O)(=O)C2=C(C=C(C=C2)Cl)Cl)CO)C=C1)F Chemical compound NCC1=C(C=C(OCC2(CN(C2)S(=O)(=O)C2=C(C=C(C=C2)Cl)Cl)CO)C=C1)F QOYFVEHSTTZSNY-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 206010056677 Nerve degeneration Diseases 0.000 description 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- SUHOOTKUPISOBE-UHFFFAOYSA-N O-phosphoethanolamine Chemical compound NCCOP(O)(O)=O SUHOOTKUPISOBE-UHFFFAOYSA-N 0.000 description 1
- JVRPNIPRPPBYEK-UHFFFAOYSA-N OC(=O)N1CC(C(O)=O)(C(O)=O)C1 Chemical compound OC(=O)N1CC(C(O)=O)(C(O)=O)C1 JVRPNIPRPPBYEK-UHFFFAOYSA-N 0.000 description 1
- 206010052143 Ocular discomfort Diseases 0.000 description 1
- 208000021957 Ocular injury Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000004146 Propane-1,2-diol Substances 0.000 description 1
- WUGQZFFCHPXWKQ-UHFFFAOYSA-N Propanolamine Chemical compound NCCCO WUGQZFFCHPXWKQ-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 206010038423 Renal cyst Diseases 0.000 description 1
- 206010038848 Retinal detachment Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 1
- 241000220010 Rhode Species 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 206010040030 Sensory loss Diseases 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 208000027073 Stargardt disease Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 108060008646 TRPA Proteins 0.000 description 1
- 108010037150 Transient Receptor Potential Channels Proteins 0.000 description 1
- 102000011753 Transient Receptor Potential Channels Human genes 0.000 description 1
- BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 description 1
- 241000223104 Trypanosoma Species 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000024967 X-linked recessive disease Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- TUXSUKLRDNJDOR-NUBCRITNSA-N [(2R)-oxolan-2-yl]methanamine hydrochloride Chemical compound Cl.NC[C@H]1CCCO1 TUXSUKLRDNJDOR-NUBCRITNSA-N 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 1
- GANNOFFDYMSBSZ-UHFFFAOYSA-N [AlH3].[Mg] Chemical class [AlH3].[Mg] GANNOFFDYMSBSZ-UHFFFAOYSA-N 0.000 description 1
- FXAZHUQRDDWVOE-UHFFFAOYSA-N [Si](C)(C)(C(C)(C)C)OCC1(CN(C1)C(=O)OC(C)(C)C)C(=O)OCC Chemical compound [Si](C)(C)(C(C)(C)C)OCC1(CN(C1)C(=O)OC(C)(C)C)C(=O)OCC FXAZHUQRDDWVOE-UHFFFAOYSA-N 0.000 description 1
- YAFXBQPRLYHIOZ-UHFFFAOYSA-N [Si](C)(C)(C(C)(C)C)OCC1(CN(C1)S(=O)(=O)C1=C(C=C(C=C1)Cl)Cl)CNC1=CC(=C(C#N)C=C1)F Chemical compound [Si](C)(C)(C(C)(C)C)OCC1(CN(C1)S(=O)(=O)C1=C(C=C(C=C1)Cl)Cl)CNC1=CC(=C(C#N)C=C1)F YAFXBQPRLYHIOZ-UHFFFAOYSA-N 0.000 description 1
- QNMQOGKHYNCQGD-UHFFFAOYSA-N [Si](C)(C)(C(C)(C)C)OCC1(CN(C1)S(=O)(=O)C1=C(C=C(C=C1)Cl)Cl)CO Chemical compound [Si](C)(C)(C(C)(C)C)OCC1(CN(C1)S(=O)(=O)C1=C(C=C(C=C1)Cl)Cl)CO QNMQOGKHYNCQGD-UHFFFAOYSA-N 0.000 description 1
- ZMUJBSWJQNACNF-UHFFFAOYSA-N [Si](C)(C)(C(C)(C)C)OCC1(CN(C1)S(=O)(=O)C1=C(C=C(C=C1)Cl)Cl)COC1=CC(=C(C=C1)F)F Chemical compound [Si](C)(C)(C(C)(C)C)OCC1(CN(C1)S(=O)(=O)C1=C(C=C(C=C1)Cl)Cl)COC1=CC(=C(C=C1)F)F ZMUJBSWJQNACNF-UHFFFAOYSA-N 0.000 description 1
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- AXJDEHNQPMZKOS-UHFFFAOYSA-N acetylazanium;chloride Chemical compound [Cl-].CC([NH3+])=O AXJDEHNQPMZKOS-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 150000003973 alkyl amines Chemical group 0.000 description 1
- 150000005215 alkyl ethers Chemical group 0.000 description 1
- 125000005600 alkyl phosphonate group Chemical group 0.000 description 1
- 150000001343 alkyl silanes Chemical group 0.000 description 1
- 125000004688 alkyl sulfonyl alkyl group Chemical group 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- NWCHELUCVWSRRS-UHFFFAOYSA-N atrolactic acid Chemical compound OC(=O)C(O)(C)C1=CC=CC=C1 NWCHELUCVWSRRS-UHFFFAOYSA-N 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000008335 axon cargo transport Effects 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- KVVMXWRFYAGASO-UHFFFAOYSA-N azetidine-1-carboxylic acid Chemical compound OC(=O)N1CCC1 KVVMXWRFYAGASO-UHFFFAOYSA-N 0.000 description 1
- GETUVALQSXUKQD-UHFFFAOYSA-N azetidine-3,3-dicarboxylic acid Chemical compound OC(=O)C1(C(O)=O)CNC1 GETUVALQSXUKQD-UHFFFAOYSA-N 0.000 description 1
- VALZSZJVEFACEZ-UHFFFAOYSA-N azetidine-3-carboxamide Chemical compound NC(=O)C1CNC1 VALZSZJVEFACEZ-UHFFFAOYSA-N 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 201000007917 background diabetic retinopathy Diseases 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- NIAVNUYMOQONIY-UHFFFAOYSA-N benzyl carbamate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.NC(=O)OCC1=CC=CC=C1 NIAVNUYMOQONIY-UHFFFAOYSA-N 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- AGSPXMVUFBBBMO-UHFFFAOYSA-N beta-aminopropionitrile Chemical compound NCCC#N AGSPXMVUFBBBMO-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 230000008436 biogenesis Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 239000012455 biphasic mixture Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004155 blood-retinal barrier Anatomy 0.000 description 1
- 230000004378 blood-retinal barrier Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- DHAZIUXMHRHVMP-UHFFFAOYSA-N butyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCCCC DHAZIUXMHRHVMP-UHFFFAOYSA-N 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 230000001964 calcium overload Effects 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- HHTWOMMSBMNRKP-UHFFFAOYSA-N carvacrol Natural products CC(=C)C1=CC=C(C)C(O)=C1 HHTWOMMSBMNRKP-UHFFFAOYSA-N 0.000 description 1
- RECUKUPTGUEGMW-UHFFFAOYSA-N carvacrol Chemical compound CC(C)C1=CC=C(C)C(O)=C1 RECUKUPTGUEGMW-UHFFFAOYSA-N 0.000 description 1
- 235000007746 carvacrol Nutrition 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000029215 cell volume homeostasis Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229940074979 cetyl palmitate Drugs 0.000 description 1
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- JYWJULGYGOLCGW-UHFFFAOYSA-N chloromethyl chloroformate Chemical compound ClCOC(Cl)=O JYWJULGYGOLCGW-UHFFFAOYSA-N 0.000 description 1
- VZWXIQHBIQLMPN-UHFFFAOYSA-N chromane Chemical compound C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 description 1
- 210000004240 ciliary body Anatomy 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125877 compound 31 Drugs 0.000 description 1
- 229940125878 compound 36 Drugs 0.000 description 1
- 229940125807 compound 37 Drugs 0.000 description 1
- 229940127573 compound 38 Drugs 0.000 description 1
- 229940126540 compound 41 Drugs 0.000 description 1
- 229940125936 compound 42 Drugs 0.000 description 1
- 229940125844 compound 46 Drugs 0.000 description 1
- 229940127271 compound 49 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 229940126545 compound 53 Drugs 0.000 description 1
- 229940127113 compound 57 Drugs 0.000 description 1
- 229940125900 compound 59 Drugs 0.000 description 1
- 229940126179 compound 72 Drugs 0.000 description 1
- 230000009989 contractile response Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960005168 croscarmellose Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- WVIIMZNLDWSIRH-UHFFFAOYSA-N cyclohexylcyclohexane Chemical group C1CCCCC1C1CCCCC1 WVIIMZNLDWSIRH-UHFFFAOYSA-N 0.000 description 1
- 125000006547 cyclononyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000004452 decreased vision Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 230000036576 dermal application Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000005828 desilylation reaction Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 239000011903 deuterated solvents Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical class O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 description 1
- 125000005959 diazepanyl group Chemical group 0.000 description 1
- RCJVRSBWZCNNQT-UHFFFAOYSA-N dichloridooxygen Chemical compound ClOCl RCJVRSBWZCNNQT-UHFFFAOYSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- KGNAKGKJEBUHRV-UHFFFAOYSA-N diethyl 1-benzylazetidine-3,3-dicarboxylate Chemical compound C1C(C(=O)OCC)(C(=O)OCC)CN1CC1=CC=CC=C1 KGNAKGKJEBUHRV-UHFFFAOYSA-N 0.000 description 1
- ZRMCEVQIPPFZSA-UHFFFAOYSA-N diethyl azetidine-3,3-dicarboxylate Chemical compound CCOC(=O)C1(C(=O)OCC)CNC1 ZRMCEVQIPPFZSA-UHFFFAOYSA-N 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 229940028356 diethylene glycol monobutyl ether Drugs 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- MGHPNCMVUAKAIE-UHFFFAOYSA-N diphenylmethanamine Chemical compound C=1C=CC=CC=1C(N)C1=CC=CC=C1 MGHPNCMVUAKAIE-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- QQQMUBLXDAFBRH-UHFFFAOYSA-N dodecyl 2-hydroxypropanoate Chemical compound CCCCCCCCCCCCOC(=O)C(C)O QQQMUBLXDAFBRH-UHFFFAOYSA-N 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000011833 dog model Methods 0.000 description 1
- IAVUPMFITXYVAF-XPUUQOCRSA-N dorzolamide Chemical compound CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 IAVUPMFITXYVAF-XPUUQOCRSA-N 0.000 description 1
- 229960003933 dorzolamide Drugs 0.000 description 1
- OSRUSFPMRGDLAG-QMGYSKNISA-N dorzolamide hydrochloride Chemical compound [Cl-].CC[NH2+][C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 OSRUSFPMRGDLAG-QMGYSKNISA-N 0.000 description 1
- 229960002506 dorzolamide hydrochloride Drugs 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 208000010118 dystonia Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- ZCRZCMUDOWDGOB-UHFFFAOYSA-N ethanesulfonimidic acid Chemical compound CCS(N)(=O)=O ZCRZCMUDOWDGOB-UHFFFAOYSA-N 0.000 description 1
- GWNFQAKCJYEJEW-UHFFFAOYSA-N ethyl 3-[8-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]octanoylamino]benzoate Chemical compound CCOC(=O)C1=CC(NC(=O)CCCCCCCSC2=NN=C(CC3=NN(C)C(=O)C4=CC=CC=C34)N2C)=CC=C1 GWNFQAKCJYEJEW-UHFFFAOYSA-N 0.000 description 1
- RJCGNNHKSNIUAT-UHFFFAOYSA-N ethyl 3-aminopropanoate;hydron;chloride Chemical compound Cl.CCOC(=O)CCN RJCGNNHKSNIUAT-UHFFFAOYSA-N 0.000 description 1
- XMPYGISDPFZDMC-UHFFFAOYSA-N ethyl azetidine-3-carboxylate 2,2,2-trifluoroacetic acid Chemical compound FC(C(=O)O)(F)F.N1CC(C1)C(=O)OCC XMPYGISDPFZDMC-UHFFFAOYSA-N 0.000 description 1
- 229960004667 ethyl cellulose Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000000720 eyelash Anatomy 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000010304 firing Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 238000010575 fractional recrystallization Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000008369 fruit flavor Substances 0.000 description 1
- 229910000286 fullers earth Inorganic materials 0.000 description 1
- 229910021485 fumed silica Inorganic materials 0.000 description 1
- 208000022059 functional hyperemia Diseases 0.000 description 1
- VPSRLGDRGCKUTK-UHFFFAOYSA-N fura-2-acetoxymethyl ester Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=C(C)C=C1OCCOC(C(=C1)N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=CC2=C1OC(C=1OC(=CN=1)C(=O)OCOC(C)=O)=C2 VPSRLGDRGCKUTK-UHFFFAOYSA-N 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 1
- PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940100463 hexyl laurate Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 102000052408 human TRPA1 Human genes 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000002706 hydrostatic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 230000000544 hyperemic effect Effects 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000009540 indirect ophthalmoscopy Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000006759 inflammatory activation Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 102000030582 inositol polyphosphate 5-phosphatase Human genes 0.000 description 1
- 108060004006 inositol polyphosphate 5-phosphatase Proteins 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 230000003447 ipsilateral effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 239000001282 iso-butane Substances 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- WYXXLXHHWYNKJF-UHFFFAOYSA-N isocarvacrol Natural products CC(C)C1=CC=C(O)C(C)=C1 WYXXLXHHWYNKJF-UHFFFAOYSA-N 0.000 description 1
- 229940078545 isocetyl stearate Drugs 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940093629 isopropyl isostearate Drugs 0.000 description 1
- 229940033357 isopropyl laurate Drugs 0.000 description 1
- 229940074928 isopropyl myristate Drugs 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 229940075495 isopropyl palmitate Drugs 0.000 description 1
- 229940089456 isopropyl stearate Drugs 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000005969 isothiazolinyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000003041 laboratory chemical Substances 0.000 description 1
- 230000004317 lacrimation Effects 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- HTBVGZAVHBZXMS-UHFFFAOYSA-N lithium;tris[(2-methylpropan-2-yl)oxy]alumane Chemical compound [Li].[Al+3].CC(C)(C)[O-].CC(C)(C)[O-].CC(C)(C)[O-] HTBVGZAVHBZXMS-UHFFFAOYSA-N 0.000 description 1
- RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000010687 lubricating oil Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000010230 macular retinal edema Diseases 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- WNVARFWSYISQGK-UHFFFAOYSA-N methyl 3-chloro-4-chlorosulfonylbenzoate Chemical compound COC(=O)C1=CC=C(S(Cl)(=O)=O)C(Cl)=C1 WNVARFWSYISQGK-UHFFFAOYSA-N 0.000 description 1
- CZNGTXVOZOWWKM-UHFFFAOYSA-N methyl 4-bromobenzoate Chemical compound COC(=O)C1=CC=C(Br)C=C1 CZNGTXVOZOWWKM-UHFFFAOYSA-N 0.000 description 1
- MOFQDKOKODUZPK-UHFFFAOYSA-N methyl 4-chlorosulfonylbenzoate Chemical compound COC(=O)C1=CC=C(S(Cl)(=O)=O)C=C1 MOFQDKOKODUZPK-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 239000006082 mold release agent Substances 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 230000007510 mood change Effects 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940078812 myristyl myristate Drugs 0.000 description 1
- 229940078555 myristyl propionate Drugs 0.000 description 1
- PRVZYDDRMVHWOS-UHFFFAOYSA-N n'-benzhydrylethane-1,2-diamine Chemical compound C=1C=CC=CC=1C(NCCN)C1=CC=CC=C1 PRVZYDDRMVHWOS-UHFFFAOYSA-N 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- VQSRKMNBWMHJKY-YTEVENLXSA-N n-[3-[(4ar,7as)-2-amino-6-(5-fluoropyrimidin-2-yl)-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-7a-yl]-4-fluorophenyl]-5-methoxypyrazine-2-carboxamide Chemical compound C1=NC(OC)=CN=C1C(=O)NC1=CC=C(F)C([C@@]23[C@@H](CN(C2)C=2N=CC(F)=CN=2)CSC(N)=N3)=C1 VQSRKMNBWMHJKY-YTEVENLXSA-N 0.000 description 1
- YGBMCLDVRUGXOV-UHFFFAOYSA-N n-[6-[6-chloro-5-[(4-fluorophenyl)sulfonylamino]pyridin-3-yl]-1,3-benzothiazol-2-yl]acetamide Chemical compound C1=C2SC(NC(=O)C)=NC2=CC=C1C(C=1)=CN=C(Cl)C=1NS(=O)(=O)C1=CC=C(F)C=C1 YGBMCLDVRUGXOV-UHFFFAOYSA-N 0.000 description 1
- LILMKEPBJGENKO-UHFFFAOYSA-N n-benzhydryl-3-phenylpropan-1-amine Chemical compound C=1C=CC=CC=1CCCNC(C=1C=CC=CC=1)C1=CC=CC=C1 LILMKEPBJGENKO-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- LQVZUXUQGFIYEK-UHFFFAOYSA-N n-methyloxolan-3-amine Chemical compound CNC1CCOC1 LQVZUXUQGFIYEK-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-M naphthalene-1-sulfonate Chemical compound C1=CC=C2C(S(=O)(=O)[O-])=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-M 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000003959 neuroinflammation Effects 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 239000001272 nitrous oxide Substances 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- OXGBCSQEKCRCHN-UHFFFAOYSA-N octadecan-2-ol Chemical compound CCCCCCCCCCCCCCCCC(C)O OXGBCSQEKCRCHN-UHFFFAOYSA-N 0.000 description 1
- 229940060184 oil ingredients Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- IPBPLHNLRKRLPJ-UHFFFAOYSA-N oxan-4-ylmethanamine Chemical compound NCC1CCOCC1 IPBPLHNLRKRLPJ-UHFFFAOYSA-N 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003551 oxepanyl group Chemical group 0.000 description 1
- KTHZBRAXOLUNBN-UHFFFAOYSA-N oxetan-3-ylmethanamine Chemical compound NCC1COC1 KTHZBRAXOLUNBN-UHFFFAOYSA-N 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- JCGNDDUYTRNOFT-UHFFFAOYSA-N oxolane-2,4-dione Chemical compound O=C1COC(=O)C1 JCGNDDUYTRNOFT-UHFFFAOYSA-N 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 239000007967 peppermint flavor Substances 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000003916 phosphatidylinositol 3,4,5-trisphosphates Chemical class 0.000 description 1
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 208000003580 polydactyly Diseases 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 201000007914 proliferative diabetic retinopathy Diseases 0.000 description 1
- XEIOPEQGDSYOIH-MURFETPASA-N propan-2-yl (9z,12z)-octadeca-9,12-dienoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC(C)C XEIOPEQGDSYOIH-MURFETPASA-N 0.000 description 1
- NEOZOXKVMDBOSG-UHFFFAOYSA-N propan-2-yl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OC(C)C NEOZOXKVMDBOSG-UHFFFAOYSA-N 0.000 description 1
- ZPWFUIUNWDIYCJ-UHFFFAOYSA-N propan-2-yl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(C)C ZPWFUIUNWDIYCJ-UHFFFAOYSA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- YYFIGOPUHPDIBO-UHFFFAOYSA-N propanoic acid;hydrochloride Chemical compound Cl.CCC(O)=O YYFIGOPUHPDIBO-UHFFFAOYSA-N 0.000 description 1
- 229960001371 proparacaine hydrochloride Drugs 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- PXGPLTODNUVGFL-UHFFFAOYSA-N prostaglandin F2alpha Natural products CCCCCC(O)C=CC1C(O)CC(O)C1CC=CCCCC(O)=O PXGPLTODNUVGFL-UHFFFAOYSA-N 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 201000003004 ptosis Diseases 0.000 description 1
- 239000013014 purified material Substances 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000004264 retinal detachment Effects 0.000 description 1
- 210000001116 retinal neuron Anatomy 0.000 description 1
- 210000000880 retinal rod photoreceptor cell Anatomy 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- CRPCXAMJWCDHFM-UHFFFAOYSA-M sodium;5-oxopyrrolidine-2-carboxylate Chemical compound [Na+].[O-]C(=O)C1CCC(=O)N1 CRPCXAMJWCDHFM-UHFFFAOYSA-M 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- GEDPXILIQSHPKM-UHFFFAOYSA-N tert-butyl 3-(hydroxymethyl)-3-(phenylmethoxycarbonylamino)azetidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CC1(CO)NC(=O)OCC1=CC=CC=C1 GEDPXILIQSHPKM-UHFFFAOYSA-N 0.000 description 1
- BICRNSAVYHWHIC-UHFFFAOYSA-N tert-butyl 3-(hydroxymethyl)-3-methylazetidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC(C)(CO)C1 BICRNSAVYHWHIC-UHFFFAOYSA-N 0.000 description 1
- PCEAZBVTZGTIEC-UHFFFAOYSA-N tert-butyl n-(2-chlorosulfonylethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCS(Cl)(=O)=O PCEAZBVTZGTIEC-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 125000005207 tetraalkylammonium group Chemical group 0.000 description 1
- BORJONZPSTVSFP-UHFFFAOYSA-N tetradecyl 2-hydroxypropanoate Chemical compound CCCCCCCCCCCCCCOC(=O)C(C)O BORJONZPSTVSFP-UHFFFAOYSA-N 0.000 description 1
- YRZGMTHQPGNLEK-UHFFFAOYSA-N tetradecyl propionate Chemical compound CCCCCCCCCCCCCCOC(=O)CC YRZGMTHQPGNLEK-UHFFFAOYSA-N 0.000 description 1
- DZKXJUASMGQEMA-UHFFFAOYSA-N tetradecyl tetradecanoate Chemical compound CCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCC DZKXJUASMGQEMA-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 125000005304 thiadiazolidinyl group Chemical group 0.000 description 1
- 125000005305 thiadiazolinyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000002769 thiazolinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 229940100616 topical oil Drugs 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
- 229940066528 trichloroacetate Drugs 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 1
- 125000000725 trifluoropropyl group Chemical group [H]C([H])(*)C([H])([H])C(F)(F)F 0.000 description 1
- 125000005455 trithianyl group Chemical group 0.000 description 1
- 229960004791 tropicamide Drugs 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 230000006442 vascular tone Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- GSQBIOQCECCMOQ-UHFFFAOYSA-N β-alanine ethyl ester Chemical compound CCOC(=O)CCN GSQBIOQCECCMOQ-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/568—Four-membered rings
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/30—Animals modified by surgical methods
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0375—Animal model for cardiovascular diseases
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
本发明描述了瞬时受体电位阳离子通道亚家族V成员4(TRPV4)的受体配体、包含此类化合物的药物组合物以及使用此类化合物和组合物治疗眼部障碍的方法。
Description
与相关申请的交叉引用
本申请要求2019年11月21日提交的美国临时专利申请号62/938,693的优先权,所述临时专利申请整体通过参考并入本文。
技术领域
本公开涉及用于治疗TRPV4相关疾病和/或障碍例如青光眼和相关疾病的化合物、组合物和方法。
背景技术
瞬时受体电位阳离子通道亚家族V成员4(TRPV4)是OSM9样瞬时受体电位通道(OTRPC)亚家族的一个成员,在人类中由TRPV4基因编码。TRPV4蛋白是一种Ca2+通透性非选择性阳离子通道,被认为参与系统渗透压的调节。TRPV4还用作纤毛机械感受通道。已将TRPV4基因的突变与包括3型短躯干症、先天性远端脊髓性肌萎缩症、肩腓脊髓性肌萎缩症和腓骨肌萎缩症2C亚型在内的障碍相关联。
纤毛形成或维持的缺陷是包括色素性视网膜炎、肾囊肿、多指畸形和发育迟缓在内的被统称为纤毛病的许多人类疾病的基础。OCRL这种肌醇多磷酸酯5-磷酸酶调节纤毛生物发生,已将OCRL与Lowe眼脑肾综合征(Lowe综合征)相关联,这是一种罕见的X连锁隐性疾病,在男性中表现为双侧白内障和青光眼以及肾功能衰竭、肌张力减退和智力迟钝。OCRL的底物包括磷脂酰肌醇-4,5-二磷酸[PI(4,5)P2]和磷脂酰肌醇-3,4,5-三磷酸[PI(3,4,5)P3]。在来自于Lowe患者的成纤维细胞中证实了5-磷酸酶活性的降低以及PI(4,5)P2:PI(4)P比率的2至3倍的升高。
压力的机械感受是包括高血压和青光眼的发生在内的许多重要的人类疾病的基础。在肾上皮细胞中,已显示纤毛蛋白多囊蛋白(PC1/2)对流量依赖性钙通量是重要的。在脑室的内衬中,脑脊液受纤毛调节。与肾脏相似,眼是一个封闭的器官,对流体的产生和流出具有敏感的稳态调节。有缺陷的压力感受可能引起房水失衡,导致眼内压升高。眼压低会导致视网膜结构改变和视力下降,而眼压升高可能会损害视神经。青光眼是一种与眼内压升高相关的视神经病变,是世界上不可逆失明的主导原因。
小梁网(TM)细胞负责大部分房水的排出。小梁流出的功能障碍导致眼内压升高,这在易感个体中导致视网膜神经节细胞死亡,从而导致不可逆的视力丧失。眼的小梁网细胞具有对压力变化具有响应性的初级纤毛。
与压力增加在青光眼病理中的中心作用相一致,唯一被证明的治疗方法是降低压力。对开发用于降低眼压的治疗方法存在着需求。
青光眼的一个显著特点是后眼(视网膜)中的视神经病变,反映了视网膜神经胶质细胞的炎性激活和视网膜神经节细胞(RGC)的变性和丧失。发生所述疾病的主要风险因素是眼内压(IOP)升高,IOP依赖性占青光眼病例的~30–70%。尽管“青光眼”是受损视网膜的晚期名称,但RGC对压力的急性变化非常敏感,这会导致兴奋性的立即变化、时空对比敏感度丧失和视敏度下降。功能障碍与RGC树突的收缩、变薄和复杂性降低、突触丧失和轴突运输的变化相关。压力引起的细胞放电的变化和树突损伤被神经营养因子和细胞器的(顺行/逆行)运输受阻加剧,如果这种情况持续存在,可能在视神经头处导致总体结构重塑。压力诱导的损伤的一种似乎合理的多室调控物可能是钙离子,它通过Ca2+依赖性蛋白酶、半胱天冬酶、MAP激酶、ER应激、自噬和细胞凋亡来驱动树突、胞体和轴突的重塑。
目前公认的青光眼治疗主要限于降低IOP。因为降低IOP也可以在具有“正常”IOP(8-15mm Hg)水平的患者中减轻视力丧失的进展,因此青光眼可以被视为一种涉及病理性细胞机械转导的疾病,其在任何IOP水平下均提高RGC对机械应力的易感性(Krizaj,2019)。不幸的是,最常用的降低IOP的药剂拉坦前列素(一种前列腺素F2α类似物)靶向房水排出的次级葡萄膜巩膜机制,并且在相当一部分(25-50%)的患者中降低IOP不超过20%,而高达6%的POAG患者无响应或不耐受任何IOP药物。因此,一个有吸引力的策略是靶向前眼中的IOP产生机制和视网膜神经节细胞和神经胶质的压力敏感性两者。
本发明是基于下述发现,即视网膜神经节细胞、穆勒神经胶质细胞和小神经胶质细胞的压力敏感性部分由TRPV4(瞬时受体电位香草酸亚型4)介导,所述TRPV4是一种钙通透性通道,被一系列机械应激源(应变、压力、压缩、剪切)、中等温度和多不饱和脂肪酸激活。所述通道的过度激活诱导RGC的选择性死亡(Ryskamp等,Journal of Neuroscience2011)和反应性神经胶质增生(Ryskamp等,Journal of Neuroscience 2014),而所述通道的抑制或基因消融具有神经保护作用(Ryskamp等,Scientific Reports 2016)。据信,TRPV4拮抗剂通过抑制神经胶质(减少神经炎症)和RGC(抑制神经变性)两者的压力敏感性,可用于在高眼压症中提供神经保护作用。它们据信还对抗在青光眼中可能损伤RGC树突和轴突的压力依赖性钙超载。因为这些化合物也降低IOP(Ryskamp等,Scientific Reports2016),因此本发明提供了一种将降低IOP与神经保护相结合的治疗策略。此外,TRPV4拮抗剂在视网膜中减少神经胶质和神经元肿胀和细胞因子释放方面的功效(Jo等,Journal ofNeuroscience 2015;Matsumoto等,Journal of Neuroscience 2018),为在诸如糖尿病性视网膜病变和黄斑变性的疾病中治疗过度肿胀和/或水肿提供了一种神经保护策略。
Ryskamp DA,Jo AO,Frye A,Macaulay N,Vazquez-Chona F,Thoreson WB和D(2014),肿胀和类花生酸代谢物在视网膜神经元和神经胶质细胞中差异门控TRPV4通道(Swelling and eicosanoid metabolites differentially gate TRPV4 channelsin retinal neurons and glia),Journal of Neuroscience 34(47):15689-15700.PMID:25411497;PMC4236400
Jo AO*,Ryskamp DA*,Phuong TTT,Verkman A,Yarishkin O,MacAulay N和D(2015),视网膜穆勒神经胶质的细胞体积和钙稳态调节需要TRPV4和AQP4通道的协同信号传导(Synergistic signaling of TRPV4 and AQP4 channels is required forcell volume and calcium homeostasis regulation in retinal Müller glia),Journal of Neuroscience,35(39):13525-13537.PMID:26424896.PMC4588615
Ryskamp DA,Frye AM,Phuong TTT,Yarishkin O,Jo AO,Xu Y,Lakk M,Redmon S,Iuso A,Hageman G,Ambati B,Prestwich GD,Torrejon KY和D(2016),TRPV4调节哺乳动物眼中的钙稳态、细胞骨架重塑、常规流出和眼内压(TRPV4 regulates calciumhomeostasis,cytoskeletal remodeling,conventional outflow and intraocularpressure in the mammalian eye),Scientific Reports 6:30583.PMID:27510430.PMC4980693
Matsumoto H,Sugio S,D,Ishizaki Y和Shibasaki K(2018),视网膜脱离诱导的穆勒神经胶质细胞肿胀激活TRPV4离子通道并触发视杆细胞死亡(Retinaldetachment-induced Müller glial cell swelling activates TRPV4 ion channelsand triggers rod photoreceptor death),Journal of Neuroscience 38(41):8745-8758.PMID:30143574.PMC6181316
发明内容
一方面,公开了式(I)的化合物:
或其可药用盐,其中:
L1是-C(O)-、-S(O2)-、-S(O)-或C1-C4亚烷基;
X是O或NR1;
m是0、1、2、3或4;
n是0、1、2、3或4;
Ar1和Ar2各自独立地选自5-10元芳基或杂芳基;
Z是CHR2R3、COR4或NHR5;
R1选自氢和C1-C4烷基;
R2、R3、R4和R5各自独立地选自氢、羟基、C1-C6烷基、羟基-C1-C6烷基、C1-C6烷氧基、C1-C6烷氧基-C1-C6烷基、磷酸酯、C1-C6烷基磷酸酯、C4-C8杂环基、NR6R7、-OC(O)R8、-C(O)R9、-S(O)2R10和-OS(O)2R11;
R6、R7、R8、R9、R10和R11各自独立地选自氢、C1-C6烷基、C1-C6杂烷基、C1-C6烷氧基、C4-C8环烷基、C4-C8杂环基、C5-C8芳基、C5-C8杂芳基、C1-C6烷氧基-C1-C6烷基、C5-C8芳基-C1-C6烷基、C5-C8杂芳基-C1-C6烷基、C5-C8杂环基-C1-C6烷基、氨基-C1-C6烷基、羟基-C1-C6烷基、羟基-C3-C8环烷基、氰基-C1-C6烷基、羟基磺酰基-C1-C6烷基、磷酸酯-C1-C6烷基、烷基磷酸酯-C1-C6烷基、-COR12和-CR13R14C(O)R15;
R12选自C1-C6烷基、C1-C6杂烷基、C1-C6烷氧基、氨基-C1-C6烷基、C4-C8杂环基、羟基-C1-C6烷基、氨基-C4-C8杂环基、磷酸酯-C1-C6烷基和C1-C6烷基磷酸酯;
R13和R14各自独立地选自氢、C1-C6烷基和C1-C6杂烷基,或者任选地与它们所连接的原子合在一起形成环;并且
R15是羟基、C1-C6烷氧基或氨基;
其中m和n中的至少一者不是零,并且每个芳基、杂芳基、环烷基或杂环独立地是未取代的,或者被独立地选自氰基、卤素、C1-C6烷基、C1-C6烷氧基、氨基-C1-C6烷基、卤代烷基、磺酰基、-C(O)-C1-C6烷氧基和-C(O)-NH2的一个或多个取代基取代。
还公开了包含所述化合物的药物组合物,以及使用所述化合物和组合物治疗障碍例如高眼压症或青光眼或其他相关的TRPV4相关医学障碍和/或疾病的方法。
附图说明
图1是示出了在高眼压症的微珠(MB)小鼠模型中两种浓度的局部用化合物11(0.01%和0.1%)、0.5%噻吗洛尔和对照PBS对IOP的影响的图(N=3个独立实验,其中每个实验组群7-10只小鼠)。误差条=±S.E.M.。在原发性开角青光眼(POAG)的小鼠模型中使用聚苯乙烯微珠的前房内注射诱导高眼压症。拮抗剂储用溶液(10mM)在DMSO中制备,最终浓度在PBS中制备,稀释至<0.0001%DMSO。
具体实施方式
本文公开了瞬时受体电位阳离子通道亚家族V成员4(TRPV4)的受体配体(例如拮抗剂)。所述化合物可以具有式(I)的结构。式(I)的化合物可以对TRPV4表现出超过其他TRPV受体(例如TRPV3)的选择性。通过调节TRPV4活性,式(I)的化合物可用于治疗或预防与TRPV4相关的疾病和障碍。例如,式(I)的化合物被用于治疗或预防眼部疾病和障碍例如青光眼。
1.定义
除非另有定义,否则本文中使用的所有技术和科学术语均具有与本领域普通技术人员通常理解的相同的含义。在有冲突的情况下,以包括定义在内的本文件为准。下面描述优选的方法和材料,尽管与本文中描述的相似或等同的方法和材料也可用于本发明的实践或试验。本文中提到的所有出版物、专利申请和其他参考文献整体通过参考并入本文。本文公开的材料、方法和实例仅仅是说明性的,而不打算是限制性的。
当在本文中使用时,术语“包含”、“包括”、“具有”、“可以”、“含有”及其变化形式意指开放式过渡性短语、术语或词语,其不排除其他方案或结构的可能性。除非上下文另有明确叙述,否则没有具体数目的指称包括复数指称物。
与数量相结合使用的修饰语“约”包括所陈述的值,并具有由上下文所规定的含义(例如,它至少包括与所述特定数量的测量相关的误差程度)。修饰语“约”还应该被认为公开了由两个端点的绝对值所定义的范围。例如,表述“约2至约4”也公开了“2至4”的范围。术语“约”可以是指指定数字的加减10%。例如,“约10%”可以表示9%至11%的范围,并且“约1”可以意味着0.9-1.1。“约”的其他含义可以从上下文显而易见,例如四舍五入,因此例如“约1”也可能意味着0.5至1.4。
特定官能团和化学术语的定义在下文中更详细描述。出于本公开的目的,化学元素根据《元素周期表》(Periodic Table of the Elements,CAS版本,《化学和物理学手册》(Handbook of Chemistry and Physics)第75版,内封面)来标识,并且特定官能团通常如其中所述来定义。此外,有机化学的一般性原理以及特定功能组成部分和反应性描述在《有机化学》(Organic Chemistry,Thomas Sorrell,University Science Books,Sausalito,1999)、Smith和March的《March高级有机化学》(March's Advanced Organic Chemistry,第5版,John Wiley&Sons,Inc.,New York,2001)、Larock的《综合有机转化》(ComprehensiveOrganic Transformations,VCH Publishers,Inc.,New York,1989)、Carruthers的《有机合成的一些现代方法》(Some Modern Methods of Organic Synthesis,第3版,CambridgeUniversity Press,Cambridge,1987)中,每个所述文献的全部内容通过参考并入本文。
当在本文中使用时,术语“烷氧基”是指通过氧原子连接到母体分子组成部分的本文中所定义的烷基。烷氧基的代表性实例包括但不限于甲氧基、乙氧基、丙氧基、2-丙氧基、丁氧基和叔丁氧基。
当在本文中使用时,术语“烷基”意味着含有1至10个碳原子的直链或支链饱和烃链。术语“短链烷基”或“C1-C6烷基”意味着含有1至6个碳原子的直链或支链烃。术语“C1-C3烷基”意味着含有1至3个碳原子的直链或支链烃。烷基的代表性实例包括但不限于甲基、乙基、正丙基、异丙基、正丁基、仲丁基、异丁基、叔丁基、正戊基、异戊基、新戊基、正己基、3-甲基己基、2,2-二甲基戊基、2,3-二甲基戊基、正庚基、正辛基、正壬基和正癸基。
当在本文中使用时,术语“烷氧基烷基”是指通过本文中所定义的烷基连接到母体分子组成部分的本文中所定义的烷氧基。
当在本文中使用时,术语“烷基氨基”意味着至少一个本文中所定义的烷基通过本文中所定义的氨基连接到母体分子组成部分。
当在本文中使用时,术语“烷基磷酸酯”意味着一种磷酸H3PO4的酯,其中任何或所有的氢可以被本文中所定义的烷基代替,使得所述烷基磷酸酯可以是单取代的R1H2PO4、双取代的R1R2H2PO4或三取代的R1R2R3H2PO4,其中R1、R2和R3可以是相同或不同的烷基。
当在本文中使用时,术语“烷基磷酸酯烷基”是指通过本文中所定义的烷基连接到母体分子组成部分的本文中所定义的烷基磷酸酯。
当在本文中使用时,术语“酰胺”意味着-C(O)NR-或-NRC(O)-,其中R可以是氢、烷基、环烷基、芳基、杂芳基、杂环、烯基或杂烷基。
当在本文中使用时,术语“氨基”意味着–NRxRy,其中Rx和Ry可以是氢、烷基、环烷基、芳基、杂芳基、杂环、烯基或杂烷基。在氨基烷基或其中氨基与两个其他组成部分连接在一起的任何其他组成部分的情况下,氨基可以是–NRx–,其中Rx可以是氢、烷基、环烷基、芳基、杂芳基、杂环、烯基或杂烷基。
当在本文中使用时,术语“氨基烷基”意味着至少一个本文中所定义的氨基通过本文中所定义的亚烷基连接到母体分子组成部分。
当在本文中使用时,术语“氨基杂环基”意味着至少一个本文中所定义的氨基通过本文中所定义的杂环基连接到母体分子组成部分。
当在本文中使用时,术语“芳基”是指苯基或双环稠合环系统。双环稠合环系统的实例是连接到母体分子组成部分并与本文中所定义的环烷基、苯基、本文中所定义的杂芳基或本文中所定义的杂环稠合的苯基。芳基的代表性实例包括但不限于吲哚基、萘基、苯基、喹啉基和四氢喹啉基。
当在本文中使用时,术语“芳基烷基”意味着至少一个本文中所定义的芳基通过本文中所定义的亚烷基连接到母体分子组成部分。
当在本文中使用时,术语“氰基”意味着至少一个-CN基团。
当在本文中使用时,术语“氰基烷基”意味着至少一个-CN基团通过本文中所定义的亚烷基连接到母体分子组成部分。
当在本文中使用时,术语“环烷基”是指含有3至10个碳原子、零个杂原子和零个双键的碳环环系统。环烷基的代表性实例包括但不限于环丙基、环丁基、环戊基、环己基、环庚基、环辛基、环壬基和环癸基。“环烷基”还包括其中环烷基连接到母体分子组成部分并与本文中所定义的芳基(例如苯基)、本文中所定义的杂芳基或本文中所定义的杂环稠合的碳环环系统。此类环烷基的代表性实例包括但不限于2,3-二氢-1H-茚基(例如2,3-二氢-1H-茚-1-基和2,3-二氢-1H-茚-2-基)、6,7-二氢-5H-环戊并[b]吡啶基(例如6,7-二氢-5H-环戊并[b]吡啶-6-基)和5,6,7,8-四氢喹啉基(例如5,6,7,8-四氢喹啉-5-基)。
当在本文中使用时,术语“氟代烷基”意味着其中1、2、3、4、5、6、7或8个氢原子被氟代替的本文中所定义的烷基。氟代烷基的代表性实例包括但不限于2-氟乙基、2,2,2-三氟乙基、三氟甲基、二氟甲基、五氟乙基和三氟丙基例如3,3,3-三氟丙基。
当在本文中使用时,术语“卤素”或“卤”意味着Cl、Br、I或F。
当在本文中使用时,术语“卤代烷基”意味着其中1、2、3、4、5、6、7或8个氢原子被卤素代替的本文中所定义的烷基。
当在本文中使用时,术语“杂烷基”意味着其中一个或多个碳原子已被选自S、O、P和N的杂原子代替的本文中所定义的烷基。杂烷基的代表性实例包括但不限于烷基醚、仲烷基胺和叔烷基胺、酰胺和烷基硫醚。
当在本文中使用时,术语“杂芳基”是指芳香族单环或芳香族双环环系统。所述芳香族单环是含有至少一个独立地选自N、O和S的杂原子(例如1、2、3或4个独立地选自O、S和N的杂原子)的5元或6元环。所述5元芳香族单环具有两个双键,并且所述6元芳香族单环具有三个双键。所述双环杂芳基的实例是连接到母体分子组成部分并与本文中所定义的单环环烷基、本文中所定义的单环芳基、本文中所定义的单环杂芳基或本文中所定义的单环杂环稠合的单环杂芳环。杂芳基的代表性实例包括但不限于吲哚基、吡啶基(包括吡啶-2-基、吡啶-3-基、吡啶-4-基)、嘧啶基、吡嗪基、哒嗪基、吡唑基、吡咯基、苯并吡唑基、1,2,3-三唑基、1,3,4-噻二唑基、1,2,4-噻二唑基、1,3,4-二唑基、1,2,4-二唑基、咪唑基、噻唑基、异噻唑基、噻吩基、苯并咪唑基、苯并噻唑基、苯并唑基、苯并二唑基、苯并噻吩基、苯并呋喃基、异苯并呋喃基、呋喃基、唑基、异唑基、嘌呤基、异吲哚基、喹喔啉基、吲唑基、喹唑啉基、1,2,4-三嗪基、1,3,5-三嗪基、异喹啉基、喹啉基、6,7-二氢-1,3-苯并噻唑基、咪唑并[1,2-a]吡啶基、萘啶基、吡啶并咪唑基、噻唑并[5,4-b]吡啶-2-基、噻唑并[5,4-d]嘧啶-2-基。
当在本文中使用时,术语“杂芳基烷基”意味着至少一个本文中所定义的杂芳基通过本文中所定义的亚烷基连接到母体分子组成部分。
当在本文中使用时,术语“杂环”或“杂环的”意味着单环杂环、双环杂环或三环杂环。所述单环杂环是含有至少一个独立地选自O、N和S的杂原子的3、4、5、6、7或8元环。所述3或4元环含有零或一个双键和一个选自O、N和S的杂原子。所述5元环含有零或一个双键和1、2或3个选自O、N和S的杂原子。所述6元环含有0、1或2个双键和1、2或3个选自O、N和S的杂原子。所述7和8元环含有0、1、2或3个双键和1、2或3个选自O、N和S的杂原子。单环杂环的代表性实例包括但不限于氮杂环丁烷基、氮杂环庚烷基、氮杂环丙烷、二氮杂环庚烷基、1,3-二氧杂环己烷基、1,3-二氧杂环戊烷基、1,3-二硫代环戊烷基、1,3-二硫代环己烷基、咪唑啉基、咪唑烷基、异噻唑啉基、异噻唑烷基、异唑啉基、异唑烷基、吗啉基、2-酮基-3-哌啶基、2-酮基氮杂环丁烷-3-基、二唑啉基、二唑烷基、唑啉基、唑烷基、氧杂环丁烷基、氧杂环庚烷基、氧杂环辛基、哌嗪基、哌啶基、吡喃基、吡唑啉基、吡唑烷基、吡咯啉基、吡咯烷基、四氢呋喃基、四氢吡喃基、四氢吡啶基、四氢噻吩基、噻二唑啉基、噻二唑烷基、1,2-噻嗪烷基、1,3-噻嗪烷基、噻唑啉基、噻唑烷基、硫代吗啉基、1,1-二氧代硫代吗啉基(硫代吗啉砜)、噻喃基和三噻烷基。所述双环杂环是与苯基稠合的单环杂环,或与单环环烷基稠合的单环杂环,或与单环环烯基稠合的单环杂环,或与单环杂环稠合的单环杂环,或螺杂环基,或其中环的两个不相邻原子通过1、2、3或4个碳原子的亚烷基桥或2、3或4个碳原子的亚烯基桥相连的桥接单环杂环环系统。双环杂环的代表性实例包括但不限于苯并吡喃基、苯并硫代吡喃基、色满基、2,3-二氢苯并呋喃基、2,3-二氢苯并噻吩基、2,3-二氢异喹啉、2-氮杂螺[3.3]庚-2-基、2-氧杂-6-氮杂螺[3.3]庚-6-基、氮杂双环[2.2.1]庚基(包括2-氮杂双环[2.2.1]庚-2-基)、氮杂双环[3.1.0]己基(包括3-氮杂双环[3.1.0]己-3-基)、2,3-二氢-1H-吲哚基、异吲哚啉基、八氢环戊并[c]吡咯基、八氢吡咯并吡啶基和四氢异喹啉基。三环杂环的实例是与苯基稠合的双环杂环,或与单环环烷基稠合的双环杂环,或与单环环烯基稠合的双环杂环,或与单环杂环稠合的双环杂环,或其中双环的两个不相邻原子通过1、2、3或4个碳原子的亚烷基桥或2、3或4个碳原子的亚烯基桥相连的双环杂环。三环杂环的实例包括但不限于八氢-2,5-环氧戊搭烯、六氢-2H-2,5-亚甲基桥接环戊并[b]呋喃、六氢-1H-1,4-亚甲基桥接环戊并[c]呋喃、氮杂-金刚烷(1-氮杂三环[3.3.1.13,7]癸烷)和氧杂-金刚烷(2-氧杂三环[3.3.1.13,7]癸烷)。所述单环、双环和三环杂环通过环内包含的任何碳原子或任何氮原子连接到母体分子组成部分,并且可以是未取代或取代的。
当在本文中使用时,术语“杂环基烷基”意味着本文中所定义的至少一个杂环通过本文中所定义的亚烷基连接到母体分子组成部分。
当在本文中使用时,术语“羟基”意味着-OH基团。
当在本文中使用时,术语“羟基烷基”意味着至少一个-OH基团通过本文中所定义的亚烷基连接到母体分子组成部分。
当在本文中使用时,术语“羟基环烷基”意味着至少一个-OH基团通过本文中所定义的环烷基连接到母体分子组成部分。
羟基磺酰基
当在本文中使用时,术语“羟基磺酰基-烷基”意味着至少一个本文中所定义的羟基磺酰基通过本文中所定义的亚烷基连接到母体分子组成部分。
当在本文中使用时,术语“磷酸酯烷基”意味着至少一个磷酸酯基团通过本文中所定义的亚烷基连接到母体分子组成部分。
当在本文中使用时,术语“磺酰基”意味着-SO2-基团。
在某些情况下,烃基取代基(例如烷基或环烷基)中的碳原子数目由前缀“Cx-Cy-”注明,其中x是所述取代基中碳原子的最小数目,y是最大数目。因此,例如,“C1-C3烷基”是指含有1至3个碳原子的烷基取代基。
术语“取代基”是指在芳基、杂芳基、苯基或吡啶基上,在该基团的任何原子处“取代的”基团。任何原子都可以被取代。
术语“取代的”是指基团可以被一个或多个非氢取代基进一步取代。取代基包括但不限于卤素、=O(酮基)、=S(硫酮基)、氰基、硝基、氟代烷基、烷氧基氟代烷基、氟代烷氧基、烷基、烯基、炔基、卤代烷基、卤代烷氧基、杂烷基、环烷基、环烯基、芳基、杂芳基、杂环、环烷基烷基、杂芳基烷基、芳基烷基、羟基、羟基烷基、烷氧基、烷氧基烷基、亚烷基、芳氧基、苯氧基、苯甲氧基、氨基、烷基氨基、酰基氨基、氨基烷基、芳基氨基、磺酰基氨基、亚磺酰基氨基、磺酰基、烷基磺酰基、芳基磺酰基、氨基磺酰基、亚磺酰基、-COOH、酮、酰胺、氨基甲酸酯和酰基。例如,如果基团被描述为“任选取代的”(例如烷基、烯基、炔基、芳基、杂芳基、环烷基、杂烷基、杂环或其他基团例如R基团),则它可能具有0、1、2、3、4或5个独立地选自卤素、=O(酮基)、=S(硫酮基)、氰基、硝基、氟代烷基、烷氧基氟代烷基、氟代烷氧基、烷基、烯基、炔基、卤代烷基、卤代烷氧基、杂烷基、环烷基、环烯基、芳基、杂芳基、杂环、环烷基烷基、杂芳基烷基、芳基烷基、羟基、羟基烷基、烷氧基、烷氧基烷基、亚烷基、芳氧基、苯氧基、苯甲氧基、氨基、烷基氨基、酰基氨基、氨基烷基、芳基氨基、磺酰基氨基、亚磺酰基氨基、磺酰基、烷基磺酰基、芳基磺酰基、氨基磺酰基、亚磺酰基、-COOH、酮、酰胺、氨基甲酸酯和酰基的取代基。
对于本文中描述的化合物来说,基团及其取代基可以根据原子和取代基容许的价数来选择,使得所述选择和取代产生稳定的化合物,例如不通过重排、环化、消除等自发地经历转化的化合物。
对于本文中数值范围的叙述来说,明确地考虑了其间具有相同精度的每个中间数字。例如,对于6-9的范围来说,除了6和9之外还设想了数字7和8,并且对于6.0-7.0的范围来说,明确设想了数字6.0、6.1、6.2、6.3、6.4、6.5、6.6、6.7、6.8、6.9和7.0。
2.化合物
一方面,公开了式(I)的化合物:
或其可药用盐,其中:
L1是-C(O)-、-S(O2)-、-S(O)-或C1-C4亚烷基;
X是O或NR1;
m是0、1、2、3或4;
n是0、1、2、3或4;
Ar1和Ar2各自独立地选自5-10元芳基或杂芳基;
Z是CHR2R3、COR4或NHR5;
R1选自氢和C1-C4烷基;
R2、R3、R4和R5各自独立地选自氢、羟基、C1-C6烷基、羟基-C1-C6烷基、C1-C6烷氧基、C1-C6烷氧基-C1-C6烷基、磷酸酯、C1-C6烷基磷酸酯、C4-C8杂环基、NR6R7、-OC(O)R8、-C(O)R9、-S(O)2R10和-OS(O)2R11;
R6、R7、R8、R9、R10和R11各自独立地选自氢、C1-C6烷基、C1-C6杂烷基、C1-C6烷氧基、C4-C8环烷基、C4-C8杂环基、C5-C8芳基、C5-C8杂芳基、C1-C6烷氧基-C1-C6烷基、C5-C8芳基-C1-C6烷基、C5-C8杂芳基-C1-C6烷基、C5-C8杂环基-C1-C6烷基、氨基-C1-C6烷基、羟基-C1-C6烷基、羟基-C3-C8环烷基、氰基-C1-C6烷基、羟基磺酰基-C1-C6烷基、磷酸酯-C1-C6烷基、烷基磷酸酯-C1-C6烷基、-COR12和-CR13R14C(O)R15;
R12选自C1-C6烷基、C1-C6杂烷基、C1-C6烷氧基、氨基-C1-C6烷基、C4-C8杂环基、羟基-C1-C6烷基、氨基-C4-C8杂环基、磷酸酯-C1-C6烷基和C1-C6烷基磷酸酯;
R13和R14各自独立地选自氢、C1-C6烷基和C1-C6杂烷基,或者任选地与它们所连接的原子合在一起形成环;并且
R15是羟基、C1-C6烷氧基或氨基;
其中m和n中的至少一者不是零,并且每个芳基、杂芳基、环烷基或杂环独立地是未取代的,或者被独立地选自氰基、卤素、C1-C6烷基、C1-C6烷氧基、氨基-C1-C6烷基、卤代烷基、磺酰基、-C(O)-C1-C6烷氧基和-C(O)-NH2的一个或多个取代基取代。
在某些实施方式中,L1是-S(O2)-。
在某些实施方式中,Ar1选自5元芳基、5元杂芳基、6元芳基或6元杂芳基。每个芳基或杂芳基可以是未取代的,或者被一个或两个独立地选自氰基、卤素、C1-C6烷基、C1-C6烷氧基、卤代烷基、磺酰基和-C(O)-C1-C6烷氧基的取代基取代。在某些实施方式中,所述卤素是氟或氯。在某些实施方式中,所述卤代烷基是三氟甲基。
在某些实施方式中,Ar2选自5元芳基、5元杂芳基、6元芳基或6元杂芳基。每个芳基或杂芳基可以是未取代的,或者被一个或两个独立地选自氰基、卤素、C1-C6烷基、C1-C6烷氧基、-C(O)-C1-C6烷氧基和-C(O)-NH2的取代基取代。在某些实施方式中,所述卤素是氟或氯。
在某些实施方式中,Z是CHR2R3、COR4或NHR5;
R2和R3各自独立地选自氢、羟基、C1-C6烷氧基、C4-C8杂环基、磷酸酯、NR6R7、-OC(O)R8和S(O)2R10;R4选自羟基、C1-C6烷氧基、和NR6R7;
R5选自氢、C1-C6烷基、-C(O)R9和-S(O)2R10;
R6和R7各自独立地选自氢、C1-C6烷基、C1-C6杂烷基、C4-C8杂环基、C1-C6烷氧基-C1-C6烷基、C5-C8杂芳基-C1-C6烷基、C5-C8杂环基-C1-C6烷基、氨基-C1-C6烷基、羟基-C1-C6烷基、羟基-C3-C8环烷基、氰基-C1-C6烷基、羟基磺酰基-C1-C6烷基、烷基磷酸酯-C1-C6烷基、-COR12和-CHR13C(O)R14;
R8是C5-C8芳基或C5-C8杂芳基;
R9选自C1-C6烷基、C1-C6杂烷基、氨基-C1-C6烷基、羟基-C1-C6烷基或-COR12;
R10是氨基-C1-C6烷基;
R12选自C1-C6烷基、C1-C6杂烷基、C1-C6烷氧基、氨基-C1-C6烷基、C4-C8杂环基、氨基-C4-C8杂环基、磷酸酯-C1-C6烷基和C1-C6烷基磷酸酯;
R13和R14各自独立地选自氢和C1-C6烷基;并且
R15选自羟基、C1-C6烷氧基和氨基。
在示例性实施方式中,Z是–CH2OH、-C(O)OH、NH2、-NHC(O)CH2、-CH2NH2、-CH2NHCH3、-CH2NH(CH2)2OH、-CH2NH(CH2)3OH、-CH2NH(C5H9O)、-CH2NH(CH2)2OCH3、-CH2NHCH2(C4H7O)、-CH2NHCH2CH3、-CH2NHCH2CH(OH)CH3、-CH2NH(C3H5O)或-CH2NHCH2(C3H5O)。
在某些实施方式中,X是O并且n是0。在某些实施方式中,m是1。在某些实施方式中,X是O,m是1,并且n是0。
在某些实施方式中,X是NR1。在某些实施方式中,R1是氢。
在某些实施方式中,X是NR1并且m是0。在某些实施方式中,X是NR1,m是0,并且n是1。
在某些实施方式中,X是NR1并且n是0。在某些实施方式中,X是NR1,m是1,并且n是0。
所述化合物可以作为其中存在不对称或手性中心的立体异构体存在。取决于取代基在手性碳原子周围的构型,所述立体异构体是“R”或“S”。本文中使用的术语“R”和“S”是在IUPAC 1974年为基础立体化学E部分的推荐意见(IUPAC 1974Recommendations forSection E,Fundamental Stereochemistry,Pure Appl.Chem.,1976,45:13-30)中所定义的构型。本公开设想了各种不同的立体异构体及其混合物,并且它们被具体包括在本公开的范围之内。立体异构体包括对映异构体和非对映异构体以及对映异构体或非对映异构体的混合物。所述化合物的各个立体异构体可以从可商购的含有不对称或手性中心的起始原料合成制备,或通过制备外消旋混合物,然后使用本领域普通技术人员公知的拆分方法来制备。这些拆分方法的实例是(1)将对映异构体的混合物连接到手性助剂,通过重结晶或层析分离得到的非对映异构体混合物,并任选地从所述助剂释放出光学纯产物,如Furniss,Hannaford,Smith和Tatchell,《Vogel实用有机化学教科书》(Vogel's Textbook ofPractical Organic Chemistry),第5版(1989),Longman Scientific&Technical,EssexCM202JE,England)中所述,或(2)在手性层析柱上直接分离光学对映异构体的混合物,或(3)分级重结晶方法。
应该理解,所述化合物可以具有互变异构形式以及几何异构体,并且它们也构成本公开的实施方式。
本公开还包括同位素标记的化合物,其与式(I)中叙述的相同,但一个或多个原子被原子质量或质量数与自然界中通常存在的原子质量或质量数不同的原子代替。适合于包含在本发明的化合物中的同位素的实例是氢、碳、氮、氧、磷、硫、氟和氯,分别例如但不限于2H、3H、13C、14C、15N、18O、17O、31P、32P、35S、18F和36Cl。用较重的同位素例如氘(即2H)进行取代可以提供某些治疗优势,这些优势源于更高的代谢稳定性,例如体内半衰期增加或剂量要求降低,因此在某些情况下可能是优选的。所述化合物可以并入用于医学成像和正电子发射断层扫描(PET)研究的正电子发射性同位素,用于确定受体的分布。可以并入到式(I)化合物中的适合的正电子发射性同位素是11C、13N、15O和18F。同位素标记的式(I)的化合物通常可以通过本领域技术人员已知的常规技术,或通过类似于在伴随的实施例中描述的那些方法,使用适合的同位素标记的试剂代替非同位素标记的试剂来制备。
在某些实施方式中,在式(I)的化合物中,任何氢原子可以是氘。
所述公开的化合物可以充当或用作TRPV4的拮抗剂。在某些实施方式中,所述公开的化合物可以以约0.1nM至约50μM、约0.1nM至约10μM、约0.1nM至约1μM、约0.1nM至约100nM或约0.1nM至约50nM范围内的IC50抑制TRPV4。在某些实施方式中,所述公开的化合物可以以低于50μM、低于49μM、低于48μM、低于47μM、低于46μM、低于45μM、低于44μM、低于43μM、低于42μM、低于41μM、低于40μM、低于39μM、低于38μM、低于37μM、低于36μM、低于35μM、低于34μM、低于33μM、低于32μM、低于31μM、低于30μM、低于29μM、低于28μM、低于27μM、低于26μM、低于25μM、低于24μM、低于23μM、低于22μM、低于21μM、低于20μM、低于19μM、低于18μM、低于17μM、低于16μM、低于15μM、低于14μM、低于13μM、低于12μM、低于11μM、低于10μM、低于9μM、低于8μM、低于7μM、低于6μM、低于5μM、低于4μM、低于3μM、低于2μM、低于1μM、低于950nM、低于900nM、低于850nM、低于800nM、低于750nM、低于700nM、低于650nM、低于600nM、低于550nM、低于500nM、低于450nM、低于400nM、低于350nM、低于300nM、低于250nM、低于200nM、低于150nM、低于100nM、低于50nM、低于10nM、低于5nM或低于1nM的IC50抑制TRPV4。
所述公开的化合物可以是TRPV4相对于其他TRPV受体例如TRPV3的选择性调节剂。
所述公开的化合物可以作为可药用盐存在。术语“可药用盐”是指所述化合物的可以在水或油中溶解或分散,适用于治疗障碍而没有过度毒性、刺激性和过敏反应,与合理的利益/风险比相称,并对其预期用途有效的盐或两性离子。所述盐可以在所述化合物的最后分离和纯化过程中制备,或通过使所述化合物的氨基与适合的酸反应分开地制备。例如,可以将化合物溶解在适合的溶剂例如但不限于甲醇和水中,并用至少一当量的酸例如盐酸处理。所述得到的盐可以被沉淀出来,并通过过滤分离并在减压下干燥。或者,可以在减压下除去溶剂和过量的酸以提供盐。代表性的盐包括乙酸盐、己二酸盐、藻酸盐、柠檬酸盐、天冬氨酸盐、苯甲酸盐、苯磺酸盐、硫酸氢盐、丁酸盐、樟脑酸盐、樟脑磺酸盐、二葡萄糖酸盐、甘油磷酸盐、半硫酸盐、庚酸盐、己酸盐、甲酸盐、羟乙基磺酸盐、延胡索酸盐、乳酸盐、马来酸盐、甲磺酸盐、萘磺酸盐、烟酸盐、草酸盐、双羟萘酸盐、果胶酸盐、过硫酸盐、3-苯基丙酸盐、苦味酸盐、草酸盐、马来酸盐、新戊酸盐、丙酸盐、琥珀酸盐、酒石酸盐、三氯乙酸盐、三氟乙酸盐、谷氨酸盐、对甲苯磺酸盐、十一烷酸盐、盐酸盐、氢溴酸盐、硫酸盐、磷酸盐等。所述化合物的氨基也可以被氯化、溴化和碘化烷基例如甲基、乙基、丙基、异丙基、丁基、月桂基、肉豆蔻基、硬脂基等季铵化。
碱加成盐可以在所述公开的化合物的最终分离和纯化期间通过羧基与适合的碱的反应来制备,所述碱例如金属阳离子如锂、钠、钾、钙、镁或铝的氢氧化物、碳酸盐或碳酸氢盐,或有机伯胺、仲胺或叔胺。可以制备季胺盐,例如源自于甲胺、二甲胺、三甲胺、三乙胺、二乙胺、乙胺、三丁胺、吡啶、N,N-二甲基苯胺、N-甲基哌啶、N-甲基吗啉、二环己胺、普鲁卡因、二苯甲胺、N,N-二苯甲基苯乙基胺、1-二苯羟甲胺(1-ephenamine)和N,N’-二苯甲基乙二胺、乙二胺、乙醇胺、二乙醇胺、哌啶、哌嗪等的季胺盐。
所述化合物和中间体可以通过有机合成领域中的专业技术人员公知的方法来分离和纯化。用于分离和纯化化合物的常规方法的实例可以包括但不限于在固相支持物例如硅胶、氧化铝或用烷基硅烷基团衍生的二氧化硅上层析,通过在高温或低温下重结晶并任选地用活性炭预处理,薄层层析,在各种不同压力下蒸馏,在真空下升华和研磨,正如在《Vogel实用有机化学教科书》(Vogel's Textbook of Practical Organic Chemistry),第5版(1989),Furniss,Hannaford,Smith和Tatchell,Longman Scientific&Technical,Essex CM202JE,England)中所述。
公开的化合物可以具有至少一个碱性氮,由此可以用酸处理所述化合物以形成所需的盐。例如,可以将化合物与酸在等于或高于室温下反应以提供所需的盐,在冷却后将其沉积并通过过滤收集。适合于所述反应的酸的实例包括但不限于酒石酸、乳酸、琥珀酸以及扁桃酸、阿卓乳酸、甲磺酸、乙磺酸、甲苯磺酸、萘磺酸、苯磺酸、碳酸、延胡索酸、马来酸、葡萄糖酸、乙酸、丙酸、水杨酸、盐酸、氢溴酸、磷酸、硫酸、柠檬酸、羟基丁酸、樟脑磺酸、苹果酸、苯乙酸、天冬氨酸或谷氨酸等。
每个单独步骤的反应条件和反应时间可以根据所使用的特定反应物和使用的反应物中存在的取代基而变。具体程序提供在实施例部分中。反应可以以常规方式进行,例如通过从残留物中除去溶剂并根据本领域中通常已知的方法进一步纯化,例如但不限于结晶、蒸馏、萃取、研磨和层析法。除非另有说明,否则起始材料和试剂是可商购的或者可以由本领域技术人员使用化学文献中描述的方法从可商购的材料制备。起始材料如果不是可商购的,可以通过选自标准有机化学技术、与已知的结构相似化合物的合成类似的技术或与上述方案或合成例部分中描述的程序类似的技术的程序来制备。
常规实验,包括对反应条件、试剂和合成路线顺序的适当操控、不能与反应条件相容的任何化学官能团的保护以及在方法的反应顺序中的适合点处的去保护,都包含在本发明的范围内。适合的保护基团以及使用此类适合的保护基团保护和去保护不同取代基的方法是本领域技术人员公知的;其实例可以在Wuts和TW Greene,Greene的名为《有机合成中的保护基团》(Protective Groups in Organic Synthesis,(第4版),John Wiley&Sons,NY(2006))的书中找到,所述书籍整体通过参考并入本文。本发明的化合物的合成可以通过与上文所述的合成方案和具体实施例中描述的方法类似的方法来完成。
当需要所公开的化合物的光学活性形式时,它可以通过使用光学活性起始材料进行本文所述的程序之一来获得(例如通过适合的反应步骤的不对称诱导制备),或通过使用标准程序将化合物或中间体的立体异构体的混合物拆分(例如层析分离、重结晶或酶拆分)来获得。
同样地,当需要化合物的纯几何异构体时,它可以通过使用纯的几何异构体作为起始材料进行上述程序之一来获得,或者通过使用标准程序例如层析分离将化合物或中间体的几何异构体的混合物拆分来获得。
可以认识到,所描述的合成方案和具体实例是说明性的,并且不应被理解为限制本发明的范围,因为本发明的范围在权利要求书中定义。所述合成方法和具体实例的所有替选方案、修改和等同物都包括在权利要求书的范围之内。
3.药物组合物
所述公开的化合物可以并入到适合于给药到对象(例如患者,其可以是人类或非人类)的药物组合物中。
所述药物组合物可以包括“治疗有效量”或“预防有效量”的所述药剂。“治疗有效量”是指在必需的剂量和时间长度下有效地实现所需治疗结果的量。组合物的治疗有效量可以由本领域技术人员确定,并且可能随着多种因素例如个体的疾病状态、年龄、性别和体重以及所述组合物在所述个体中引发所需响应的能力而变。治疗有效量也是本发明的化合物(例如式(I)的化合物)的任何有毒或有害效应被治疗有益效应超越的量。“预防有效量”是指在必需的剂量和时间长度下有效地实现所需预防结果的量。通常,由于在对象中预防剂量在疾病之前或其早期阶段时使用,因此预防有效量会低于治疗有效量。
例如,式(I)的化合物的治疗有效量可以是约1mg/kg至约1000mg/kg、约5mg/kg至约950mg/kg、约10mg/kg至约900mg/kg、约15mg/kg至约850mg/kg、约20mg/kg至约800mg/kg、约25mg/kg至约750mg/kg、约30mg/kg至约700mg/kg、约35mg/kg至约650mg/kg、约40mg/kg至约600mg/kg、约45mg/kg至约550mg/kg、约50mg/kg至约500mg/kg、约55mg/kg至约450mg/kg、约60mg/kg至约400mg/kg、约65mg/kg至约350mg/kg、约70mg/kg至约300mg/kg、约75mg/kg至约250mg/kg、约80mg/kg至约200mg/kg、约85mg/kg至约150mg/kg和约90mg/kg至约100mg/kg。
所述药物组合物可以包含可药用载剂。当在本文中使用时,术语“可药用载剂”意味着任何类型的无毒、惰性的固体、半固体或液体填充剂、稀释剂、包封材料或配制助剂。可以充当可药用载剂的材料的一些实例是糖类例如但不限于乳糖、葡萄糖和蔗糖,淀粉例如但不限于玉米淀粉和马铃薯淀粉,纤维素及其衍生物例如但不限于羧甲基纤维素钠、乙基纤维素和纤维素乙酸酯,黄耆胶粉,麦芽,明胶,滑石,赋形剂例如但不限于可可脂和栓剂用蜡,油类例如但不限于花生油、棉籽油、红花油、芝麻油、橄榄油、玉米油和大豆油;二醇类例如丙二醇,酯类例如但不限于油酸乙酯和月桂酸乙酯,琼脂,缓冲剂例如但不限于氢氧化镁和氢氧化铝,海藻酸,无热原水,等渗盐水,林格氏溶液,乙醇,磷酸盐缓冲液,以及其他无毒相容性润滑剂例如但不限于月桂基硫酸钠和硬脂酸镁,并且根据配料师的判断,着色剂、脱模剂、包衣剂、甜味剂、调味剂和增香剂、防腐剂和抗氧化剂也可以存在于所述组合物中。
因此,所述化合物和它们的生理上可接受的盐可以被配制成通过例如固体给药、滴眼剂、局部用油基制剂、注射、吸入(通过口或鼻)、植入物或口服、颊、肠胃外或直肠给药来给药。技术和配方通常可以在《Remington制药学》(Remington's PharmaceuticalSciences)(Meade Publishing Co.,Easton,Pa.)中找到。治疗组合物在制造和储存条件下通常必须是无菌和稳定的。
所述公开的化合物的给药途径和组合物的形式将决定所使用的载剂的类型。所述组合物可以采取各种不同形式,例如适合于系统给药(例如口服、直肠、鼻、舌下、颊、植入物或肠胃外)或局部给药(例如皮肤、肺、鼻、耳、眼、脂质体递送系统或离子电渗疗法)。
用于系统给药的载剂通常包括稀释剂、润滑剂、粘合剂、崩解剂、着色剂、调味剂、甜味剂、抗氧化剂、防腐剂、助流剂、溶剂、悬浮剂、润湿剂、表面活性剂中的至少一者、它们的组合等。所有载剂在所述组合物中都是任选的。
适合的稀释剂包括糖类例如葡萄糖、乳糖、右旋糖和蔗糖,二醇类例如丙二醇,碳酸钙,碳酸钠,糖醇例如甘油、甘露醇和山梨糖醇。在系统或局部组合物中稀释剂的量通常为约50至约90%。
适合的润滑剂包括二氧化硅、滑石、硬脂酸及其镁盐和钙盐、硫酸钙,以及液体润滑剂例如聚乙二醇和植物油如花生油、棉籽油、芝麻油、橄榄油、玉米油和可可油。在系统或局部组合物中润滑剂的量通常为约5至约10%。
适合的粘合剂包括聚乙烯吡咯烷酮、硅酸铝镁、淀粉例如玉米淀粉和马铃薯淀粉、明胶、黄蓍胶和纤维素及其衍生物例如羧甲基纤维素钠、乙基纤维素、甲基纤维素、微晶纤维素和羧甲基纤维素钠。在系统组合物中粘合剂的量通常为约5至约50%。
适合的崩解剂包括琼脂、海藻酸及其钠盐、泡腾混合物、交联羧甲基纤维素、交联聚维酮、羧甲基淀粉钠、羟基乙酸淀粉钠、粘土和离子交换树脂。在系统或局部组合物中崩解剂的量通常为约0.1至约10%。
适合的着色剂包括着色剂例如FD&C染料。当使用时,在系统或局部组合物中着色剂的量通常为约0.005至约0.1%。
适合的调味剂包括薄荷醇、胡椒薄荷和水果调味剂。当使用时,在系统或局部组合物中调味剂的量通常为约0.1至约1.0%。
适合的甜味剂包括阿斯巴甜和糖精。在系统或局部组合物中甜味剂的量通常为约0.001至约1%。
适合的抗氧化剂包括丁基化羟基苯甲醚(“BHA”)、丁基化羟基甲苯(“BHT”)和维生素E。在系统或局部组合物中抗氧化剂的量通常为约0.1至约5%。
适合的防腐剂包括苯扎氯铵、对羟基苯甲酸甲酯和苯甲酸钠。在系统或局部组合物中防腐剂的量通常为约0.01至约5%。
适合的助流剂包括二氧化硅。在系统或局部组合物中助流剂的量通常为约1至约5%。
适合的溶剂包括水、等渗盐水、油酸乙酯、甘油、羟化蓖麻油、醇类例如乙醇和磷酸盐缓冲液。在系统或局部组合物中溶剂的量通常为约0至约100%。
适合的悬浮剂包括AVICEL RC-591(来自于FMC Corporation,Philadelphia,PA)和海藻酸钠。在系统或局部组合物中悬浮剂的量通常为约1至约8%。
适合的表面活性剂包括卵磷脂、聚山梨醇酯80、月桂基硫酸钠和TWEENS(来自于Atlas Powder Company,Wilmington,Delaware)。适合的表面活性剂包括在C.T.F.A.化妆品成分手册(Cosmetic Ingredient Handbook,1992,pp.587-592)、《Remington制药学》(Remington's Pharmaceutical Sciences,第15版,1975,pp.335-337)和McCutcheon的《乳化剂和去污剂》(Emulsifiers&Detergents,Volume 1,1994,North American Edition,pp.236-239)中公开的那些。在系统或局部组合物中表面活性剂的量通常为约0.1%至约5%。
尽管在系统组合物中组分的量可以随着制备的系统组合物的类型而变,但总的来说,系统组合物包含0.01%至50%的活性化合物(例如式(I)的化合物)和50%至99.99%的一种或多种载剂。用于肠胃外给药的组合物通常包含0.1%至10%的活性成分和90%至99.9%的包括稀释剂和溶剂在内的载剂。
用于口服给药的组合物可以具有各种不同的剂型。例如,固体形式包括片剂、胶囊、颗粒剂和散装粉剂。这些口服剂型包括安全有效量、通常为至少约5%、更特别地约25%至约50%的活性成分。口服剂量组合物包含约50%至约95%、更特别地约50%至约75%的载剂。
片剂可以进行压制、片剂研磨、肠溶包衣、糖包衣、薄膜包衣或多次压制。片剂通常包括活性组分和载剂,所述载剂包括选自稀释剂、润滑剂、粘合剂、崩解剂、着色剂、调味剂、甜味剂、助流剂及其组合的成分。具体的稀释剂包括碳酸钙、碳酸钠、甘露糖醇、乳糖和纤维素。具体的粘合剂包括淀粉、明胶和蔗糖。具体的崩解剂包括海藻酸和交联羧甲基纤维素。具体的润滑剂包括硬脂酸镁、硬脂酸和滑石。具体的着色剂是FD&C染料,其可以被添加用于外观。咀嚼片剂优选地含有甜味剂例如阿斯巴甜和糖精或调味剂例如薄荷醇、胡椒薄荷、水果调味剂,或它们的组合。
胶囊(包括植入物、时间释放和持续释放制剂)通常在包含明胶的胶囊中包含活性化合物(例如式(I)的化合物)和载剂,所述载剂包括上文公开的一种或多种稀释剂。颗粒剂通常包含公开的化合物,并且优选地包含助流剂例如二氧化硅以改善流动特性。植入物可以是可生物降解或不可生物降解的类型。
用于口服组合物的载剂中成分的选择取决于次要考虑因素如口味、成本和储存稳定性,这对于本发明的目的来说不是关键的。
固体组合物可以通过常规方法,通常用pH或时间依赖性包衣进行包衣,使得所公开的化合物在所需施用部位附近释放到胃肠道中或在不同位点和时间释放以延长所需作用。所述包衣通常包括选自邻苯二甲酸乙酸纤维素、聚乙烯乙酸邻苯二甲酸酯、醋酸乙烯酯、邻苯二甲酸纤维素、羟丙基甲基纤维素邻苯二甲酸酯、乙基纤维素、包衣(可以从Evonik Industries,Essen,Germany获得)、蜡和虫胶的一种或多种组分。
用于口服给药的组合物可以具有液体形式。例如,适合的液体形式包括水溶液、乳液、悬液、由非泡腾颗粒剂重构的溶液、由非泡腾颗粒剂重构的悬液、由泡腾颗粒剂重构的泡腾制剂、酏剂、酊剂、糖浆剂等。液体口服给药组合物通常包括公开的化合物和载剂,即选自稀释剂、着色剂、调味剂、甜味剂、防腐剂、溶剂、悬浮剂和表面活性剂的载剂。经口液体组合物优选包括选自着色剂、调味剂和甜味剂的一种或多种成分。
可用于实现主题化合物的系统性递送的其他组合物包括舌下、颊和鼻剂型。此类组合物通常包括一种或多种可溶性填充物质,例如稀释剂包括蔗糖、山梨糖醇和甘露糖醇,以及粘合剂例如阿拉伯胶、微晶纤维素、羧甲基纤维素和羟丙基甲基纤维素。此类组合物还可以包括润滑剂、着色剂、调味剂、甜味剂、抗氧化剂和助流剂。
所述公开的化合物可以局部给药。可以局部施用到皮肤的局部组合物可以采取任何形式,包括固体、溶液、油、霜剂、软膏、凝胶、洗剂、洗发水、免洗型和漂洗型护发素、乳剂、清洁剂、保湿剂、喷雾剂、皮肤贴片等。局部组合物包括所公开的化合物(例如式(I)的化合物)和载剂。所述局部组合物的载剂优选地有助于所述化合物渗透到皮肤中。所述载剂还可以包括一种或多种任选组分。
与所公开的化合物相结合使用的载剂的量足以为每单位剂量的所述化合物提供用于给药的组合物的实用量。用于制备可用于本发明的方法的剂型的技术和组合物描述在下述参考文献中:《现代制药学》(Modern Pharmaceutics),第9和10章,Banker&Rhodes主编(1979);Lieberman等,《药物剂型:片剂》(Pharmaceutical Dosage Forms:Tablets)(1981);和Ansel,《药物剂型简介》(Introduction to Pharmaceutical Dosage Forms),第2版,(1976)。
载剂可以包括单一成分或两种或更多种成分的组合。在局部组合物中,载剂包括局部载剂。适合的局部载剂包括选自磷酸盐缓冲液、等渗水、去离子水、单官能醇、对称醇、芦荟凝胶、尿囊素、甘油、维生素A和E油、矿物油、丙二醇、PPG-2肉豆蔻基丙酸酯、二甲基异山梨酯、蓖麻油它们的组合等的一种或多种成分。更具体来说,用于皮肤施用的载剂包括丙二醇、二甲基异山梨酯和水,甚至更具体为磷酸盐缓冲液、等渗水、去离子水、单官能醇和对称醇。
局部组合物的载剂还可以包括选自选自润肤剂、推进剂、溶剂、保湿剂、增稠剂、粉末、香料、颜料和防腐剂的一种或多种成分,所有这些成分都是任选的。
适合的润肤剂包括硬脂醇、单蓖麻油酸甘油酯、单硬脂酸甘油酯、丙-1,2-二醇、丁-1,3-二醇、貂油、鲸蜡醇、异硬脂酸异丙醇、硬脂酸、棕榈酸异丁酯、硬脂酸异鲸蜡酯、油醇、月桂酸异丙酯、月桂酸己酯、油酸癸酯、十八烷-2-醇、异鲸蜡醇、棕榈酸鲸蜡酯、癸二酸二正丁酯、肉豆蔻酸异丙酯、棕榈酸异丙酯、硬脂酸异丙酯、硬脂酸丁酯、聚乙二醇、三乙二醇、羊毛脂、芝麻油、椰子油、花生油、蓖麻油、乙酰化羊毛脂醇、石油、矿物油、肉豆蔻酸丁酯、异硬脂酸、棕榈酸、亚油酸异丙酯、乳酸月桂酯、乳酸肉豆蔻酯、油酸癸酯、肉豆蔻酸肉豆蔻酯及其组合。用于皮肤的具体润肤剂包括硬脂醇和聚二甲基硅氧烷。基于皮肤的局部组合物中润肤剂的量通常为约5%至约95%。
适合的推进剂包括丙烷、丁烷、异丁烷、二甲醚、二氧化碳、一氧化二氮及其组合。局部组合物中推进剂的量通常为约0%至约95%。
适合的溶剂包括水、乙醇、二氯甲烷、异丙醇、蓖麻油、乙二醇单乙醚、二乙二醇单丁醚、二乙二醇单乙醚、二甲基亚砜、二甲基甲酰胺、四氢呋喃及其组合。具体的溶剂包括乙醇和等位醇。局部组合物中溶剂的量通常为约0%至约95%。
适合的保湿剂包括甘油、山梨糖醇、2-吡咯烷酮-5-甲酸钠、可溶性胶原蛋白、邻苯二甲酸二丁酯、明胶及其组合。具体的保湿剂包括甘油。局部组合物中保湿剂的量通常为0%至95%。
局部组合物中增稠剂的量通常为约0%至约95%。
适合的粉末包括β-环糊精、羟丙基环糊精、白垩、滑石、富勒斯土、高岭土、淀粉、树胶、胶体二氧化硅、聚丙烯酸钠、四烷基铵蒙皂石、三烷基芳基铵蒙皂石、化学改性的硅酸镁铝、有机改性的蒙脱石粘土、水合硅酸铝、气相二氧化硅、羧基乙烯基聚合物、羧甲基纤维素钠、单硬脂酸乙二醇酯及其组合。局部组合物中粉末的量通常为0%至95%。
局部组合物中香料的量通常为约0%至约0.5%,特别是约0.001%至约0.1%。
适合的pH调节添加剂包括HCl或NaOH,其量足以调节局部药物组合物的pH。
4.治疗方法
所述公开的化合物可用于治疗TRPV4相关的医学障碍和/或疾病的方法中。所述治疗方法可以包括向需要此类治疗的对象给药包含治疗有效量的式(I)的化合物或其可药用盐的组合物。
可以将所述化合物给药到有需要的对象以调节TRPV4,用于各种不同的生物学过程。
所述化合物可用于在人类和动物中治疗和预防某些与TRPV4功能障碍相关的疾病和障碍。此类疾病和障碍的治疗或预防可以通过将本公开的化合物或组合物单独地或作为治疗方案的一部分与另一种活性药剂相组合给药到有需要的对象,通过调节对象中的TRPV4来实现。
在组合疗法中,所述其他药物可以通过通常使用的途径和量,与所公开的化合物同时或顺序给药。当所公开的化合物与一种或多种其他药物同时使用时,含有此类药物和所述公开的化合物的采取单位剂型的药物组合物是优选的。然而,所述组合疗法也可以按照重叠的时间表给药。还设想了一种或多种活性成分与所公开的化合物的组合可以比使用任一单一药剂更加有效。
所述化合物可用于治疗或预防与TPRV4功能障碍相关的疾病或障碍,例如眼部疾病,例如视网膜病包括非增殖性和增殖性糖尿病性视网膜病和早产儿视网膜病、青光眼、黄斑变性、年龄相关性黄斑变性(湿型和干型)、视网膜色素变性、Stargardt病、黄斑水肿、葡萄膜炎、高眼压症和视网膜感染包括巨细胞病毒造成的感染。所述疾病可能是慢性的,也可能是急性的。本文公开的化合物和药物组合物也可用于预防由例如IED、飞行期间的高离心力和机械创伤介导的爆震性眼部损伤。在一个实施方式中,本文公开的化合物和药物组合物可用于治疗或预防青光眼。
暴露于系统血压、来自于CSF的流体静压和固有IOP的脊椎动物视网膜含有一种或多种压力敏感性TRP和/或压电通道。IOP或系统压力的病理性升高是许多病症的主要风险因子,例如青光眼,一组以RGC的凋亡性丧失、视神经退化和视野的进行性丧失为特征的遗传性视神经病变。青光眼的细胞病理生理学尚未被充分了解,这部分是因为将机械刺激(ΔIOP)与细胞信号转导耦合的机制仍有待表征。
本文公开的化合物和组合物可用于治疗或预防眼部疾病之外的TRPV4通道拮抗剂可能对其有益的疾病和障碍。例如,式(I)的化合物可用于治疗和/或预防膀胱的障碍、心力衰竭、肺水肿、动脉粥样硬化、与肠水肿、手术后腹部水肿、局部和全身水肿相关的障碍、体液潴留、脓毒症、高血压、炎症、骨相关功能障碍和充血性心力衰竭、肺部障碍、慢性阻塞性肺部障碍、呼吸机引起的肺损伤、高原引起的肺水肿、急性呼吸窘迫综合征、急性肺损伤、肺纤维化、鼻窦炎/鼻炎、哮喘、膀胱过度活动症、疼痛、运动神经元障碍、遗传性功能获得障碍、心血管疾病、肾功能不全、骨关节炎、克罗恩病、结肠炎、腹泻、肠道不规则(高反应性/低反应性)、大便失禁、肠易激综合征(IBS)、便秘、肠痛和痉挛、乳糜泻、乳糖不耐症或肠胃胀气。
还提供了一种在对象中治疗TRPV4受体调节预计将对其有益的一种或多种障碍的方法,所述方法包括以在所述对象中有效治疗所述障碍的剂量和量向所述对象给药至少一种所公开的化合物、至少一种所公开的药物组合物和/或至少一种所公开的产品的步骤。
本公开涉及所描述的化学组合物的用途,其通过给药一种或多种所公开的化合物或产品在患者(优选为人类)中治疗TRPV4受体调节预计将对其具有治疗效果的疾病或障碍,例如动脉粥样硬化、与肠水肿相关的障碍、体液潴留、脓毒症、高血压、炎症、骨相关功能障碍和充血性心力衰竭、肺部障碍、膀胱过度活动症、疼痛、运动神经元障碍、遗传性功能获得障碍、心血管疾病、肾功能不全、骨关节炎、肠道不规则(高反应性/低反应性)。
还提供了一种在哺乳动物中治疗障碍的方法,所述方法包括向所述哺乳动物给药至少一种所公开的化合物、组合物或药物的步骤。
所述化合物进一步可用于预防、治疗、控制、改善本文提到的疾病、障碍和病症或降低其风险的方法中。所述化合物可以进一步与其他药剂相组合,用于预防、治疗、控制、改善上述疾病、障碍和病症或降低其风险的方法中。
此外,各种不同的眼部创伤能够对眼产生长期退行性影响。例如,由于爆炸对眼睛的压缩性影响,靠近爆炸的对象可能会发生随后的退行性病症。在某些情况下,这种损害可能不会立即发生,而是会随着时间的推移而发生。此类眼部创伤的治疗可以包括在此类创伤后将TRPV4拮抗剂递送至眼中,以缓和、降低或消除相关的长期影响。
此外,在某些情况下,RGC的凋亡可能与具有退行性组分的眼部病症相关。在某些情况下,TRPV4受体拮抗剂可以至少对RGC具有神经保护作用,从而治疗或缓和此类病症的破坏作用。值得注意的是,用TRPV4拮抗剂治疗眼对于那些经历IOP增加的对象以及那些没有表现出IOP或IOP有中度增加的对象来说是可能有益的。
一方面,TRPV4拮抗剂可以在体外和体内条件下针对压力诱导的Ca2+过载提供保护。这种拮抗剂降低眼前房中的IOP,表明它调节前眼小梁网中的体液产生/吸收,并阻断压力诱导的RGC凋亡。
已知TRPV4离子通道参与调节钙通量,并与IOP慢性增加期间发生的视网膜重塑有关(Ryskamp等,J.Neuroscience 2011,31(19),7089-7101,并入本文)。在某些实施方式中,式(I)的化合物可以拮抗过度的TRPV4激活。通过调节前眼中的体液产生来调节IOP,可用于治疗眼部疾病,尤其是青光眼。
5.药剂盒
一方面,本公开提供了药剂盒,其包含至少一种所公开的化合物或其可药用盐,和任选的下述一者或多者:
(a)至少一种已知调节TRPV4活性的药剂;
(b)至少一种已知治疗与TPRV4活性相关的障碍的药剂;
(c)治疗与TPRV4活性相关的障碍的说明书;或
(d)与眼部治疗相结合的给药所述化合物的说明书。
在某些实施方式中,所述至少一种所公开的化合物和至少一种药剂被共同配制。在某些实施方式中,所述至少一种所公开的化合物和至少一种药剂被共同包装。所述药剂盒也可以包含与其他组分共同包装、共同配制和/或共同递送的化合物和/或产品。例如,药品制造商、药品经销商、医师、配药店或药剂师可以提供包含所公开的化合物和/或产品和用于递送到患者的另一种组分的药剂盒。
所述公开的药剂盒可以与所公开的使用方法相结合使用。
所述药剂盒可以含有信息、说明或两者,说明所述药剂盒的使用为哺乳动物(特别是人类)中的医学病症提供治疗。所述信息和说明可以采取文字、图片或两者等的形式。此外或可选地,所述药剂盒可以包括化合物、组合物或两者,以及关于化合物或组合物的施用方法的信息、说明或两者,优选地有益于在哺乳动物(例如人类)中治疗或预防医学病症。
通过参考下述实施例,本发明的化合物和方法会被更好地理解,所述实施例打算作为对本发明范围的说明而不是限制。
6.实施例
提供下述实施例作为本公开的部分范围和特定实施方式的说明,并不意味着限制本公开的范围。除非另有说明,否则缩略语和化学符号具有其通常和惯用的含义。除非另有说明,否则本文描述的化合物已使用本文公开的方案和其他方法制备、分离和表征,或者可以使用所述反应路线和方法制备。
未描述可商购的、文献中描述的或本领域技术人员可以容易地获得的起始材料的制备。专业技术人员会理解,在陈述化合物类似于较早的实施例或中间体来制备的情况下,可以针对每个具体的反应修改反应时间、试剂的当量数和温度,并且可能需要或希望采用不同的后处理或纯化技术。
可以使用下述缩略语:双(三甲基甲硅烷基)酰胺锂(LHMDS),偶氮二甲酸二异丙酯(DIAD),三氟乙酸(TFA),二氯甲烷(DCM),三乙胺(Et3N),N,N-二异丙基乙基胺(DIPEA),乙酸乙酯(EtOAc),三苯基膦(PPh3),氮杂苯并三唑四甲基六氟磷酸脲(HATU),乙醇(EtOH),三叔丁氧基氢化锂铝(LiAlH(Ot-Bu)3),硼烷二甲基硫醚络合物(BH3·SMe2),N,N-二甲基氨基吡啶(DMAP),乙腈(CH3CN),二乙醚(Et2O),四氢呋喃(THF),二甲基亚砜(DMSO),N,N’-二甲基甲酰胺(DMF),三乙酰氧基硼氢化钠(NaBH(OAc)3),乙酸(AcOH),1,2-二氯乙烷(DCE),乙酸钠(NaOAc),氰基硼氢化钠(NaBH3CN),叔丁基二甲基甲硅烷基氯(TBS-Cl),和四丁基氟化铵(TBAF)。
通用方法。所有需要无水条件的反应在烤箱或火焰干燥的玻璃器皿中进行。可商购的试剂原样使用;在其他情况下,材料遵照实验室化学品纯化流程相应地纯化。将二氯甲烷、N,N’-二甲基甲酰胺、甲苯、乙腈和四氢呋喃用氮气脱气并通过溶剂纯化系统(Innovative Technologies Pure Solv)。无水1,4-二烷购自Acros Organics,在AcrosSealTM瓶中。三乙胺和N,N-二异丙基乙基胺在分子筛上储存或在使用前在分子筛上蒸馏。微波反应在908005型CEM Discover System中进行。反应通过TLC监测,通过双重短波/长波UV灯可视化,并用KMnO4或12-磷钼酸的乙醇溶液染色。快速层析在来自于EMScience的Merck硅胶Kieselgel 60(230-400目)上,使用指定的HPLC级溶剂或使用自动中压柱层析系统(Teledyne ISCO CombiFlash RF75或CombiFlash Rf+)进行。反相HPLC在Waters HPLC Semi Prep 150B系统上,使用Sunfire C18 Prep柱或Atlantis T3 Prep柱进行。LCMS数据在带有电化学检测器的Thermo ScientificTM UltiMateTM 3000UHPLC上采集,荧光检测器在214或254nm处监测。LC/MS/MS数据在带有Genesis Lightn C18、4uM 50mm柱(ID 2.1mm)的ThermoFinnigan TSQ Quantum上,以正模式或负模式采集。流动相对于正离子模式来说由乙腈(0.1%甲酸)和水(0.1%甲酸)组成,对于负离子模式来说由甲醇(5mM碳酸氢铵)和水(5mM碳酸氢铵)组成。1H NMR波谱在500MHz、400MHz和300MHz下记录,13C在125MHz下记录。质子共振相对于氘代溶剂峰来报告:对于CDCl3来说7.27ppm,对于CD3OD来说3.31ppm(中心线信号),对于DMSO-d6来说2.50,对于D2O来说4.79,使用了下述格式:化学位移(δ)[多重性(s单峰,br s宽单峰,d双重峰,t三重峰,q四重峰,m多重峰)]。碳共振被报告为以百万分率为单位的化学位移(δ),相对于相应溶剂峰的中心线信号:对于CDCl3来说77.23ppm,对于CD3OD来说49.15ppm。
实施例1–化合物1
4-((1-((2,4-二氯苯基)磺酰基)-3-甲基氮杂环丁烷-3-基)甲氧基)苯甲腈按照反应路线1制备:
试剂:步骤1)LiHMDS,CH3I,THF,–78℃至rt;2)LiBH4,THF,CH3OH;3)DIAD,PPh3,4-羟基苯甲腈,THF;4)TFA,DCM;5)2,4-二氯苯磺酰氯,Et3N,DCM。
步骤1.3-甲基氮杂环丁烷-1,3-二甲酸1-(叔丁基)3-甲基酯。在3颈烧瓶中,在N2下向无水THF(30mL)添加LHMDS溶液(1.0M,在THF中,11.3mL),并将混合物冷却至-78℃。逐滴添加氮杂环丁烷-1,3-二甲酸1-(叔丁基)3-甲基酯(2.00g,9.29mmol)在无水THF(20mL)中的溶液,将混合物在-78℃搅拌20min。逐滴添加碘代甲烷(0.75mL,12.05mmol)在无水THF(8mL)中的溶液,将混合物升温至rt并搅拌3天。将所述反应用半饱和的NH4Cl(200mL)淬灭并用EtOAc(200mL)萃取。将有机层用盐水(200mL)洗涤,在Na2SO4上干燥并真空浓缩。将残留物通过快速层析进行纯化(己烷/EtOAc),给出作为浅黄色油状物的标题化合物(1.07g)。1HNMR(500MHz,CDCl3)δppm 4.21(d,2H),3.75(s,3H),3.67(d,2H),1.53(s,3H),1.44(s,9H)。
步骤2.3-(羟甲基)-3-甲基氮杂环丁烷-1-甲酸叔丁酯。向3-甲基氮杂环丁烷-1,3-二甲酸1-(叔丁基)3-甲基酯(1.07g,4.67mmol)在无水THF(40mL)中的溶液添加LiBH4(208mg,9.54mmol),并将混合物在rt和N2下搅拌19h。与另一部分LiBH4(510mg,23.39mmol)一起向反应混合物添加CH3OH(10mL),并在rt继续搅拌25h。添加第三部分LiBH4(510mg,23.39mmol),并将混合物继续搅拌25h。将反应用半饱和的NH4Cl(100mL)猝灭并用EtOAc(2×50mL)萃取。将萃取物用盐水(75mL)洗涤,在Na2SO4上干燥,过滤并真空浓缩。将残留物通过快速层析进行纯化(己烷/EtOAc),给出作为无色半固体的标题化合物(800mg)。1H NMR(500MHz,CDCl3)δppm 3.76(d,2H),3.56-3.62(m,2H),3.54(d,2H),2.00-2.05(m,1H),1.43(s,9H),1.25(s,3H)。
步骤3.3-((4-氰基苯氧基)甲基)-3-甲基氮杂环丁烷-1-甲酸叔丁酯。向3-(羟甲基)-3-甲基氮杂环丁烷-1-甲酸叔丁酯(103mg,0.512mmol)、4-羟基苯甲腈(70mg,0.588mmol)和PPh3(230mg,0.877mmol)在无水THF(5mL)中的溶液逐滴添加纯净的DIAD(0.17mL,0.86mmol),并将混合物在rt和N2下搅拌18h。将反应混合物用EtOAc(30mL)稀释,用饱和NaHCO3水溶液(2×25mL)和盐水(25mL)洗涤,在Na2SO4上干燥,过滤并真空浓缩。将残留物通过快速层析进行纯化(己烷/EtOAc),给出纯度约为60%的标题化合物(234mg)。
步骤4.4-((3-甲基氮杂环丁烷-3-基)甲氧基)苯甲腈。将3-((4-氰基苯氧基)甲基)-3-甲基氮杂环丁烷-1-甲酸叔丁酯(纯度为约60%,234mg,0.46mmol)和TFA(1.5mL)在无水DCM(7mL)中的混合物在rt和N2下搅拌24h。将所述反应混合物真空浓缩,并将残留物在1M HCl(15mL)和DCM(15mL)中分配。将水层用另一部分DCM(15mL)洗涤,用1M NaOH(20mL)调整到碱性(约pH 12),并用DCM(3×15mL)萃取。将萃取液在Na2SO4上干燥,过滤并真空浓缩,给出作为无色油状物的标题化合物(60mg)。1H NMR(500MHz,CDCl3)δppm 7.54-7.63(m,2H),6.95-7.01(m,2H),4.03(s,2H),3.58(d,2H),3.45(d,2H),2.07(br s,1H),1.38(s,3H)。
步骤5.4-((1-((2,4-二氯苯基)磺酰基)-3-甲基氮杂环丁烷-3-基)甲氧基)苯甲腈。向4-((3-甲基氮杂环丁烷-3-基)甲氧基)苯甲腈(60mg,0.30mmol)和Et3N(85μL,0.61mmol)在无水DCM(3mL)中的溶液添加固体2,4-二氯苯磺酰氯(80mg,0.33mmol),并将混合物在rt和N2下搅拌18h。将反应混合物真空浓缩,并将残留物通过快速层析进行纯化(己烷/EtOAc),给出作为泡沫的标题化合物(106mg)。1H NMR(500MHz,CDCl3)δppm 7.98(d,1H),7.58-7.62(m,2H),7.57(d,1H),7.38(dd,1H),6.88-6.94(m,2H),4.02(d,2H),3.95(s,2H),3.79(d,2H),1.41(s,3H)。LCMS[M+H]+410.9,412.9。
实施例2-化合物2
3-((4-氰基苯氧基)甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-甲酸按照反应路线2来制备:
试剂:步骤1)LHMDS,多聚甲醛,THF,–78℃至rt;2)DIAD,PPh3,4-羟基苯甲腈,THF;3)TFA,DCM,2,4-二氯苯磺酰氯,NaOH,H2O,DCM。
步骤1.3-(羟甲基)氮杂环丁烷-1,3-二甲酸1-(叔丁基)3-甲基酯。将装备有加液漏斗的干燥的3颈250mL烧瓶置于N2气氛下并装入无水THF(60mL)。将其冷却至–78℃并添加LHMDS(1.0M,在THF中,11.8mL,11.8mmol)。逐滴添加氮杂环丁烷-1,3-二甲酸1-(叔丁基)3-甲基酯(2.10g,9.75mmol)在无水THF(25mL)中的溶液,并将混合物在–78℃和N2下搅拌1.5h。在单独的烧瓶中,在N2下用加热枪加热多聚甲醛(3.56g,118.7mmol),并将产生的甲醛气体鼓泡通入反应混合物中。将反应升温至rt,同时搅拌18h。将反应混合物用半饱和的NH4Cl(200mL)淬灭并用EtOAc(2×100mL)萃取。将有机相用盐水(200mL)洗涤,在Na2SO4上干燥,过滤并真空浓缩。将残留物通过快速层析进行纯化(己烷/EtOAc),给出作为浅黄色油状物的标题化合物(268mg)。1H NMR(500MHz,CDCl3)δppm 4.15(d,2H),4.04(d,2H),3.91-3.98(m,2H),3.80(s,3H),2.27-2.36(m,1H),1.44(s,9H)。
步骤2.3-((4-氰基苯氧基)甲基)氮杂环丁烷-1,3-二甲酸1-(叔丁基)3-甲基酯。向3-(羟甲基)氮杂环丁烷-1,3-二甲酸1-(叔丁基)3-甲基酯(268mg,1.09mmol)、4-羟基苯甲腈(144mg,1.21mmol)和PPh3(430mg,1.64mmol)在无水THF(10mL)中的溶液逐滴添加纯净的DIAD(0.32mL,1.63mmol),并将混合物在rt和N2下搅拌27h。将反应混合物用EtOAc(50mL)稀释,用饱和NaHCO3水溶液(2×50mL)和盐水(50mL)洗涤,在Na2SO4上干燥,过滤并真空浓缩。将残留物转移到EtOAc(50mL)中,用K2CO3水溶液(3×50mL)和盐水(50mL)洗涤,在Na2SO4上干燥,过滤并真空浓缩。将反应混合物通过快速层析进行纯化(己烷/EtOAc),给出与DIAD副产物混合的作为无色油状物的标题化合物(444mg,~50%纯度)。1H NMR(500MHz,CDCl3)δppm 7.60(d,2H),6.97(d,2H),4.35(s,2H),4.27(d,2H),3.95(d,2H),3.80(s,3H),1.40-1.48(m,9H)。
步骤3.3-((4-氰基苯氧基)甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-甲酸。将3-((4-氰基苯氧基)甲基)氮杂环丁烷-1,3-二甲酸1-(叔丁基)3-甲基酯(444mg,50%纯度,0.64mmol)、TFA(2mL)和DCM(10mL)的混合物在rt和N2下搅拌3h。将反应混合物真空浓缩,并将残留物转移到1M HCl(25mL)中,并用DCM(2×25mL)萃取。将水层用1M NaOH(35mL)调节到碱性并用DCM(3×25mL)萃取。将水层真空浓缩至总体积为约20mL(有大量无机盐沉淀)。添加固体NaOH(49mg,1.23mmol)、DCM(10mL)和水,以便充分搅拌。一次性添加固体2,4-二氯苯磺酰氯(324mg,1.32mmol),并将双相混合物在rt和N2下剧烈搅拌7天。添加1M HCl水溶液(10mL),将反应混合物用H2O稀释直至所有盐全都溶解,并用DCM(3×25mL)萃取。将萃取液在Na2SO4上干燥,过滤并真空浓缩。将残留物通过快速层析进行纯化(DCM/CH3OH/AcOH)。将产物级分真空浓缩,添加甲苯/CH3OH和Et2O并在真空下陆续除去,给出作为白色固体的标题化合物(82mg)。1H NMR(500MHz,DMSO-d6)δppm 7.99(d,1H),7.96(d,1H),7.77(d,2H),7.68(dd,1H),7.06(d,2H),4.37(s,2H),4.23(d,2H),4.06(d,2H)。LCMS[M+H]+441.0,443.0。
实施例3–化合物3
4-((1-((2,4-二氯苯基)磺酰基)-3-(羟甲基)氮杂环丁烷-3-基)甲氧基)苯甲腈按照反应路线3来制备:
试剂:步骤1)BH3·THF,THF。
步骤1.在0℃和N2下将BH3·THF溶液(1.0M,在THF中,0.22mL,0.22mmol)逐滴添加到无水THF(2mL)中的3-((4-氰基苯氧基)甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-甲酸(32mg,0.07mmol)。将混合物升温至rt并搅拌19h。将反应混合物用半饱和的NH4Cl(5mL)淬灭并用EtOAc(2×10mL)萃取。将有机相用盐水(10mL)洗涤,在Na2SO4上干燥,过滤并真空浓缩。将残留物通过快速层析进行纯化(己烷/EtOAc),给出作为粘稠无色油状物的标题化合物(8.9mg)。1H NMR(500MHz,CDCl3)δppm 7.98(d,1H),7.60(d,2H),7.56(d,1H),7.39(dd,1H),6.93(d,2H),4.16(s,2H),3.96-4.01(m,2H),3.92-3.96(m,2H),3.91(s,2H)。LCMS[M+H]+427.0,429.0。
实施例4-化合物4
3-((4-氰基苯氧基)甲基)-1-((2,4-二氯苯基)磺酰基)-N-甲基氮杂环丁烷-3-甲酰胺按照反应路线4来制备:
试剂:步骤1)HATU,CH3NH2,DIPEA,DMF。
步骤1.向3-((4-氰基苯氧基)甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-甲酸(14.7mg,0.033mmol)和HATU(18.0mg,0.047mmol)在无水DMF(0.5mL)中的混合物添加DIPEA(18μL,0.10mmol)和甲胺(2.0M,在THF中,0.08mL,0.160mmol)的混合物,将反应混合物在rt搅拌4h。将反应混合物用EtOAc(2mL)稀释,用饱和NaHCO3水溶液(2×2mL)和盐水(2mL)洗涤,在Na2SO4上干燥,过滤并真空浓缩。将残留物通过快速层析进行纯化(己烷/EtOAc),给出作为白色固体的标题化合物(7.2mg)。1H NMR(500MHz,CDCl3)δppm 7.98(d,1H),7.62(d,2H),7.58(d,1H),7.41(dd,1H),6.95(d,2H),6.14(br s,1H),4.33(s,2H),4.28(d,2H),4.09(d,2H),2.88(d,3H)。LCMS[M+H]+453.9,456.0。
实施例5-化合物5
3-((4-氰基苯氧基)甲基)-1-((2,4-二氯苯基)磺酰基)-N-甲基-N-(2-(甲基氨基)乙基)氮杂环丁烷-3-甲酰胺以与反应路线4相似的方式来制备。1H NMR(旋转异构体的混合物,500MHz,CDCl3)δppm 7.97(d,1H),7.61(d,2H),7.56(d,1H),7.38(dd,1H),6.96(d,2H),4.53和4.47(d,2H),4.44和4.37(s,2H),3.96-4.06(m,2H),3.43-3.52(m,2H),3.14-3.22(m,1H),2.96和2.92(s,3H),2.69-2.81(m,2H),2.39(s,3H)。LCMS[M+H]+511.0,513.0。
实施例6-化合物6
3-((4-氰基苯氧基)甲基)-1-((2,4-二氯苯基)磺酰基)-N-(四氢-2H-吡喃-4-基)氮杂环丁烷-3-甲酰胺以与反应路线4相似的方式来制备。1H NMR(500MHz,CDCl3)δppm 7.98(d,1H),7.60-7.66(m,2H),7.58(d,1H),7.41(dd,1H),6.92-6.99(m,2H),5.99(d,1H),4.33(s,2H),4.27(d,2H),4.10(d,2H),3.98-4.06(m,1H),3.90-3.97(m,2H),3.42-3.52(m,2H),1.84-1.93(m,2H),1.40-1.52(m,2H)。LCMS[M+H]+523.9,526.0。
实施例7-化合物7
3-((4-氰基-3-氟苯氧基)甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-甲酸乙酯按照反应路线5来制备:
试剂:步骤1)Pd(OH)2/C,HCl,EtOH;2)2,4-二氯苯磺酰氯,Et3N,DCM;3)LiAlH(Ot-Bu)3,THF;4)甲磺酰氯,Et3N,DCM;5)2-氟-4-羟基苯甲腈,K2CO3,CH3CN,Δ。
步骤1.氮杂环丁烷-3,3-二甲酸二乙酯盐酸盐。将Pd(OH)2(20重量%,在碳上,约50%水,1.548g)、1-苯甲基氮杂环丁烷-3,3-二甲酸二乙酯(按照Syn.Commun.2003,33,3347–3353制备,7.613g,26.12mmol)和HCl(4.0M,在二烷中,7.20mL,28.80mmol)在EtOH(200mL)中在H2气氛下搅拌18h。将混合物通过硅藻土垫过滤,用CH3OH冲洗,并将滤液真空浓缩,给出作为浅黄色油状物的标题化合物(6.209g)。1H NMR(500MHz,CDCl3)δppm 10.06(brs,1H),4.49(br s,4H),4.31(q,4H),1.26-1.35(m,6H)。
步骤2.1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3,3-二甲酸二乙酯。向氮杂环丁烷-3,3-二甲酸二乙酯盐酸盐(6.209g,26.12mmol)在无水DCM(250mL)中的溶液添加纯净的Et3N(11.5mL,82.50mmol)和2,4-二氯苯磺酰氯(8.15g,33.2mmol),并将混合物在rt和N2下搅拌20h。将反应混合物倾倒在饱和NaHCO3水溶液(500mL)中,并用DCM(2×500mL)萃取。将萃取液在Na2SO4上干燥,过滤并真空浓缩。将残留物通过在硅胶上快速层析进行纯化(己烷/EtOAc),给出作为无色油状物的标题化合物(8.80g)。1H NMR(500MHz,CDCl3)δppm 7.95(d,1H),7.55(d,1H),7.37(dd,1H),4.40(s,4H),4.25(q,4H),1.27(t,6H)。
步骤3.1-((2,4-二氯苯基)磺酰基)-3-(羟甲基)氮杂环丁烷-3-甲酸乙酯。在0℃和N2下,将LiAlH(Ot-Bu)3溶液(1.0M,在THF中,45.5mL,45.5mmol)通过加液漏斗逐滴添加到1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3,3-二甲酸二乙酯(8.8g,21.45mmol)在无水THF(200mL)中的溶液。将混合物升温至rt并搅拌22h。将反应混合物用EtOAc(500mL)稀释,用1MHCl(2×500mL)和盐水(500mL)洗涤,在Na2SO4上干燥,过滤并真空浓缩。将残留物通过快速层析进行纯化(己烷/EtOAc),给出作为白色结晶固体的标题化合物(5.88g)。1H NMR(500MHz,CDCl3)δppm 7.93-8.00(m,1H),7.53-7.58(m,1H),7.35-7.40(m,1H),4.32(d,2H),4.20-4.27(m,2H),3.96(s,2H),3.92(d,2H),1.26-1.32(m,3H)。
步骤4.1-((2,4-二氯苯基)磺酰基)-3-(((甲基磺酰基)氧基)甲基)氮杂环丁烷-3-甲酸乙酯。向1-((2,4-二氯苯基)磺酰基)-3-(羟甲基)氮杂环丁烷-3-甲酸乙酯(5.88g,15.97mmol)和Et3N(3.4mL,24.4mmol)在无水DCM(200mL)中的溶液逐滴添加纯净的甲磺酰氯(1.40mL,18.08mmol),并将混合物在rt和N2下搅拌3h。将反应混合物倾倒在饱和NaHCO3水溶液(500mL)中,并用DCM(2×500mL)萃取。将萃取液在Na2SO4上干燥,过滤并真空浓缩,给出作为橙色油状物的标题化合物(6.67g)。1H NMR(500MHz,CDCl3)δppm 7.96(d,1H),7.56(d,1H),7.36-7.41(m,1H),4.55(s,2H),4.38(d,2H),4.25(q,2H),4.00(d,2H),3.07(s,3H),1.27-1.32(m,3H)。
步骤5.3-((4-氰基-3-氟苯氧基)甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-甲酸乙酯。将1-((2,4-二氯苯基)磺酰基)-3-(((甲基磺酰基)氧基)甲基)氮杂环丁烷-3-甲酸乙酯(5.33g,11.94mmol)、2-氟-4-羟基苯甲腈(1.96g,14.33mmol)和K2CO3(3.30g,23.87mmol)在无水CH3CN(50mL)中的混合物在80℃和N2下搅拌20h。将反应混合物冷却,用EtOAc(500mL)稀释,用2M K2CO3(2×400mL)和盐水(2×400mL)洗涤,在Na2SO4上干燥,过滤并真空浓缩,给出作为粘稠无色油状物的标题化合物(5.59g,11.47mmol)。1H NMR(500MHz,CDCl3)δppm 7.97(d,1H),7.56-7.58(m,1H),7.52-7.55(m,1H),7.39(dd,1H),6.78(dd,1H),6.73(dd,1H),4.41(d,2H),4.36(s,2H),4.25(q,2H),4.10(d,2H),1.27(t,3H)。LCMS[M+H]+487,488。
实施例8-化合物8
3-((4-氰基-3-氟苯氧基)甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-甲酸按照反应路线6来制备:
试剂:步骤1)4M NaOH水溶液,THF。
步骤1.向3-((4-氰基-3-氟苯氧基)甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-甲酸乙酯(1.02g,2.09mmol)在THF(20mL)中的溶液添加4M NaOH水溶液(5.30mL,21.2mmol),并将混合物在rt和N2下搅拌3h。将反应混合物真空浓缩以除去THF,用1M HCl(50mL)调整到酸性,用水(50mL)稀释,用固体NaCl饱和并用DCM(3×100mL)萃取。将萃取液在Na2SO4上干燥,过滤并真空浓缩,给出作为白色泡沫的标题化合物(910mg)。1H NMR(500MHz,CDCl3)δppm 7.97(d,1H),7.53-7.59(m,2H),7.39(dd,1H),6.79(dd,1H),6.75(dd,1H),4.47(d,2H),4.39(s,2H),4.13(d,2H)。LCMS[M+H]+459,461。
实施例9-化合物9
3-((4-氰基-3-氟苯氧基)甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-甲酰胺按照反应路线7来制备:
试剂:步骤1)HATU,NH3,DIPEA,DMF
步骤1.在N2下向3-((4-氰基-3-氟苯氧基)甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-甲酸(27.0mg,0.059mmol)和HATU(28.5mg,0.075mmol)在无水DMF(2mL)中的溶液添加纯净的DIPEA(32μL,0.184mmol),并将混合物在rt搅拌30min。将氨气鼓泡通过所述反应混合物5min,并将混合物在rt搅拌19h。将反应混合物用EtOAc(10mL)稀释,用饱和NaHCO3水溶液(2×10mL)和盐水(2×10mL)洗涤,在Na2SO4上干燥,过滤并真空浓缩。将残留物通过快速层析进行纯化(己烷/EtOAc),给出作为黄色油状物的标题化合物(5.0mg)。1HNMR(500MHz,CDCl3)δppm 7.99(d,1H),7.55-7.61(m,2H),7.42(dd,1H),6.79(dd,1H),6.75(dd,1H),6.18(br s,br s,1H),5.60(br s,br s,1H),4.34(s,2H),4.28(d,2H),4.16(d,2H)。LCMS[M+H]+458.0,460.0。
实施例10-化合物10
(3-((4-(氨基甲基)-3-氟苯氧基)甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-基)甲醇按照反应路线8来制备:
试剂:步骤1)BH3·THF,THF。
步骤1.在0℃和N2下向3-((4-氰基-3-氟苯氧基)甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-甲酸(248mg,0.54mmol)在无水THF(5mL)中的溶液逐滴添加BH3·THF溶液(1.0M,在THF中,1.65mL)。将混合物升温至rt并搅拌21h。将反应混合物用1M HCl(10mL)淬灭,用饱和NaHCO3水溶液(35mL)中和,并用EtOAc(2×35mL)萃取。将有机相用盐水(35mL)洗涤,干燥(Na2SO4),过滤并真空浓缩。将残留物在硅胶上通过快速层析进行纯化(EtOAc/己烷,然后是DCM/CH3OH/NH4OH),给出作为白色泡沫的标题化合物(111mg)。1H NMR(500MHz,DMSO-d6)δppm 7.96(d,1H),7.95(d,1H),7.67(dd,1H),7.32(t,1H),6.55-6.61(m,2H),5.06(t,1H),3.93(s,2H),3.76-3.82(m,4H),3.64(s,2H),3.52(d,2H),1.98(br s,2H)。LCMS[M+H]+449。
实施例11–化合物11
4-((1-((2,4-二氯苯基)磺酰基)-3-(羟甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈按照反应路线9来制备:
试剂:步骤1)BH3·SMe2(1.0M,在THF中),THF。
步骤1.在0℃和N2下将BH3·SMe2溶液(0.30mL,3.16mmol)逐滴添加到无水THF(20mL)中的3-((4-氰基-3-氟苯氧基)甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-甲酸(971mg,2.12mmol)。将混合物升温至rt并搅拌20h。将反应混合物用1M NaOH(15mL)淬灭,倾倒在饱和NaHCO3水溶液(100mL)中,并用EtOAc(2×75mL)萃取。将有机相用盐水(75mL)洗涤,在Na2SO4上干燥,过滤并真空浓缩。将残留物通过快速层析进行纯化(己烷/EtOAc),给出作为粘稠无色油状物的标题化合物(760mg,1.71mmol)。1H NMR(500MHz,CDCl3)δppm 7.98(d,1H),7.57(d,1H),7.53(dd,1H),7.39(dd,1H),6.75(dd,1H),6.71(dd,1H),4.16(s,2H),3.95-3.99(m,2H),3.92-3.95(m,2H),3.90(d,2H),1.75(t,1H)。LCMS[M+H]+445,447。LC/MS/MS[M-H]-442.7。
实施例12-化合物12
(3-((4-氰基-3-氟苯氧基)甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-基)甲基乙酸酯按照反应路线10来制备:
试剂:步骤1)乙酸酐,Et3N,DMAP,DCM。
步骤1.向4-((1-((2,4-二氯苯基)磺酰基)-3-(羟甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈(19.7mg,0.044mmol)、Et3N(12μL,0.088mmol)和乙酸酐(10μL,0.088mmol)在无水DCM(0.5mL)中的溶液添加催化性DMAP,并将混合物在rt搅拌6h。将反应混合物在硅胶上通过快速层析直接纯化(EtOAc/己烷),给出作为粘稠无色油状物的标题化合物(20.1mg)。1H NMR(500MHz,CDCl3)δppm 7.97(d,1H),7.52-7.59(m,2H),7.39(dd,1H),6.76(dd,1H),6.71(dd,1H),4.32(s,2H),4.12(s,2H),4.01(d,2H),3.96(d,2H),2.07(s,3H)。LCMS[M+H]+487,489。
实施例13-化合物13
4-((1-((2,4-二氯苯基)磺酰基)-3-(甲氧基甲基)氮杂环丁烷-3-基)甲氧基)-氟苯甲腈按照反应路线11来制备:
试剂:步骤1)NaH,CH3I,THF。
步骤1.向装有搅拌棒的烤箱干燥的烧瓶添加NaH(9.2mg,0.383mmol),将烧瓶盖上盖子并置于N2气氛下,添加无水THF(0.5mL)。逐滴添加4-((1-((2,4-二氯苯基)磺酰基)-3-(羟甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈(53.2mg,0.119mmol)在无水THF(0.5mL)中的溶液,然后添加CH3I(16.0μL,0.257mmol)在无水THF(0.5mL)中的溶液,并将混合物在rt搅拌20h。将反应混合物用EtOAc(15mL)稀释,并用饱和NaHCO3水溶液(2×10mL)和盐水(2×10mL)洗涤。将有机层在Na2SO4上干燥,倾析并真空浓缩。将残留物在硅胶上通过快速层析进行纯化(己烷/EtOAc),给出作为白色固体的标题化合物(17.2mg)。1H NMR(500MHz,CDCl3)δppm 7.97(d,1H),7.56-7.59(m,1H),7.53(dd,1H),7.39(dd,1H),6.74(dd,1H),6.69(dd,1H),4.09(s,2H),3.97(d,2H),3.88-3.92(m,2H),3.57(s,2H),3.34(s,3H)。
实施例14-化合物14
(3-((4-氰基-3-氟苯氧基)甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-基)甲基磷酸钠按照反应路线12来制备:
试剂:步骤1)三氯氧磷(V),Et3N,THF。
步骤1.向4-((1-((2,4-二氯苯基)磺酰基)-3-(羟甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈(89mg,0.20mmol)和Et3N(56μL,0.40mmol)在无水THF(2.0mL)中的溶液逐滴添加纯净的三氯氧磷(V)(30μL,0.32mmol),并将混合物在rt搅拌3h。将反应混合物用1MNaOH(5mL)淬灭,用H2O(10mL)稀释并用EtOAc(2×15mL)洗涤。将水层用6M HCl酸化至pH 1并用DCM(3×20mL)萃取。将萃取液在Na2SO4上干燥,过滤并浓缩至干,给出磷酸酯(83mg,0.16mmol)。将残留物溶解在CH3OH和THF中,并添加0.1M NaHCO3水溶液(3.2mL)。将混合物浓缩至干,并将残留物从无水CH3OH浓缩两次,给出作为白色固体的标题化合物(85mg,0.15mmol)。1H NMR(500MHz,CD3OD)δppm 8.03(d,1H),7.75(d,1H),7.63(dd,1H),7.56(dd,1H),6.92(dd,1H),6.85(dd,1H),4.17(s,2H),4.01-4.08(m,4H),3.91(d,2H)。LCMS[M+H]+524.9,526.9。LC/MS/MS[M-H]-522.8。
实施例15-化合物15
2-氨基乙烷-1-磺酸(3-((4-氰基-3-氟苯氧基)甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-基)甲基酯三氟乙酸盐按照反应路线13来制备:
试剂:步骤1)N-Boc牛磺酸氯化物,Et3N,DCM;2)TFA,DCM。
步骤1.2-((叔丁氧基羰基)氨基)乙烷-1-磺酸(3-((4-氰基-3-氟苯氧基)甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-基)甲基酯。向如Nucleosides,Nucleotides,and Nucleic Acids 2013,32,599中所述制备的N-Boc牛磺酸盐酸盐(24mg,0.10mmol)在无水DCM(0.5mL)中的混合物添加4-((1-((2,4-二氯苯基)磺酰基)-3-(羟甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈(34mg,0.077mmol)和Et3N(22μL,0.16mmol)在无水DCM(1mL)中的溶液,并将混合物在rt搅拌3天。将反应混合物通过快速层析直接纯化(EtOAc/己烷),得到作为无色油状物的标题化合物(29mg)。
步骤2.2-氨基乙烷-1-磺酸(3-((4-氰基-3-氟苯氧基)甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-基)甲基酯三氟乙酸盐。向2-((叔丁氧基羰基)氨基)乙烷-1-磺酸(3-((4-氰基-3-氟苯氧基)甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-基)甲基酯(29mg,0.044mmol)在无水DCM(1mL)中的溶液添加纯净的TFA(0.1mL),并将混合物在rt搅拌2h。将反应混合物浓缩至干,从二烷和Et2O浓缩至干各两次,得到作为粘稠黄色油状物的标题化合物(30mg)。1H NMR(500MHz,DMSO-d6)δppm 7.91-8.06(m,5H),7.85(t,1H),7.67(dd,1H),7.06(dd,1H),6.88(dd,1H),4.50(s,2H),4.21(s,2H),3.89-3.98(m,4H),3.69(t,2H),3.15-3.24(m,2H)。LCMS[M+H]+552.0,554.1。
实施例16-化合物16
4-((1-((2,4-二氯苯基)磺酰基)-3-((甲基氨基)甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈盐酸盐按照反应路线14来制备:
试剂:步骤1)Et3N,草酰氯,DMSO,DCM;–78℃;2)CH3NH2,NaBH(OAc)3,AcOH,DCE。
步骤1.4-((1-((2,4-二氯苯基)磺酰基)-3-甲酰基氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈。在-78℃和N2下,向草酰氯(0.350mL,4.027mmol)在无水DCM(3mL)中的溶液逐滴添加DMSO(0.560mL,7.887mmol)在无水DCM(3mL)中的溶液。将混合物搅拌10min,逐滴添加4-((1-((2,4-二氯苯基)磺酰基)-3-(羟甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈(760mg,1.707mmol)在无水DCM(10mL)中的溶液。将混合物在-78℃搅拌30min,逐滴添加Et3N(1.30mL,9.326mmol)。将混合物升温至rt并搅拌22h。将反应混合物倾倒在饱和NaHCO3水溶液(100mL)中并用DCM(3×50mL)萃取。将萃取液在Na2SO4上干燥,过滤并真空浓缩,给出作为黄色油状物的粗品标题化合物(681.1mg)。1H NMR(500MHz,CDCl3)δppm 9.87-9.93(m,1H),7.96-8.00(m,1H),7.51-7.60(m,2H),7.39-7.43(m,1H),6.76-6.80(m,1H),6.72-6.76(m,1H),4.38(s,2H),4.30(s,2H),4.15-4.20(m,2H)。
步骤2.4-((1-((2,4-二氯苯基)磺酰基)-3-((甲基氨基)甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈盐酸盐。向4-((1-((2,4-二氯苯基)磺酰基)-3-甲酰基氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈(258mg,0.58mmol)、甲胺(2.0M,在THF中,0.73mL,1.46mmol)和乙酸(2滴)在无水DCE(5mL)中的溶液添加固体NaBH(OAc)3(310mg,1.46mmol),并将混合物在rt搅拌22h。将反应混合物倾倒在饱和NaHCO3水溶液(100mL)中并用DCM(3×50mL)萃取。将萃取液在Na2SO4上干燥,倾析并真空浓缩。将残留物在硅胶上通过快速层析进行纯化(己烷/EtOAc/CH3OH)。向纯化的材料添加HCl溶液(4.0M,在二烷中)并浓缩。将所述固体用CH3OH/Et2O研磨并通过真空过滤收集沉淀物,给出作为白色固体的标题化合物(106mg)。1HNMR(500MHz,DMSO-d6)δppm 8.79(br s,br s,2H),7.97(m,2H),7.86(m,1H),7.67(dd,1H),7.01(dd,1H),6.87(dd,1H),4.23(s,2H),4.02(d,2H),3.87(d,2H),3.33(m,2H),2.58(brs,br s,3H)。LCMS[M+H]+458,460。
实施例17-化合物17
4-((1-((2,4-二氯苯基)磺酰基)-3-(((2-羟乙基)氨基)甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈以与反应路线14中相似的方式,从4-((1-((2,4-二氯苯基)磺酰基)-3-甲酰基氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈和乙醇胺制备。1H NMR(500MHz,CDCl3)δppm 7.98(d,1H),7.57(d,1H),7.54(dd,1H),7.39(dd,1H),6.75(dd,1H),6.72(dd,1H),4.13(s,2H),3.89-3.97(m,4H),3.62-3.67(m,2H),2.97(s,2H),2.77-2.83(m,2H)。LCMS[M+H]+488,490。
实施例18-化合物18
4-((1-((2,4-二氯苯基)磺酰基)-3-(((四氢-2H-吡喃-4-基)氨基)甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈盐酸盐以与反应路线14中相似的方式,从4-((1-((2,4-二氯苯基)磺酰基)-3-甲酰基氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈和4-氨基四氢吡喃制备。1H NMR(游离碱)(500MHz,CDCl3)δppm 7.98(d,1H),7.57(d,1H),7.53(dd,1H),7.39(dd,1H),6.74(dd,1H),6.71(dd,1H),4.11-4.13(m,2H),3.90-3.97(m,4H),3.85-3.90(m,2H),3.31-3.40(m,2H),2.95(s,2H),2.55-2.66(m,1H),1.78(d,2H),1.30(d,2H)。LCMS[M+H]+528,530。
实施例19-化合物19
4-((1-((2,4-二氯苯基)磺酰基)-3-(((3-羟丙基)氨基)甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈盐酸盐以与反应路线14中相似的方式,从4-((1-((2,4-二氯苯基)磺酰基)-3-甲酰基氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈和3-氨基-1-丙醇制备。1H NMR(游离碱)(500MHz,CDCl3)δppm 7.97(d,1H),7.56(d,1H),7.54(dd,1H),7.37-7.40(m,1H),6.75(dd,1H),6.71(dd,1H),4.09-4.12(m,2H),3.87-3.96(m,4H),3.73-3.78(m,2H),2.97(s,2H),2.86(t,2H),1.70(quin,2H)。LCMS[M+H]+502,504。
实施例20-化合物20
2-(((3-((4-氰基-3-氟苯氧基)甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-基)甲基)氨基)乙酰胺盐酸盐以与反应路线14中相似的方式,从4-((1-((2,4-二氯苯基)磺酰基)-3-甲酰基氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈和甘氨酰胺盐酸盐制备。1H NMR(游离碱)(500MHz,CDCl3)δppm 7.97(d,1H),7.52-7.58(m,2H),7.39(dd,1H),6.76(dd,1H),6.72(dd,1H),6.48(br s,1H),5.41-5.49(m,1H),4.13-4.16(m,2H),3.97-4.02(m,2H),3.90-3.95(m,2H),3.34(s,2H),2.97(s,2H)。LCMS[M+H]+501,503。
实施例21-化合物21
4-((1-((2,4-二氯苯基)磺酰基)-3-(((2-甲氧基乙基)氨基)甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈盐酸盐以与反应路线14中相似的方式,从4-((1-((2,4-二氯苯基)磺酰基)-3-甲酰基氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈和2-甲氧基乙胺制备。1HNMR(游离碱)(500MHz,CDCl3)δppm 7.97(d,1H),7.56(d,1H),7.50-7.55(m,1H),7.38(dd,1H),6.68-6.77(m,2H),4.13(s,2H),3.91-3.96(m,2H),3.87(d,2H),3.43(t,2H),3.32(s,3H),2.94(s,2H),2.76(t,2H)。LCMS[M+H]+502,504。
实施例22-化合物22
4-((1-((2,4-二氯苯基)磺酰基)-3-(((噻唑-2-基甲基)氨基)甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈盐酸盐以与反应路线14中相似的方式,从4-((1-((2,4-二氯苯基)磺酰基)-3-甲酰基氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈和噻唑-2-基甲胺制备。1HNMR(游离碱)(500MHz,CDCl3)δppm 8.10(s,1H),7.97(d,1H),7.70(d,1H),7.55(d,1H),7.54–7.51(m,1H),7.38(dd,1H),6.74(dd,1H),6.70(dd,1H),4.17(s,2H),4.15(s,2H),3.96(d,2H),3.92(d,2H),3.04(s,2H)。LCMS[M+H]+541,543。
实施例23-化合物23
4-((1-((2,4-二氯苯基)磺酰基)-3-((((四氢呋喃-3-基)甲基)氨基)甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈盐酸盐以与反应路线14中相似的方式,从4-((1-((2,4-二氯苯基)磺酰基)-3-甲酰基氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈和(四氢呋喃-3-基)甲胺制备。1H NMR(游离碱)(500MHz,CDCl3)δppm 7.91(d,1H),7.44-7.52(m,2H),7.32(dd,1H),6.61-6.71(m,2H),4.05(s,2H),3.80-3.89(m,4H),3.70-3.78(m,2H),3.62-3.68(m,1H),3.41(dd,1H),2.86(q,2H),2.47-2.60(m,2H),2.18-2.28(m,1H),1.87-1.99(m,1H),1.47(dd,1H)。LCMS[M+H]+528,530。
实施例24-化合物24
4-((1-((2,4-二氯苯基)磺酰基)-3-(((2-羟丙基)氨基)甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈盐酸盐以与反应路线14中相似的方式,从4-((1-((2,4-二氯苯基)磺酰基)-3-甲酰基氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈和1-氨基-2-丙醇制备。1H NMR(游离碱)(500MHz,CDCl3)δppm 7.91(d,1H),7.43-7.53(m,2H),7.32(dd,1H),6.62-6.72(m,2H),4.07(s,2H),3.83-3.90(m,4H),3.67-3.75(m,1H),2.85-2.97(m,2H),2.66(dd,1H),2.39(dd,1H),1.08(d,3H)。LCMS[M+H]+502,504。
实施例25-化合物25
4-((1-((2,4-二氯苯基)磺酰基)-3-((乙基氨基)甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈盐酸盐以与反应路线14中相似的方式,从4-((1-((2,4-二氯苯基)磺酰基)-3-甲酰基氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈和乙胺(2.0M,在THF中)制备。1H NMR(游离碱)(500MHz,CDCl3)δppm 7.97(d,1H),7.50-7.59(m,2H),7.39(dd,1H),6.69-6.78(m,2H),4.12(s,2H),3.92-3.96(m,2H),3.86-3.90(m,2H),2.93(s,2H),2.64(q,2H),1.06(t,3H)。LCMS[M+H]+472,474。
实施例26-化合物26
4-((1-((2,4-二氯苯基)磺酰基)-3-((氧杂环丁烷-3-基氨基)甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈以与反应路线14中相似的方式,从4-((1-((2,4-二氯苯基)磺酰基)-3-甲酰基氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈和氧杂环丁烷-3-胺制备。1H NMR(500MHz,CDCl3)δppm 7.97(d,1H),7.52-7.58(m,2H),7.39(dd,1H),6.75(dd,1H),6.71(dd,1H),4.80(t,2H),4.37(t,2H),4.12-4.15(m,2H),3.85-3.96(m,5H),2.90(s,2H)。LCMS[M+H]+500,502。
实施例27-化合物27
4-((1-((2,4-二氯苯基)磺酰基)-3-(((氧杂环丁烷-3-基甲基)氨基)甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈以与反应路线14中相似的方式,从4-((1-((2,4-二氯苯基)磺酰基)-3-甲酰基氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈和3-氧杂环丁烷甲胺制备。1H NMR(500MHz,CDCl3)δppm 7.97(d,1H),7.51-7.58(m,2H),7.36-7.40(m,1H),6.74(dd,1H),6.70(dd,1H),4.76(dd,2H),4.34(t,2H),4.11(s,2H),3.85-3.94(m,4H),2.97-3.08(m,1H),2.91-2.97(m,4H)。LCMS[M+H]+514,516。
实施例28-化合物28
(S)-4-((1-((2,4-二氯苯基)磺酰基)-3-((((四氢呋喃-2-基)甲基)氨基)甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈盐酸盐以与反应路线14中相似的方式,从4-((1-((2,4-二氯苯基)磺酰基)-3-甲酰基氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈和(S)-四氢呋喃甲胺制备。1H NMR(500MHz,DMSO-d6)δppm 9.21(br s,1H),9.04(br s,1H),7.97(dd,1H),7.86(t,1H),7.67(dd,2H),6.98(dd,1H),6.84(dd,1H),4.23-4.29(m,2H),3.98(d,2H),3.90(d,2H),3.74-3.82(m,1H),3.63-3.71(m,1H),3.30-3.48(m,3H),3.10(br s,1H),2.94(br s,1H),1.93-2.04(m,1H),1.75-1.90(m,2H),1.49-1.59(m,1H)。LCMS[M+H]+528,530。
实施例29-化合物29
4-((1-((2,4-二氯苯基)磺酰基)-3-((((四氢-2H-吡喃-4-基)甲基)氨基)甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈盐酸盐以与反应路线14中相似的方式,从4-((1-((2,4-二氯苯基)磺酰基)-3-甲酰基氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈和4-氨基甲基四氢吡喃制备。1H NMR(500MHz,DMSO-d6)δppm 9.01-8.82(m,2H),8.03-7.95(m,2H),7.91-7.83(m,1H),7.69(dd,1H),6.99(dd,1H),6.85(dd,1H),4.29(s,2H),4.03(d,2H),3.92(d,2H),3.89-3.81(m,2H),3.43-3.37(m,2H),3.26(td,2H),2.93-2.84(m,2H),2.11-1.98(m,1H),1.73-1.63(m,2H),1.30-1.14(m,2H)。LCMS[M+H]+542,544。
实施例30-化合物30
(R)-4-((1-((2,4-二氯苯基)磺酰基)-3-(((2-羟丙基)氨基)甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈盐酸盐以与反应路线14中相似的方式,从4-((1-((2,4-二氯苯基)磺酰基)-3-甲酰基氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈和(R)-(-)-1-氨基-2-丙醇制备。1H NMR(500MHz,DMSO-d6)δppm 8.95-8.78(m,2H),8.02-7.96(m,2H),7.90-7.85(m,1H),7.69(dd,1H),7.01(dd,1H),6.87(dd,1H),5.50-5.29(m,1H),4.28(s,2H),4.09-3.97(m,3H),3.94-3.88(m,2H),3.45-3.37(m,2H),3.07-2.98(m,1H),2.86-2.76(m,1H),1.11(d,3H)。LCMS[M+H]+502,504。
实施例31-化合物31
(S)-4-((1-((2,4-二氯苯基)磺酰基)-3-(((2-羟丙基)氨基)甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈盐酸盐以与反应路线14中相似的方式,从4-((1-((2,4-二氯苯基)磺酰基)-3-甲酰基氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈和(S)-(+)-1-氨基-2-丙醇制备。1H NMR(500MHz,DMSO-d6)δppm 8.96-8.78(m,2H),8.01-7.96(m,2H),7.91-7.85(m,1H),7.69(dd,1H),7.01(dd,1H),6.87(dd,1H),5.50-5.30(m,1H),4.28(s,2H),4.08-3.97(m,3H),3.94-3.88(m,2H),3.46-3.39(m,2H),3.07-2.99(m,1H),2.86-2.76(m,1H),1.11(d,3H)。LCMS[M+H]+502,504。
实施例32-化合物32
4-((1-((2,4-二氯苯基)磺酰基)-3-(((1-羟基丙-2-基)氨基)甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈盐酸盐以与反应路线14中相似的方式,从4-((1-((2,4-二氯苯基)磺酰基)-3-甲酰基氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈和(+/-)丙氨醇制备。1H NMR(500MHz,DMSO-d6)δppm 8.90-8.65(m,2H),8.03-7.96(m,2H),7.91-7.85(m,1H),7.69(dd,1H),6.99(dd,1H),6.86(dd,1H),5.41(s,1H),4.27(s,2H),4.02-3.96(m,2H),3.96-3.90(m,2H),3.73-3.64(m,2H),3.59-3.52(m,1H),3.52-3.45(m,1H),3.37-3.28(m,1H),1.23(d,3H)。LCMS[M+H]+502,504。
实施例33-化合物33
4-((1-((2,4-二氯苯基)磺酰基)-3-(((2,3-二羟基丙基)氨基)甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈盐酸盐以与反应路线14中相似的方式,从4-((1-((2,4-二氯苯基)磺酰基)-3-甲酰基氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈和3-氨基-1,2-丙二醇制备。1H NMR(500MHz,CD3OD)δppm 8.05-8.00(m,1H),7.77(d,1H),7.71(dd,1H),7.58-7.54(m,1H),7.01(dd,1H),6.97(dd,1H),4.39-4.33(m,2H),4.10-4.02(m,4H),4.01-3.95(m,1H),3.68-3.64(m,1H),3.64-3.62(m,1H),3.62-3.55(m,2H),3.28-3.26(m,1H),3.20-3.14(m,1H)。LCMS[M+H]+518,520。
实施例34-化合物34
4-((1-((2,4-二氯苯基)磺酰基)-3-(((3-羟基-2-甲基丙基)氨基)甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈盐酸盐以与反应路线14中相似的方式,从4-((1-((2,4-二氯苯基)磺酰基)-3-甲酰基氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈和3-氨基-2-甲基丙-1-醇制备。1H NMR(500MHz,CD3OD)δppm 8.02(d,1H),7.76(d,1H),7.69(dd,1H),7.56(dd,1H),6.99(dd,1H),6.95(dd,1H),4.35(s,2H),3.98-4.11(m,4H),3.71-3.78(m,1H),3.54-3.59(m,1H),3.43-3.51(m,2H),3.06-3.17(m,2H),2.16-2.27(m,1H),0.93(d,3H)。LCMS[M+H]+516,518。
实施例35-化合物35
4-((1-((2,4-二氯苯基)磺酰基)-3-(((3-羟基丁基)氨基)甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈盐酸盐以与反应路线14中相似的方式,从4-((1-((2,4-二氯苯基)磺酰基)-3-甲酰基氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈和4-氨基-2-丁醇制备。1H NMR(500MHz,CD3OD)δppm 8.02(d,1H),7.77(d,1H),7.70(dd,1H),7.53-7.58(m,1H),6.98(dd,2H),6.94(dd,2H),4.32(s,2H),4.00-4.08(m,4H),3.95(s,1H),3.44-3.57(m,2H),3.20-3.27(m,2H),1.84(d,1H),1.77(s,1H),1.18-1.24(m,3H)。LCMS[M+H]+516,518。
实施例36-化合物36
4-((3-(((2-氰基乙基)氨基)甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈以与反应路线14中相似的方式,从4-((1-((2,4-二氯苯基)磺酰基)-3-甲酰基氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈和3-氨基丙腈制备。1H NMR(500MHz,CDCl3)δppm 7.96-7.99(m,1H),7.56-7.58(m,1H),7.51-7.55(m,1H),7.37-7.41(m,1H),6.74-6.77(m,1H),6.70-6.74(m,1H),4.11(s,2H),3.85-3.96(m,4H),2.93(s,2H),2.84-2.88(m,2H),2.44-2.48(m,2H)。LCMS[M+H]+497,499。
实施例37-化合物37
3-(((3-((4-氰基-3-氟苯氧基)甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-基)甲基)氨基)丙酸乙酯盐酸盐以与反应路线14中相似的方式,从4-((1-((2,4-二氯苯基)磺酰基)-3-甲酰基氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈和β-丙氨酸乙酯盐酸盐和NaOAc代替AcOH来制备。1H NMR(500MHz,DMSO-d6)δppm 8.91-9.08(m,2H),7.94-8.04(m,2H),7.87(t,1H),7.67(d,1H),7.00(d,1H),6.86(d,1H),4.25(s,2H),4.08(q,2H),4.01(d,2H),3.88(d,2H),3.35-3.46(m,2H),3.13-3.28(m,2H),2.77-2.88(m,2H),1.15-1.26(m,3H)。LCMS[M+H]+544.0,546.1。
实施例38-化合物38
4-((1-((2,4-二氯苯基)磺酰基)-3-((((顺)-3-羟基环丁基)氨基)甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈盐酸盐以与反应路线14中相似的方式,从4-((1-((2,4-二氯苯基)磺酰基)-3-甲酰基氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈和顺-3-氨基环丁醇盐酸盐和NaOAc制备。1H NMR(500MHz,CD3OD)δppm 8.02(d,1H),7.77(d,1H),7.71(dd,1H),7.56(dd,1H),6.98(dd,1H),6.93(dd,1H),4.29(s,2H),4.07-4.14(m,1H),3.98-4.06(m,4H),3.33-3.43(m,3H),2.67-2.78(m,2H),2.01-2.14(m,2H)。LCMS[M+H]+514.1,516.2。
实施例39-化合物39
4-((1-((2,4-二氯苯基)磺酰基)-3-((((顺)-4-羟基环己基)氨基)甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈盐酸盐以与反应路线14中相似的方式,从4-((1-((2,4-二氯苯基)磺酰基)-3-甲酰基氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈和顺-4-氨基环己醇盐酸盐和NaOAc制备。1H NMR(500MHz,CD3OD)δppm 8.03(d,1H),7.78(d,1H),7.68-7.74(m,1H),7.57(dd,1H),6.97(dd,1H),6.93(dd,1H),4.29(s,2H),4.05-4.09(m,2H),3.98-4.04(m,3H),3.54(s,2H),3.13-3.23(m,1H),1.88-1.96(m,4H),1.78-1.87(m,2H),1.54-1.65(m,2H)。LCMS[M+H]+542.1,544.1。
实施例40-化合物40
(R)-4-((1-((2,4-二氯苯基)磺酰基)-3-((((四氢呋喃-2-基)甲基)氨基)甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈盐酸盐以与反应路线14中相似的方式,从4-((1-((2,4-二氯苯基)磺酰基)-3-甲酰基氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈和[(2R)-氧杂环戊烷-2-基]甲胺盐酸盐和NaOAc制备。1H NMR(500MHz,DMSO-d6+K2CO3)δppm 7.96-8.00(m,2H),7.80-7.86(m,1H),7.68(dd,1H),7.05(dd,1H),6.86(dd,1H),4.11(s,2H),3.77-3.84(m,4H),3.64-3.77(m,3H),3.52-3.61(m,2H),2.68-2.78(m,2H),1.68-1.88(m,3H),1.39-1.49(m,1H)。LCMS[M+H]+528.1,530.1。
实施例41-化合物41
4-((1-((2,4-二氯苯基)磺酰基)-3-((((反)-4-羟基环己基)氨基)甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈盐酸盐按照反应路线15来制备:
试剂:步骤1)NaBH3CN,反-4-氨基环己醇,CH3OH。
步骤1.向4-((1-((2,4-二氯苯基)磺酰基)-3-甲酰基氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈(50.1mg,0.113mmol)在CH3OH(1mL)中的溶液添加反-4-氨基环己醇(18.3mg,0.159mmol)并搅拌直至完全溶解。添加NaBH3CN(12.8mg,0.204mmol)并将混合物在rt搅拌18h。将反应混合物倾倒在2M K2CO3(15mL)中,并用DCM(3×10mL)萃取。将萃取液在Na2SO4上干燥,倾析并真空浓缩。将残留物在硅胶上通过快速层析进行纯化(己烷/EtOAC/CH3OH),给出作为白色固体的标题化合物(21.9mg)。1H NMR(500MHz,DMSO-d6)δppm 8.81-8.71(m,2H),8.02-7.96(m,2H),7.88(dd,1H),7.69(dd,1H),7.00(dd,1H),6.86(dd,1H),4.26(s,2H),3.98(d,2H),3.91(d,2H),3.73-3.69(m,1H),3.69-3.64(m,1H),3.52-3.48(m,1H),3.48-3.44(m,1H),2.09-2.00(m,2H),1.92-1.84(m,2H),1.50-1.37(m,2H),1.21-1.10(m,2H)。LCMS[M+H]+542,544。
实施例42-化合物42
4-((1-((2,4-二氯苯基)磺酰基)-3-((((反)-3-羟基环丁基)氨基)甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈盐酸盐以与反应路线15中相似的方式,从4-((1-((2,4-二氯苯基)磺酰基)-3-甲酰基氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈和反-3-氨基环丁-1-醇制备。1H NMR(500MHz,CD3OD)δppm 8.02(d,1H),7.77(d,1H),7.71(dd,1H),7.56(dd,1H),6.98(dd,1H),6.93(dd,1H),4.44-4.51(m,1H),4.29(s,2H),4.01-4.08(m,4H),3.93-4.00(m,1H),3.39(s,2H),2.47-2.56(m,2H),2.35(br s,2H)。LCMS[M+H]+514,516。
实施例43-化合物43
4-((1-((2,4-二氯苯基)磺酰基)-3-(((2-羟乙基)(甲基)氨基)甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈盐酸盐按照反应路线16来制备:
试剂:步骤1)NaBH(OAc)3,37重量%甲醛,AcOH,DCE。
步骤1.向4-((1-((2,4-二氯苯基)磺酰基)-3-(((2-羟乙基)氨基)甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈(15mg,0.031mmol)、甲醛(37重量%,在H2O中,16μL,0.16mmol)和乙酸(1滴)在无水DCE(1mL)中的溶液添加固体NaBH(OAc)3(16.9mg,0.0798mmol),并将混合物在rt搅拌16h。将反应混合物倾倒在饱和NaHCO3水溶液(15mL)中并用DCM(3×10mL)萃取。将萃取液在Na2SO4上干燥,倾析并真空浓缩。将残留物在硅胶上通过快速层析进行纯化(己烷/EtOAc/CH3OH),给出作为粘稠无色油状物的标题化合物(7.7mg)。1H NMR(游离碱)(500MHz,CDCl3)δppm 7.97(d,1H),7.56(d,1H),7.54(dd,1H),7.38(dd,1H),6.77(dd,1H),6.73(dd,1H),4.20(s,2H),3.98(d,2H),3.90(d,2H),3.56(t,2H),2.79(s,2H),2.52-2.58(m,2H),2.22(s,3H)。LCMS[M+H]+502,504。
实施例44-化合物44
4-((3-(氨基甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈按照反应路线17来制备:
试剂:步骤1)甲磺酰氯,Et3N,DCM;2)NaN3,DMF;3)Zn,NH4Cl,CH3OH。
步骤1.(3-((4-氰基-3-氟苯氧基)甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-基)甲基甲磺酸酯。向4-((1-((2,4-二氯苯基)磺酰基)-3-(羟甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈(760mg,1.71mmol)和Et3N(0.36mL,2.58mmol)在无水DCM(20mL)中的溶液逐滴添加纯净的甲磺酰氯(0.16mL,2.06mmol),并将混合物在rt和N2下搅拌1h。将反应混合物倾倒在饱和NaHCO3水溶液(100mL)中并用DCM(2×100mL)萃取。将提取物在Na2SO4上干燥,过滤并浓缩至干,得到作为灰白色泡沫的标题化合物(909mg)。
步骤2.4-((3-(叠氮基甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈。将(3-((4-氰基-3-氟苯氧基)甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-基)甲基甲磺酸酯(909mg,1.71mmol)和NaN3(566mg,8.71mmol)在无水DMF(5mL)中的混合物在50℃搅拌16h。将反应混合物冷却,用EtOAc(75mL)稀释,用饱和NaHCO3水溶液(2×50mL)和盐水(50mL)洗涤,在Na2SO4上干燥,过滤并浓缩至干,得到作为几乎无色油状物的标题化合物(755mg)。1H NMR(500MHz,CDCl3)δppm 7.97(d,1H),7.52-7.60(m,2H),7.36-7.42(m,1H),6.68-6.80(m,2H),4.08-4.12(m,2H),3.94-3.99(m,2H),3.88-3.93(m,2H),3.74(s,2H)。
步骤3.4-((3-(氨基甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈。将4-((3-(叠氮基甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈(755mg,1.61mmol)、NH4Cl(437mg,8.17mmol)和锌粉(2.09g,32.0mmol)在CH3OH(20mL)中的混合物在rt和N2下搅拌3h。将反应混合物用DCM(约20mL)稀释并通过硅藻土过滤,用DCM/CH3OH冲洗。将滤液浓缩至干,并通过快速层析进行纯化(己烷/EtOAc/CH3OH),得到作为白色固体的标题化合物(583mg)。1H NMR(500MHz,DMSO-d6)δppm7.92-8.01(m,2H),7.84(t,1H),7.63-7.70(m,1H),6.99(dd,1H),6.83(dd,1H),5.07(br.s,2H),4.12(s,2H),3.84-3.90(m,2H),3.78-3.83(m,2H),2.96(s,2H)。LCMS[M+H]+444,446。
实施例45-化合物45
N-((3-((4-氰基-3-氟苯氧基)甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-基)甲基)乙酰胺如下所述来制备。向4-((3-(氨基甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈(8.9mg,0.020mmol)和Et3N(15μL,0.108mmol)在无水DCM(0.5mL)中的溶液逐滴添加乙酰氯(8μL,0.113mmol),并将混合物在rt搅拌2h。将反应混合物倾倒在饱和NaHCO3水溶液(5mL)中,并用DCM(2×5mL)萃取。将萃取液在Na2SO4上干燥,倾析并浓缩至干。将残留物在硅胶上通过快速层析进行纯化(己烷/EtOAc),给出作为无色油状物的标题化合物(3.8mg)。1H NMR(500MHz,CDCl3)δppm 7.97(d,1H),7.57(d,1H),7.54(dd,1H),7.40(dd,1H),6.74(dd,1H),6.70(dd,1H),5.85(t,1H),4.06(s,2H),3.91-3.99(m,4H),3.60(d,2H),2.02(s,3H)。LCMS[M+H]+486,488。
实施例46-化合物46
2-氨基-N-((3-((4-氰基-3-氟苯氧基)甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-基)甲基)乙酰胺按照反应路线18来制备:
试剂:步骤1)Boc-甘氨酸,HATU,DIPEA,DMF;2)TFA,DCM。
步骤1.(2-(((3-((4-氰基-3-氟苯氧基)甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-基)甲基)氨基)-2-酮基乙基)氨基甲酸叔丁酯。将4-((3-(氨基甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈(43mg,0.10mmol)、Boc-甘氨酸(21mg,0.12mmol)、HATU(46mg,0.12mmol)和DIPEA(60μL,0.34mmol)在无水DMF(1mL)中的混合物在rt搅拌18h。将反应混合物用EtOAc(10mL)稀释,用饱和NaHCO3水溶液(2×10mL)和盐水(2×10mL)洗涤,在Na2SO4上干燥,倾析并浓缩。将残留物通过快速层析进行纯化(EtOAc/己烷),给出标题化合物,将其立即用于下一步骤。
步骤2.2-氨基-N-((3-((4-氰基-3-氟苯氧基)甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-基)甲基)乙酰胺。将(2-(((3-((4-氰基-3-氟苯氧基)甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-基)甲基)氨基)-2-酮基乙基)氨基甲酸叔丁酯(0.10mmol)和TFA(0.25mL)在无水DCM(0.75mL)中的混合物在rt搅拌2h并浓缩。将残留物添加到饱和NaHCO3水溶液(10mL),并用DCM(3×10mL)萃取。将萃取液在Na2SO4上干燥,倾析并浓缩,并将残留物通过快速层析进行纯化(DCM/CH3OH/NH4OH),得到作为白色固体的标题化合物(20mg)。1H NMR(500MHz,CDCl3)δppm 7.96(d,1H),7.87-7.94(m,1H),7.51-7.59(m,2H),7.39(dd,1H),6.76(dd,1H),6.71(dd,1H),4.08(s,2H),3.97-4.01(m,2H),3.92-3.97(m,2H),3.63(d,2H),3.39(s,2H)。LCMS[M+H]+501.1,503.1。
实施例47-化合物47
N-((3-((4-氰基-3-氟苯氧基)甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-基)甲基)-2-羟基乙酰胺以与反应路线18中相似的方式,从4-((3-(氨基甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈和乙醇酸制备。1H NMR(500MHz,CDCl3)δppm 7.96(d,1H),7.56(d,1H),7.52-7.55(m,1H),7.36-7.41(m,1H),6.96-7.03(m,1H),6.76(dd,1H),6.72(dd,1H),4.18(d,2H),4.10(s,2H),4.03(d,2H),3.95(d,2H),3.67(d,2H),2.42(t,1H)。LCMS[M+H]+502.0,504.0。
实施例48-化合物48
N-((3-((4-氰基-3-氟苯氧基)甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-基)甲基)-2-(甲基氨基)乙酰胺以与反应路线18中相似的方式,从4-((3-(氨基甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈和Boc-肌氨酸制备。1HNMR(500MHz,CDCl3)δppm 7.96(d,1H),7.73-7.81(m,1H),7.51-7.58(m,2H),7.38(dd,1H),6.75(dd,1H),6.71(dd,1H),4.08(s,2H),3.92-3.99(m,4H),3.63(d,2H),3.27(s,2H),2.42(s,3H),1.75(br s,1H)。LCMS[M+H]+515.0,517.1。
实施例49-化合物49
2-氨基-N-((3-((4-氰基-3-氟苯氧基)甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-基)甲基)乙烷-1-磺酰胺以与反应路线13中相似的方式,从4-((3-(氨基甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈和Boc-牛磺酸氯化物制备。1H NMR(500MHz,CDCl3)δppm 7.97(d,1H),7.57(d,1H),7.52-7.56(m,1H),7.40(dd,1H),6.75(dd,1H),6.70(dd,1H),5.76-5.94(m,2H),4.16(s,2H),3.91-4.00(m,4H),3.45(s,2H),3.24-3.31(m,2H),3.07-3.13(m,2H)。LCMS[M+H]+550.9,553.0。
实施例50-化合物50
4-((1-((2,4-二氯苯基)磺酰基)-3-(吗啉代甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈盐酸盐按照反应路线19来制备:
试剂:步骤1)2-溴乙基醚,K2CO3,CH3CN,85℃。
步骤1.向4-((3-(氨基甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈(44mg,0.10mmol)和K2CO3添加2-溴乙基醚(19μL,0.15mmol)在无水CH3CN(1.0mL)中的溶液,并将混合物在加盖瓶中在85℃搅拌16h。将反应混合物冷却,用EtOAc(10mL)稀释,用饱和NaHCO3水溶液(2×10mL)和盐水(10mL)洗涤,在Na2SO4上干燥,倾析并浓缩。将残留物通过快速层析进行纯化(EtOAc/己烷)。将产物级分浓缩,用二烷中的4.0MHCl转变成HCl盐并浓缩至干,得到作为白色固体的标题化合物(33mg,0.06mmol)。1H NMR(500MHz,DMSO-d6+K2CO3)ppm 7.94-7.99(m,2H),7.82(t,1H),7.67(dd,1H),7.07(dd,1H),6.89(dd,1H),4.16(s,2H),3.86(d,2H),3.78(d,2H),3.39-3.46(m,4H),2.51(s,2H),2.23-2.32(m,4H)。LCMS[M+H]+514.1,516.1。
实施例51-化合物51
(3-((4-氰基-3-氟苯氧基)甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-基)氨基甲酸叔丁酯按照反应路线20来制备:
试剂:步骤1)二苯基磷酰基叠氮化物,Et3N,甲苯,100℃;叔丁醇,100℃。
步骤1.向3-((4-氰基-3-氟苯氧基)甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-甲酸(124mg,0.27mmol)在甲苯(4mL)中的悬液添加纯净的Et3N(50μL,0.36mmol)和二苯基磷酰基叠氮化物(70μL,0.33mmol),并将混合物在100℃和N2下搅拌17h。将反应混合物冷却至rt,添加叔丁醇(2mL),并将它加热至100℃继续4h。将反应混合物冷却,真空浓缩以除去大多数甲苯和叔丁醇,转移到EtOAc(15mL)中,用饱和NaHCO3水溶液(2×15mL)和盐水(15mL)洗涤,在Na2SO4上干燥,过滤并真空浓缩。将残留物通过快速层析进行纯化(己烷/EtOAc),给出作为无色玻璃状物质的标题化合物(33.8mg)。1H NMR(500MHz,CDCl3)δppm7.97(d,1H),7.51-7.58(m,2H),7.39(dd,1H),6.77(dd,1H),6.73(dd,1H),4.98(br.s,1H),4.29(s,2H),4.21(d,2H),4.08(d,2H),1.42(s,9H)。LCMS[M+H]+530.1,531.8。
实施例52-化合物52
4-((3-氨基-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈盐酸盐按照反应路线21来制备:
试剂:步骤1)LHMDS,THF,–78℃;CBr4;2)NaN3,DMSO;3)H2,Pd/C,EtOH;4)氯甲酸苯甲酯,饱和NaHCO3水溶液,二烷;5)LiAlH(Ot-Bu)3,THF;6)甲磺酰氯,Et3N,DCM;7)2-氟-4-羟基苯甲腈,K2CO3,CH3CN,Δ;8)TFA,DCM;9)2,4-二氯苯磺酰氯,Et3N,DCM;10)TFA,50℃。
步骤1.3-溴氮杂环丁烷-1,3-二甲酸1-(叔丁基)3-乙基酯。将LHMDS(1.0M,在THF/乙苯中,15.8mL,15.8mmol)和无水THF(60mL)的混合物在N2下冷却至–78℃。逐滴添加1-boc-氮杂环丁烷-3-甲酸乙酯(3.01g,13.1mmol)在无水THF(30mL)中的溶液,并将混合物在-78℃搅拌15min。逐滴添加CBr4(6.56g,19.8mmol)在无水THF(30mL)中的溶液,将混合物升温至rt并搅拌20h。将反应混合物用Et2O(350mL)稀释,用饱和NaHCO3水溶液(2×250mL)和盐水(250mL)洗涤,在Na2SO4上干燥,倾析并浓缩。将残留物通过快速层析进行纯化(EtOAc/己烷),得到作为橙色油状物的标题化合物(2.53g)。1H NMR(500MHz,CDCl3)δppm 4.64(dd,2H),4.25-4.33(m,4H),1.45(s,9H),1.33(t,3H)。
步骤2.3-叠氮基氮杂环丁烷-1,3-二甲酸1-(叔丁基)3-乙基酯。将3-溴氮杂环丁烷-1,3-二甲酸1-(叔丁基)3-乙基酯(2.53g,8.2mmol)和NaN3(1.59g,24.5mmol)在无水DMSO(20mL)中的混合物在50℃和N2下搅拌18h。将反应混合物冷却,用Et2O(250mL)稀释,用饱和NaHCO3水溶液(150mL)和盐水(2×150mL)洗涤,在Na2SO4上干燥,过滤并浓缩至干,得到作为黄色油状物的标题化合物(2.10g)。1H NMR(500MHz,CDCl3)δppm 4.30-4.36(m,4H),3.97(d,2H),1.45(s,9H),1.36(t,3H)。
步骤3.3-氨基氮杂环丁烷-1,3-二甲酸1-(叔丁基)3-乙基酯。将3-叠氮基氮杂环丁烷-1,3-二甲酸1-(叔丁基)3-乙基酯(1.93g,7.15mmol)和Pd/C(300mg,10重量%,50%H2O,Degussa)在EtOH(70mL)中的混合物在H2气氛下搅拌16h。将反应混合物通过硅藻土过滤,并将滤液浓缩至干,得到作为黄色油状物的标题化合物(1.73g)。1H NMR(500MHz,CDCl3)δppm 4.22-4.32(m,4H),3.79(d,2H),2.37(br.s,2H),1.44(s,9H),1.31(t,3H)。
步骤4.3-(((苯甲氧基)羰基)氨基)氮杂环丁烷-1,3-二甲酸1-(叔丁基)3-乙基酯。将3-氨基氮杂环丁烷-1,3-二甲酸1-(叔丁基)3-乙基酯(1.89g,7.72mmol)和氯甲酸苯甲酯(1.76mL,12.4mmol)在饱和NaHCO3水溶液(40mL)和二烷(40mL)中的混合物在N2下剧烈搅拌4天。将反应混合物用EtOAc(250mL)稀释,用饱和NaHCO3水溶液(200mL)和盐水(200mL)洗涤,在Na2SO4上干燥,倾析并浓缩。将残留物通过快速层析进行纯化(EtOAc/己烷),得到作为无色油状物的标题化合物(2.49g),其部分固化。1H NMR(500MHz,CDCl3)δppm7.29-7.41(m,5H),5.58(br.s,1H),5.13(s,2H),4.22-4.39(m,4H),4.07-4.22(m,2H),1.45(s,9H),1.23-1.34(m,3H)。
步骤5.3-(((苯甲氧基)羰基)氨基)-3-(羟甲基)氮杂环丁烷-1-甲酸叔丁酯。在rt和N2下向3-(((苯甲氧基)羰基)氨基)氮杂环丁烷-1,3-二甲酸1-(叔丁基)3-乙基酯(2.31g,6.11mmol)在无水THF中的溶液逐滴添加LiAlH(Ot-Bu)3(1.0M,在THF中,15.3mL),并将混合物搅拌22h。将反应混合物用EtOAc(250mL)稀释,用1M HCl(2×150mL)和盐水(150mL)洗涤,在Na2SO4上干燥,过滤并浓缩至干,得到作为白色固体的标题化合物(1.89g)。1H NMR(500MHz,CDCl3)δppm 7.31-7.40(m,5H),5.34(br.s,1H),5.09(s,2H),3.93-4.02(m,2H),3.82-3.92(m,4H),2.63(br.s,1H),1.43(s,9H)。
步骤6.3-(((苯甲氧基)羰基)氨基)-3-(((甲基磺酰基)氧基)甲基)氮杂环丁烷-1-甲酸叔丁酯。向3-(((苯甲氧基)羰基)氨基)-3-(羟甲基)氮杂环丁烷-1-甲酸叔丁酯(1.94g,5.8mmol)在无水DCM(50mL)中的溶液添加Et3N(1.2mL,8.6mmol)和甲磺酰氯(0.53mL,6.8mmol)。将混合物在rt和N2下搅拌3h,倾倒在饱和NaHCO3水溶液(100mL)中并用DCM(2×100mL)萃取。将萃取液在Na2SO4上干燥,过滤并浓缩至干,得到作为浅橙色泡沫的标题化合物(2.36g)。1H NMR(500MHz,CDCl3)δppm 7.29-7.44(m,5H),5.41(br s,1H),5.10(s,2H),4.50(s,2H),3.88-4.00(m,4H),2.95(s,3H),1.43(s,9H)。
步骤7.3-(((苯甲氧基)羰基)氨基)-3-((4-氰基-3-氟苯氧基)甲基)氮杂环丁烷-1-甲酸叔丁酯。将3-(((苯甲氧基)羰基)氨基)-3-(((甲基磺酰基)氧基)甲基)氮杂环丁烷-1-甲酸叔丁酯(2.36g,5.7mmol)、2-氟-4-羟基苯甲腈(936mg,6.8mmol)和K2CO3(1.59g,11.5mmol)在无水CH3CN(50mL)中的混合物在N2下回流搅拌16h。将反应混合物冷却,用EtOAc(250mL)稀释,用2M K2CO3(4×150mL)和盐水(150mL)洗涤,在Na2SO4上干燥,倾析并浓缩。将残留物通过快速层析进行纯化(EtOAc/己烷),得到作为泡沫的标题化合物(1.81g)。1H NMR(500MHz,CDCl3)δppm 7.51(dd,1H),7.29-7.39(m,5H),6.66-6.81(m,2H),5.30(br.s,1H),5.08(s,2H),4.29(m,2H),3.95-4.08(m,4H),1.44(s,9H)。
步骤8.(3-((4-氰基-3-氟苯氧基)甲基)氮杂环丁烷-3-基)氨基甲酸苯甲酯三氟乙酸盐。将3-(((苯甲氧基)羰基)氨基)-3-((4-氰基-3-氟苯氧基)甲基)氮杂环丁烷-1-甲酸叔丁酯(1.81g,3.97mmol)和TFA(10mL)在无水DCM(40mL)中的混合物在rt和N2下搅拌2h。将反应混合物浓缩至干,得到作为泡沫的粗品标题化合物(2.21g)。
步骤9.(3-((4-氰基-3-氟苯氧基)甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-基)氨基甲酸苯甲酯。将(3-((4-氰基-3-氟苯氧基)甲基)氮杂环丁烷-3-基)氨基甲酸苯甲酯三氟乙酸盐(2.21g,3.97mmol)、Et3N(1.70mL,12.2mmol)和2,4-二氯苯磺酰氯(1.17g,4.77mmol)在无水DCM(40mL)中的混合物在rt和N2下搅拌18h。将反应混合物倾倒在饱和NaHCO3水溶液(100mL)中并用DCM(2×100mL)萃取。将萃取液在Na2SO4上干燥,倾倒并浓缩,并将残留物通过快速层析进行纯化(EtOAc/己烷),得到作为泡沫的标题化合物(2.07g)。1H NMR(500MHz,CDCl3)δppm 7.97(d,1H),7.56(d,1H),7.52(dd,1H),7.38(dd,1H),7.28-7.36(m,5H),6.65-6.78(m,2H),5.26(br s,1H),5.07(s,2H),4.30(br s,2H),4.24(d,2H),4.11(d,2H)。
步骤10.4-((3-氨基-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈盐酸盐。将(3-((4-氰基-3-氟苯氧基)甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-基)氨基甲酸苯甲酯(883mg,1.56mmol)和TFA(12mL)的混合物在50℃搅拌7h。将反应混合物浓缩,转移到DCM中,倾倒在饱和NaHCO3水溶液(100mL)中,并用DCM(3×75mL)萃取。将萃取液在Na2SO4上干燥,倾析并浓缩,并将残留物通过快速层析纯化两次(DCM/CH3OH/NH4OH和己烷/EtOAc/CH3OH)。将纯产物用二烷中的4M HCl处理,浓缩,并用CH3OH/Et2O研磨。通过真空过滤收集沉淀物,得到作为白色固体的标题化合物(216mg)。1H NMR(500MHz,DMSO-d6)δppm 9.05(br s,3H),7.93-8.01(m,2H),7.87(t,1H),7.65(dd,1H),7.12(dd,1H),6.96(dd,1H),4.43(s,2H),4.23(d,2H),4.04(d,2H)。LCMS[M+H]+430.0,432.0。
实施例53-化合物53
N-(3-((4-氰基-3-氟苯氧基)甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-基)乙酰胺如下所述来制备。向4-((3-氨基-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈盐酸盐(10.4mg,0.022mmol)在无水DCM(0.5mL)中的悬液添加纯净的三乙胺(10μL,0.072mmol)和乙酰氯(0.33mL,0.1M,在DCM中),并将混合物在rt搅拌24h。添加额外的三乙胺(40μL,0.287mmol)和乙酰氯(16μL,0.225mmol)并继续搅拌另外18h。将混合物用CH3OH(0.5mL)淬灭,用DCM(5mL)稀释,干装在硅藻土上,并通过快速层析进行纯化(EtOAc/己烷),给出作为浅黄色固体的标题化合物(7.2mg)。1H NMR(500MHz,CDCl3)δppm7.97(d,1H),7.51-7.58(m,2H),7.39(dd,1H),6.75(dd,1H),6.70(dd,1H),5.90(s,1H),4.34(s,2H),4.20(d,2H),4.14(d,2H),2.00(s,3H)。LCMS[M+H]+472.0,474.1。
实施例54-化合物54
4-((1-((2,4-二氯苯基)磺酰基)-3-(二甲基氨基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈如下所述来制备。将4-((3-氨基-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈盐酸盐(10.8mg,0.023mmol)和甲醛(37%水溶液,1.9μL,0.03mmol)在无水THF(0.25mL)中的混合物在rt搅拌15min。添加NaBH(OAc)3(21mg,0.1mmol),并将混合物在rt搅拌23h。将反应混合物用饱和NaHCO3水溶液(1mL)淬灭并用EtOAc(2×1mL)萃取。将萃取液在Na2SO4上干燥,倾析并真空浓缩。将残留物通过快速层析进行纯化(己烷/EtOAc/CH3OH),给出作为白色固体的标题化合物(5.1mg)(~80%纯度)。1H NMR(500MHz,CDCl3)δppm 7.97(d,1H),7.52-7.58(m,2H),7.38(dd,1H),6.79(dd,1H),6.74(dd,1H),4.24(s,2H),4.03(d,2H),3.91(d,2H),2.31(s,6H)。LCMS[M+H]+458.1,460.1。
实施例55-化合物55
2-氨基-N-(3-((4-氰基-3-氟苯氧基)甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-基)乙酰胺按照反应路线22来制备:
步骤1.(2-((3-((4-氰基-3-氟苯氧基)甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-基)氨基)-2-酮基乙基)氨基甲酸叔丁酯。将4-((3-氨基-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈盐酸盐(25mg,0.053mmol)、Boc-甘氨酸(12mg,0.067mmol)、HATU(24mg,0.063mmol)和DIPEA(28μL,0.16mmol)在无水DMF(0.4mL)中的混合物在rt搅拌17h。将反应混合物用EtOAc(10mL)稀释,用饱和NaHCO3水溶液(2×7mL)和盐水(7mL)洗涤,在Na2SO4上干燥,倾析并浓缩。将残留物通过快速层析进行纯化(EtOAc/己烷),得到标题化合物。
步骤2.2-氨基-N-(3-((4-氰基-3-氟苯氧基)甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-基)乙酰胺。将(2-((3-((4-氰基-3-氟苯氧基)甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-基)氨基)-2-酮基乙基)氨基甲酸叔丁酯(0.053mmol)和二烷中的4.0M HCl(1.0mL)的混合物在rt搅拌18hr,浓缩至干。将残留物通过快速层析进行纯化(DCM/CH3OH/NH4OH),得到作为白色固体的标题化合物(9.8mg)。1H NMR(500MHz,CDCl3)δppm7.93-8.01(m,2H),7.49-7.59(m,2H),7.39(dd,1H),6.67-6.78(m,2H),4.34(s,2H),4.27(d,2H),4.18(d,2H),3.30-3.39(m,2H)。LCMS[M+H]+487.1,489.0。
实施例56-化合物56
N-(3-((4-氰基-3-氟苯氧基)甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-基)-2-羟基乙酰胺以与反应路线22中相似的方式,从4-((3-氨基-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈盐酸盐和乙醇酸制备。1H NMR(500MHz,CDCl3)δppm 7.97(d,1H),7.57(d,1H),7.54(dd,1H),7.39(dd,1H),7.03(s,1H),6.76(dd,1H),6.71(dd,1H),4.36(s,2H),4.28(d,2H),4.19(d,2H),4.13(s,2H),2.81(s,1H)。LCMS[M+H]+488.1,490.1。
实施例57-化合物57
2-氨基-N-(3-((4-氰基-3-氟苯氧基)甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-基)乙烷-1-磺酰胺盐酸盐以与反应路线13中相似的方式,从4-((3-氨基-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈盐酸盐和Boc-牛磺酸氯化物制备。1H NMR(500MHz,DMSO-d6)δppm 8.58(s,1H),8.05(br s,3H),7.94-7.99(m,2H),7.86(t,1H),7.67(dd,1H),7.17(dd,1H),6.97(dd,1H),4.34(s,2H),4.16(d,2H),4.01(d,2H),3.36-3.42(m,2H),3.08-3.17(m,2H)。LCMS[M+H]+537.1,538.9。
实施例58-化合物58
4-((1-((2-氯苯基)磺酰基)-3-(羟甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈按照反应路线23来制备:
试剂:步骤1)二碳酸二叔丁酯,饱和NaHCO3水溶液,二烷;2)LiAlH(Ot-Bu)3,THF;3)甲磺酰氯,Et3N,DCM;4)2-氟-4-羟基苯甲腈,K2CO3,CH3CN,Δ;5)LiAlH(Ot-Bu)3,THF;6)TFA,DCM;7)2-氯苯磺酰氯,Et3N,DCM。
步骤1.氮杂环丁烷-1,3,3-三甲酸1-(叔丁基)3,3-二乙基酯。将氮杂环丁烷-3,3-二甲酸二乙基酯盐酸盐(3.46g,14.55mmol)、二碳酸二叔丁酯(4.7mL,20.5mmol)、饱和NaHCO3水溶液(75mL)和二烷(75mL)的混合物在rt剧烈搅拌18h。将反应混合物用饱和NaHCO3水溶液(100mL)和水稀释,并用EtOAc(3×100mL)萃取。将萃取液用盐水(200mL)洗涤,在Na2SO4上干燥,过滤并浓缩至干。将残留物在硅胶上通过快速层析进行纯化(己烷/EtOAc),给出作为无色油状物的标题化合物(4.02g)。1H NMR(500MHz,CDCl3)δppm 4.23-4.29(m,8H),1.44(s,9H),1.28(t,6H)。
步骤2.3-(羟甲基)氮杂环丁烷-1,3-二甲酸1-(叔丁基)3-乙基酯。在0℃和N2下,通过加液漏斗向氮杂环丁烷-1,3,3-三甲酸1-(叔丁基)3,3-二乙基酯(4.02g,13.3mmol)在无水THF(120mL)中的溶液逐滴添加LiAlH(Ot-Bu)3(1.0M,在THF中,27.5mL),将混合物升温至rt并搅拌18h。将反应混合物用EtOAc(150mL)稀释并用1M HCl(200mL)洗涤。将水层用EtOAc(150mL)萃取,并将合并的有机相用盐水(200mL)洗涤,在Na2SO4上干燥,过滤并浓缩,给出作为无色油状物的标题化合物(3.85g)。1H NMR(500MHz,CDCl3)δppm 4.26(q,2H),4.15(d,2H),3.95(s,2H),3.81(d,2H),1.45(s,9H),1.32(t,3H)。
步骤3.3-(((甲基磺酰基)氧基)甲基)氮杂环丁烷-1,3-二甲酸1-(叔丁基)3-乙基酯。向3-(羟甲基)氮杂环丁烷-1,3-二甲酸1-(叔丁基)3-乙基酯(460mg,1.774mmol)和Et3N(0.37mL,2.654mmol)在无水DCM(12mL)中的溶液逐滴添加甲磺酰氯(0.17mL,2.2mmol),并将混合物在rt搅拌2.5h。将反应混合物倾倒在饱和NaHCO3水溶液(75mL)中并用DCM(3×35mL)萃取。将萃取液在Na2SO4上干燥,过滤并真空浓缩,给出作为无色油状物的粗品标题化合物(679mg)。
步骤4.3-((4-氰基-3-氟苯氧基)甲基)氮杂环丁烷-1,3-二甲酸1-(叔丁基)3-乙基酯。将粗品3-(((甲基磺酰基)氧基)甲基)氮杂环丁烷-1,3-二甲酸1-(叔丁基)3-乙基酯(679mg,2.2mmol)、2-氟-4-羟基苯甲腈(294mg,2.14mmol)和K2CO3(493mg,3.6mmol)在无水DMF(10mL)中的混合物在85℃和N2下搅拌18h。将反应混合物冷却,用Et2O(100mL)稀释,用2MK2CO3(2×75mL)和盐水(75mL)洗涤,在Na2SO4上干燥,过滤并浓缩至干。将残留物在硅胶上通过快速层析进行纯化(己烷/EtOAc),给出作为粘稠无色油状物的标题化合物(590mg,1.56mmol)。1H NMR(500MHz,CDCl3)δppm 7.54(dd,1H),6.78(dd,1H),6.74(dd,1H),4.35(s,2H),4.22-4.30(m,4H),3.93(d,2H),1.45(s,9H),1.28(t,3H)。
步骤5.3-((4-氰基-3-氟苯氧基)甲基)-3-(羟甲基)氮杂环丁烷-1-甲酸叔丁酯。在0℃和N2下向3-((4-氰基-3-氟苯氧基)甲基)氮杂环丁烷-1,3-二甲酸1-(叔丁基)3-乙基酯(590mg,1.56mmol)在无水THF(12mL)中的溶液逐滴添加LiAlH(Ot-Bu)3的溶液(1.0M,在THF中,4.4mL)。将混合物升温至rt并搅拌4天。将反应混合物用EtOAc(50mL)稀释,用1M HCl(2×50mL)和盐水(50mL)洗涤,在Na2SO4上干燥,过滤并浓缩至干,给出作为粘稠无色油状物的标题化合物(523mg)。1H NMR(500MHz,CDCl3)δppm 7.54(dd,1H),6.79(dd,1H),6.75(dd,1H),4.18(s,2H),3.91(s,2H),3.77-3.83(m,4H),1.45(s,9H)。
步骤6.3-((4-氰基-3-氟苯氧基)甲基)-3-(羟甲基)氮杂环丁烷-1-正离子三氟乙酸盐。将3-((4-氰基-3-氟苯氧基)甲基)-3-(羟甲基)氮杂环丁烷-1-甲酸叔丁酯(523mg,1.555mmol)和TFA(1.5mL)在无水DCM(15mL)中的混合物在rt和N2下搅拌3h。将反应混合物浓缩至干,再次从DCE、甲苯和CH3OH浓缩,最后从Et2O浓缩,给出作为粘稠无色油状物的标题化合物(577mg),其缓慢固化。
步骤7.4-((1-((2-氯苯基)磺酰基)-3-(羟甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈。向3-((4-氰基-3-氟苯氧基)甲基)-3-(羟甲基)氮杂环丁烷-1-正离子三氟乙酸盐(19.6mg,0.056mmol)和Et3N(31μL,0.222mmol)在无水DCM(0.5mL)中的溶液添加2-氯苯磺酰氯(12.0mg,0.057mmol),并将混合物在rt搅拌6h。将混合物浓缩,并在硅胶上通过快速层析进行纯化(己烷/DCM/CH3CN),给出作为无色玻璃状物质的目标化合物(13.1mg)。1H NMR(500MHz,CDCl3)δppm 8.05(dd,1H),7.49-7.59(m,3H),7.38-7.44(m,1H),6.75(dd,1H),6.69(dd,1H),4.16(s,2H),3.97(d,2H),3.93(d,2H),3.90(s,2H),1.72(br s,1H)。LCMS[M+H]+411,413。
实施例59-化合物59
4-((1-((2-氯-4-(三氟甲基)苯基)磺酰基)-3-(羟甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈以与反应路线23中相似的方式,从3-((4-氰基-3-氟苯氧基)甲基)-3-(羟甲基)氮杂环丁烷-1-正离子三氟乙酸盐和2-氯-4-(三氟甲基)苯磺酰氯制备。1H NMR(500MHz,CDCl3)δppm 8.18(d,1H),7.81(d,1H),7.66(dd,1H),7.54(dd,1H),6.69-6.78(m,2H),4.17(s,2H),3.97-4.06(m,4H),3.92(s,2H),1.71(br s,1H)。LCMS[M+H]+479,481。
实施例60-化合物60
4-((1-((2-氯-4-氰基苯基)磺酰基)-3-(羟甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈以与反应路线23中相似的方式,从3-((4-氰基-3-氟苯氧基)甲基)-3-(羟甲基)氮杂环丁烷-1-正离子三氟乙酸盐和2-氯-4-氰基苯磺酰氯制备。1H NMR(500MHz,CDCl3)δppm8.16(d,1H),7.83(d,1H),7.69(dd,1H),7.55(dd,1H),6.79(dd,1H),6.74(dd,1H),4.18(s,2H),4.05(d,2H),4.01(d,2H),3.91(s,2H),1.70(br.s,1H)。LCMS[M+H]+436。
实施例61-化合物61
4-((1-((3,4-二氯苯基)磺酰基)-3-(羟甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈以与反应路线23中相似的方式,从3-((4-氰基-3-氟苯氧基)甲基)-3-(羟甲基)氮杂环丁烷-1-正离子三氟乙酸盐和3,4-二氯苯磺酰氯制备。1H NMR(500MHz,CDCl3)δppm 7.93-7.97(m,1H),7.65-7.72(m,2H),7.48-7.55(m,1H),6.55-6.63(m,2H),4.04(s,2H),3.79(s,2H),3.72-3.78(m,4H),1.70(br s,1H)。LCMS[M+H]+445,447。
实施例62-化合物62
4-((1-((2,4-二甲基苯基)磺酰基)-3-(羟甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈以与反应路线23中相似的方式,从3-((4-氰基-3-氟苯氧基)甲基)-3-(羟甲基)氮杂环丁烷-1-正离子三氟乙酸盐和2,4-二甲基苯磺酰氯制备。1H NMR(500MHz,CDCl3)δppm7.82(d,1H),7.51(dd,1H),7.10-7.17(m,2H),6.72(dd,1H),6.64(dd,1H),4.11(s,2H),3.88(d,2H),3.77(d,2H),3.73(d,2H),2.61(s,3H),2.39(s,3H),1.69(t,1H)。LCMS[M+H]+405。
实施例63-化合物63
4-((3-((4-氰基-3-氟苯氧基)甲基)-3-(羟甲基)氮杂环丁烷-1-基)磺酰基)苯甲酸甲酯以与反应路线23中相似的方式,从3-((4-氰基-3-氟苯氧基)甲基)-3-(羟甲基)氮杂环丁烷-1-正离子三氟乙酸盐和4-(氯磺酰基)苯甲酸甲酯制备。1H NMR(500MHz,CDCl3)δppm8.25(d,2H),7.93(d,2H),7.48(dd,1H),6.58(dd,1H),6.48(dd,1H),3.99(s,3H),3.98(s,2H),3.68-3.77(m,6H),1.61(t,1H)。LCMS[M+H]+435。
实施例64-化合物64
2-氟-4-((3-(羟甲基)-1-((6-(三氟甲基)吡啶-3-基)磺酰基)氮杂环丁烷-3-基)甲氧基)苯甲腈以与反应路线23中相似的方式,从3-((4-氰基-3-氟苯氧基)甲基)-3-(羟甲基)氮杂环丁烷-1-正离子三氟乙酸盐和6-(三氟甲基)吡啶-3-磺酰氯制备。1H NMR(500MHz,CDCl3)δppm 9.18(d,1H),8.34(dd,1H),7.92(d,1H),7.47-7.56(m,1H),6.56-6.66(m,2H),4.06(s,2H),3.80-3.88(m,4H),3.78(d,2H),1.62(t,1H)。LCMS[M+H]+446。
实施例65-化合物65
4-((1-((2,4-二甲基噻唑-5-基)磺酰基)-3-(羟甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈以与反应路线23中相似的方式,从3-((4-氰基-3-氟苯氧基)甲基)-3-(羟甲基)氮杂环丁烷-1-正离子三氟乙酸盐和2,4-二甲基噻唑-5-磺酰氯制备。1H NMR(500MHz,CDCl3)δppm 7.53(dd,1H),6.69(dd,1H),6.63(dd,1H),4.08(s,2H),3.81-3.87(m,4H),3.75-3.80(m,2H),2.73(s,3H),2.67(s,3H),1.69(t,1H)。LCMS[M+H]+412。
实施例66-化合物66
4-((1-((1,3-二甲基-1H-吡唑-4-基)磺酰基)-3-(羟甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈以与反应路线23中相似的方式,从3-((4-氰基-3-氟苯氧基)甲基)-3-(羟甲基)氮杂环丁烷-1-正离子三氟乙酸盐和1,3-二甲基-1H-吡唑-4-磺酰氯制备。1H NMR(500MHz,CDCl3)δppm 7.76(s,1H),7.53(dd,1H),6.70(dd,1H),6.65(dd,1H),4.08(s,2H),3.89(s,3H),3.85(s,2H),3.72(d,2H),3.67(d,2H),2.45(s,3H)。LCMS[M+H]+395。
实施例67-化合物67
4-((1-((3-氯-4-氟苯基)磺酰基)-3-(羟甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈以与反应路线23中相似的方式,从3-((4-氰基-3-氟苯氧基)甲基)-3-(羟甲基)氮杂环丁烷-1-正离子三氟乙酸盐和3-氯-4-氟苯磺酰氯制备。1H NMR(500MHz,CDCl3)δppm 7.95(dd,1H),7.74-7.80(m,1H),7.52(dd,1H),7.36(t,1H),6.60-6.68(m,2H),4.07(s,2H),3.71-3.80(m,6H),1.66(t,1H)。LCMS[M+H]+429,431。
实施例68-化合物68
4-((1-((3,5-二氯苯基)磺酰基)-3-(羟甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈以与反应路线23中相似的方式,从3-((4-氰基-3-氟苯氧基)甲基)-3-(羟甲基)氮杂环丁烷-1-正离子三氟乙酸盐和3,5-二氯苯磺酰氯制备。1H NMR(500MHz,CDCl3)δppm 7.74(d,2H),7.63-7.66(m,1H),7.53(dd,1H),6.67(dd,1H),6.62(dd,1H),4.07(s,2H),3.74-3.83(m,6H),1.60(t,1H)。LCMS[M+H]+445,447。
实施例69-化合物69
2-氟-4-((3-(羟甲基)-1-((4-(甲基磺酰基)苯基)磺酰基)氮杂环丁烷-3-基)甲氧基)苯甲腈以与反应路线23中相似的方式,从3-((4-氰基-3-氟苯氧基)甲基)-3-(羟甲基)氮杂环丁烷-1-正离子三氟乙酸盐和4-(甲基磺酰基)苯磺酰氯制备。1H NMR(500MHz,DMSO-d6)δppm 8.19-8.25(m,2H),8.06-8.11(m,2H),7.69-7.75(m,1H),6.97(dd,1H),6.62(dd,1H),4.98(t,1H),3.94(s,2H),3.64(s,4H),3.37(d,2H),3.32(s,3H)。LCMS[M+H]+455。
实施例70-化合物70
2-氟-4-((3-(羟甲基)-1-((3-(三氟甲基)苯基)磺酰基)氮杂环丁烷-3-基)甲氧基)苯甲腈以与反应路线23中相似的方式,从3-((4-氰基-3-氟苯氧基)甲基)-3-(羟甲基)氮杂环丁烷-1-正离子三氟乙酸盐和3-(三氟甲基)苯磺酰氯制备。1H NMR(500MHz,CDCl3)δppm 8.14(s,1H),8.07(d,1H),7.94(d,1H),7.76(t,1H),7.51(dd,1H),6.62(dd,1H),6.56(dd,1H),4.04(s,2H),3.72-3.81(m,6H),1.57(t,1H)。LCMS[M+H]+445。
实施例71-化合物71
4-((1-((2-氯吡啶-3-基)磺酰基)-3-(羟甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈以与反应路线23中相似的方式,从3-((4-氰基-3-氟苯氧基)甲基)-3-(羟甲基)氮杂环丁烷-1-正离子三氟乙酸盐和2-氯吡啶-3-磺酰氯制备。1H NMR(500MHz,CDCl3)δppm 8.58(dd,1H),8.36(dd,1H),7.54(dd,1H),7.42(dd,1H),6.78(dd,1H),6.73(dd,1H),4.18(s,2H),4.06(d,2H),4.02(d,2H),3.93(d,2H),1.76(t,1H)。LCMS[M+H]+453,455。
实施例72-化合物72
2-氟-4-((3-(羟甲基)-1-(苯基磺酰基)氮杂环丁烷-3-基)甲氧基)苯甲腈以与反应路线23中相似的方式,从3-((4-氰基-3-氟苯氧基)甲基)-3-(羟甲基)氮杂环丁烷-1-正离子三氟乙酸盐和苯磺酰氯制备。1H NMR(500MHz,CDCl3)δppm 7.85-7.90(m,2H),7.68-7.74(m,1H),7.59-7.65(m,2H),7.49(dd,1H),6.59(dd,1H),6.52(dd,1H),3.97(s,2H),3.71-3.77(m,4H),3.66-3.71(m,2H),1.58(t,1H)。LCMS[M+H]+377。
实施例73-化合物73
2-氟-4-((3-(羟甲基)-1-甲苯磺酰基氮杂环丁烷-3-基)甲氧基)苯甲腈以与反应路线23中相似的方式,从3-((4-氰基-3-氟苯氧基)甲基)-3-(羟甲基)氮杂环丁烷-1-正离子三氟乙酸盐和4-甲基-苯磺酰氯制备。1H NMR(500MHz,CDCl3)δppm 7.73-7.79(m,2H),7.50(dd,1H),7.41(d,2H),6.59(dd,1H),6.46(dd,1H),3.95(s,2H),3.77(d,2H),3.71(d,2H),3.66(d,2H),2.50(s,3H),1.57(t,1H)。LCMS[M+H]+391。
实施例74-化合物74
4-((1-((4-氯-2-甲基苯基)磺酰基)-3-(羟甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈以与反应路线23中相似的方式,从3-((4-氰基-3-氟苯氧基)甲基)-3-(羟甲基)氮杂环丁烷-1-正离子三氟乙酸盐和2-甲基-4-氯苯磺酰氯制备。1H NMR(500MHz,CDCl3)δppm7.89(d,1H),7.54(dd,1H),7.35(d,1H),7.31(dd,1H),6.73(dd,1H),6.70(dd,1H),4.14(s,2H),3.90(s,2H),3.80-3.84(m,2H),3.75-3.79(m,2H),2.63(s,3H),1.67(br s,1H)。
实施例75-化合物75
4-((1-((2,6-二氯苯基)磺酰基)-3-(羟甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈以与反应路线23中相似的方式,从3-((4-氰基-3-氟苯氧基)甲基)-3-(羟甲基)氮杂环丁烷-1-正离子三氟乙酸盐和2,6-二氯苯磺酰氯制备。1H NMR(500MHz,CDCl3)δppm 7.53(dd,1H),7.48(d,2H),7.32-7.38(m,1H),6.77(dd,1H),6.71(dd,1H),4.18(s,2H),4.04-4.09(m,2H),3.99-4.03(m,2H),3.93(s,2H),1.71(br s,1H)。
实施例76-化合物76
2-氟-4-((3-(羟甲基)-1-(邻甲苯磺酰基)氮杂环丁烷-3-基)甲氧基)苯甲腈以与反应路线23中相似的方式,从3-((4-氰基-3-氟苯氧基)甲基)-3-(羟甲基)氮杂环丁烷-1-正离子三氟乙酸盐和2-甲基-苯磺酰氯制备。1H NMR(500MHz,CDCl3)δppm 7.92-7.98(m,1H),7.46-7.55(m,2H),7.31-7.38(m,2H),6.73(dd,1H),6.68(dd,1H),4.13(s,2H),3.89(s,2H),3.79-3.83(m,2H),3.75-3.78(m,2H),2.65(s,3H),1.82(br s,1H)。
实施例77-化合物77
2-氟-4-((1-((4-氟-2-甲基苯基)磺酰基)-3-(羟甲基)氮杂环丁烷-3-基)甲氧基)苯甲腈以与反应路线23中相似的方式,从3-((4-氰基-3-氟苯氧基)甲基)-3-(羟甲基)氮杂环丁烷-1-正离子三氟乙酸盐和2-甲基-4-氟苯磺酰氯制备。1H NMR(500MHz,CDCl3)δppm 7.97(dd,1H),7.53(dd,1H),6.97-7.08(m,2H),6.75(dd,1H),6.71(dd,1H),4.16(s,2H),3.90(s,2H),3.79-3.84(m,2H),3.74-3.79(m,2H),2.65(s,3H),1.62-1.73(m,1H)。
实施例78-化合物78
4-((1-((4-氯-2-氟苯基)磺酰基)-3-(羟甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈以与反应路线23中相似的方式,从3-((4-氰基-3-氟苯氧基)甲基)-3-(羟甲基)氮杂环丁烷-1-正离子三氟乙酸盐和2-氟-4-氯苯磺酰氯制备。1H NMR(500MHz,CDCl3)δppm7.79-7.86(m,1H),7.52(dd,1H),7.28-7.36(m,2H),6.67(dd,1H),6.63(dd,1H),4.10(s,2H),3.85-3.91(m,4H),3.84(s,2H),1.78(br s,1H)。
实施例79-化合物79
4-((1-((4-氰基-2-甲基苯基)磺酰基)-3-(羟甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈以与反应路线23中相似的方式,从3-((4-氰基-3-氟苯氧基)甲基)-3-(羟甲基)氮杂环丁烷-1-正离子三氟乙酸盐和2-甲基-4-氰基苯磺酰氯制备。1H NMR(500MHz,CDCl3)δppm 8.06(d,1H),7.59-7.66(m,2H),7.49-7.57(m,1H),6.77(dd,1H),6.73(dd,1H),4.17(s,2H),3.87-3.94(m,4H),3.82-3.87(m,2H),2.68(s,3H),1.84(br s,1H)。
实施例80-化合物80
3-氯-4-((3-((4-氰基-3-氟苯氧基)甲基)-3-(羟甲基)氮杂环丁烷-1-基)磺酰基)苯甲酸甲酯以与反应路线23中相似的方式,从3-((4-氰基-3-氟苯氧基)甲基)-3-(羟甲基)氮杂环丁烷-1-正离子三氟乙酸盐和3-氯-4-(氯磺酰基)苯甲酸甲酯制备。1H NMR(500MHz,CDCl3)δppm 8.19(d,1H),8.11(d,1H),8.03(dd,1H),7.52(dd,1H),6.75(dd,1H),6.69(dd,1H),4.16(s,2H),3.94-4.03(m,7H),3.90(s,2H),1.64-1.84(m,1H)。
实施例81-化合物81
4-((1-((4-氯-2-氰基苯基)磺酰基)-3-(羟甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈以与反应路线23中相似的方式,从3-((4-氰基-3-氟苯氧基)甲基)-3-(羟甲基)氮杂环丁烷-1-正离子三氟乙酸盐和2-氰基-4-氯-苯磺酰氯制备。1H NMR(500MHz,CDCl3)δppm8.01(d,1H),7.85(d,1H),7.71(dd,1H),7.54(dd,1H),6.76(dd,1H),6.71(dd,1H),4.17(s,2H),3.96-4.05(m,4H),3.90(s,2H),1.67-1.76(m,1H)。LC/MS/MS[M-H]-479.8。
实施例82-化合物82
4-((1-((2-氯-4-甲基苯基)磺酰基)-3-(羟甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈以与反应路线23中相似的方式,从3-((4-氰基-3-氟苯氧基)甲基)-3-(羟甲基)氮杂环丁烷-1-正离子三氟乙酸盐和2-氯-4-甲基苯磺酰氯制备。1H NMR(500MHz,CDCl3)δppm7.91(d,1H),7.52(t,1H),7.37(s,1H),7.20(d,1H),6.73(dd,1H),6.65(dd,1H),4.14(s,2H),3.83-3.99(m,6H),2.42(s,3H),1.74(br s,1H)。
实施例83-化合物83
4-((1-((2-氯-4-甲氧基苯基)磺酰基)-3-(羟甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈以与反应路线23中相似的方式,从3-((4-氰基-3-氟苯氧基)甲基)-3-(羟甲基)氮杂环丁烷-1-正离子三氟乙酸盐和2-氯-4-甲氧基苯磺酰氯制备。1H NMR(500MHz,CDCl3)δppm 7.96(d,1H),7.52(dd,1H),7.06(d,1H),6.88(dd,1H),6.74(dd,1H),6.67(dd,1H),4.14(s,2H),3.82-3.94(m,9H),1.81(br s,1H)。
实施例84-化合物84
4-((1-((4-氯苯基)磺酰基)-3-(羟甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈以与反应路线23中相似的方式,从3-((4-氰基-3-氟苯氧基)甲基)-3-(羟甲基)氮杂环丁烷-1-正离子三氟乙酸盐和4-氯苯磺酰氯制备。1H NMR(500MHz,CDCl3)δppm 7.79-7.84(m,2H),7.57-7.62(m,2H),7.51(t,1H),6.53-6.61(m,2H),3.99(s,2H),3.77(s,2H),3.66-3.75(m,4H),1.66(br s,1H)。
实施例85-化合物85
4-((1-((2-氰基苯基)磺酰基)-3-(羟甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈以与反应路线23中相似的方式,从3-((4-氰基-3-氟苯氧基)甲基)-3-(羟甲基)氮杂环丁烷-1-正离子三氟乙酸盐和2-氰基苯磺酰氯制备。1H NMR(500MHz,CDCl3)δppm 8.09(dd,1H),7.90(dd,1H),7.69-7.80(m,2H),7.53(dd,1H),6.66-6.79(m,2H),4.17(s,2H),3.97-4.04(m,4H),3.90(d,2H),1.75(t,1H)。
实施例86-化合物86
4-((1-((2-氰基-4-(三氟甲基)苯基)磺酰基)-3-(羟甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈以与反应路线23中相似的方式,从3-((4-氰基-3-氟苯氧基)甲基)-3-(羟甲基)氮杂环丁烷-1-正离子三氟乙酸盐和2-氰基-4-三氟甲基苯磺酰氯制备。1H NMR(500MHz,CDCl3)δppm 8.23(d,1H),8.13(d,1H),7.98-8.02(m,1H),7.53(dd,1H),6.76(dd,1H),6.71-6.74(m,1H),4.18(s,2H),4.02-4.10(m,4H),3.91(s,2H),1.84(br s,1H)。
实施例87-化合物87
(1-((2,4-二氯苯基)磺酰基)-3-((3,4-二氟苯氧基)甲基)氮杂环丁烷-3-基)甲醇按照反应路线24来制备:
试剂:步骤1)TBS-Cl,咪唑,DMF;2)TFA,DCM;3)2,4-二氯苯磺酰氯,Et3N,DCM;4)LiAlH(Ot-Bu)3,THF;5)甲磺酰氯,Et3N,DCM;6)3,4-二氟苯酚,K2CO3,DMF,85℃;7)TBAF,THF。
步骤1. 3-(((叔丁基二甲基甲硅烷基)氧基)甲基)氮杂环丁烷-1,3-二甲酸1-(叔丁基)3-乙基酯。将3-(羟甲基)氮杂环丁烷-1,3-二甲酸1-(叔丁基)3-乙基酯(3.85g13.3mmol)、叔丁基二甲基甲硅烷基氯(2.48g,16.46mmol)和咪唑(1.84g,27.1mmol)在无水DMF(50mL)中的混合物在rt和N2下搅拌20h。添加更多的叔丁基二甲基甲硅烷基氯(1.38g,9.17mmol)和咪唑(0.95g,14mmol)并继续搅拌3天。将反应混合物用EtOAc(300mL)稀释,用1M HCl(2×150mL)和盐水(150mL)洗涤,在Na2SO4上干燥,过滤并浓缩至干。将残留物在硅胶上通过快速层析进行纯化(己烷/EtOAc),给出作为无色油状物的标题化合物(4.84g)。1HNMR(500MHz,CDCl3)δppm 4.20(q,2H),4.10(d,2H),3.88(s,2H),3.83(d,2H),1.43(s,9H),1.28(t,3H),0.87(s,9H),0.05(s,6H)。
步骤2. 3-(((叔丁基二甲基甲硅烷基)氧基)甲基)氮杂环丁烷-3-甲酸乙酯三氟乙酸盐。将3-(((叔丁基二甲基甲硅烷基)氧基)甲基)氮杂环丁烷-1,3-二甲酸1-(叔丁基)3-乙基酯(832mg,2.00mmol)和TFA(2.0mL)在无水DCM(20mL)中的混合物在rt和N2下搅拌2h。将反应混合物浓缩至干,从甲苯浓缩两次并从Et2O浓缩一次,给出标题化合物(840mg),其作为粗品直接使用。
步骤3. 3-(((叔丁基二甲基甲硅烷基)氧基)甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-甲酸乙酯。向3-(((叔丁基二甲基甲硅烷基)氧基)甲基)氮杂环丁烷-3-甲酸乙酯三氟乙酸盐(840mg,理论值2.00mmol)和Et3N(0.70mL,5.02mmol)在无水DCM(20mL)中的溶液添加2,4-二氯苯磺酰氯(467mg,1.9mmol),并将所述混合物在rt和N2下搅拌20h。将反应混合物倾倒在饱和NaHCO3水溶液(50mL)中并用DCM(3×35mL)萃取。将萃取液在Na2SO4上干燥,过滤并浓缩至干。将残留物在硅胶上通过快速层析进行纯化(己烷/EtOAc),给出作为无色油状物的脱甲硅烷化的副产物(187mg)和作为无色油状物的标题化合物(617mg)。1HNMR(500MHz,CDCl3)δppm 7.96(d,1H),7.54(d,1H),7.36(dd,1H),4.24(d,2H),4.19(q,2H),3.99(d,2H),3.89(s,2H),1.26(t,3H),0.82-0.87(m,9H),0.02-0.06(m,6H)。
步骤4.(3-(((叔丁基二甲基甲硅烷基)氧基)甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-基)甲醇。在0℃和N2下向3-(((叔丁基二甲基甲硅烷基)氧基)甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-甲酸乙酯(809mg,1.68mmol)在无水THF(12mL)中的溶液逐滴添加LiAlH(Ot-Bu)3的溶液(1M,在THF中,5mL)。将混合物升温至rt并搅拌20h。逐滴添加另一部分LiAlH(Ot-Bu)3(1M,在THF中,1.7mL)并搅拌22h。将反应混合物用EtOAc(100mL)稀释,用1M HCl(2×75mL)和盐水(75mL)洗涤,在Na2SO4上干燥,过滤并浓缩,给出作为无色油状物的标题化合物(720mg)。1H NMR(500MHz,CDCl3)δppm 7.97(d,1H),7.55(d,1H),7.37(dd,1H),3.74-3.83(m,8H),0.85-0.90(m,9H),0.05-0.09(m,6H)。
步骤5.(3-(((叔丁基二甲基甲硅烷基)氧基)甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-基)甲基甲磺酸酯。向(3-(((叔丁基二甲基甲硅烷基)氧基)甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-基)甲醇(620mg,1.41mmol)和Et3N(0.39mL,2.8mmol)在无水DCM(12mL)中的溶液逐滴添加甲磺酰氯(0.13mL,1.68mmol),将混合物在rt和N2下搅拌2h。将反应混合物浓缩至干,并将残留物在硅胶上通过快速层析进行纯化(己烷/EtOAc),给出作为无色油状物的标题化合物(684mg)。1H NMR(500MHz,CDCl3)δppm 7.96(d,1H),7.56(d,1H),7.38(dd,1H),4.33(s,2H),3.81-3.89(m,4H),3.73(s,2H),3.04(s,3H),0.85-0.90(m,9H),0.04-0.08(m,6H)。
步骤6. 3-(((叔丁基二甲基甲硅烷基)氧基)甲基)-1-((2,4-二氯苯基)磺酰基)-3-((3,4-二氟苯氧基)甲基)氮杂环丁烷。将(3-(((叔丁基二甲基甲硅烷基)氧基)甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-基)甲基甲磺酸酯(32.6mg,0.06mmol)、3,4-二氟苯酚(10.4mg,0.08mmol)和K2CO3(17.9mg,0.13mmol)在无水DMF(0.5mL)中的混合物在85℃搅拌18h。将反应混合物冷却,用EtOAc(10mL)稀释,用2M K2CO3(2×5mL)和盐水(2×5mL)洗涤,在Na2SO4上干燥,过滤并浓缩至干,给出粗品标题化合物(31.8mg)。
步骤7.(1-((2,4-二氯苯基)磺酰基)-3-((3,4-二氟苯氧基)甲基)氮杂环丁烷-3-基)甲醇。向无水THF(0.5mL)中的固体3-(((叔丁基二甲基甲硅烷基)氧基)甲基)-1-((2,4-二氯苯基)磺酰基)-3-((3,4-二氟苯氧基)甲基)氮杂环丁烷(31.8mg,0.06mmol)添加TBAF(1M,在THF中,0.175mL),并将混合物在rt搅拌20h。将反应混合物用EtOAc(10mL)稀释,用饱和NaHCO3水溶液(2×5mL)和盐水(2×5mL)洗涤,在Na2SO4上干燥,过滤并浓缩至干。将残留物在硅胶上通过快速层析进行纯化(己烷/EtOAc),给出作为无色油状物的标题化合物(18.4mg)。1H NMR(500MHz,CDCl3)δppm 7.98(d,1H),7.57(d,1H),7.39(dd,1H),7.03-7.11(m,1H),6.66-6.72(m,1H),6.54-6.59(m,1H),4.05(s,2H),3.91-3.97(m,4H),3.90(s,2H),1.65(br.s,1H)。LCMS[M+H]+438,440。
实施例88-化合物88
3-氯-4-((1-((2,4-二氯苯基)磺酰基)-3-(羟甲基)氮杂环丁烷-3-基)甲氧基)苯甲腈以与反应路线24中相似的方式,从(3-(((叔丁基二甲基甲硅烷基)氧基)甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-基)甲基甲磺酸酯和3-氯-4-羟基苯甲腈制备。1H NMR(500MHz,CDCl3)δppm 7.98(d,1H),7.66(d,1H),7.53-7.59(m,2H),7.36-7.41(m,1H),7.00(d,1H),4.26(s,2H),3.92-4.03(m,6H),1.79(t,1H)。LCMS[M+H]+461,463。
实施例89-化合物89
3-((1-((2,4-二氯苯基)磺酰基)-3-(羟甲基)氮杂环丁烷-3-基)甲氧基)苯甲腈以与反应路线24中相似的方式,从(3-(((叔丁基二甲基甲硅烷基)氧基)甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-基)甲基甲磺酸酯和3-氰基苯酚制备。1H NMR(500MHz,CDCl3)δppm 7.98(d,1H),7.57(d,1H),7.36-7.42(m,2H),7.27-7.30(m,1H),7.08-7.15(m,2H),4.13(s,2H),3.93-4.00(m,4H),3.91(s,2H),1.77(br.s,1H)。LCMS[M+H]+427,429。
实施例90-化合物90
4-((1-((2,4-二氯苯基)磺酰基)-3-(羟甲基)氮杂环丁烷-3-基)甲氧基)苯甲酸甲酯以与反应路线24中相似的方式,从(3-(((叔丁基二甲基甲硅烷基)氧基)甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-基)甲基甲磺酸酯和4-羟基苯甲酸甲酯制备。1H NMR(500MHz,CDCl3)δppm 7.97-8.01(m,3H),7.57(d,1H),7.39(dd,1H),6.85-6.90(m,2H),4.16(s,2H),3.93-4.00(m,4H),3.92(s,2H),3.89(s,3H),1.72(br.s,1H)。LCMS[M+H]+460,462。
实施例91-化合物91
(1-((2,4-二氯苯基)磺酰基)-3-((吡啶-4-基氧基)甲基)氮杂环丁烷-3-基)甲醇以与反应路线24中相似的方式,从(3-(((叔丁基二甲基甲硅烷基)氧基)甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-基)甲基甲磺酸酯和4-羟基吡啶制备。1H NMR(500MHz,CDCl3)δppm 8.37(d,2H),7.98(d,1H),7.56(d,1H),7.38(dd,1H),6.71(d,2H),4.12(s,2H),3.92-3.98(m,4H),3.90(s,2H)。LCMS[M+H]+403,405。
实施例92-化合物92
(1-((2,4-二氯苯基)磺酰基)-3-((对甲苯氧基)甲基)氮杂环丁烷-3-基)甲醇以与反应路线24中相似的方式,从(3-(((叔丁基二甲基甲硅烷基)氧基)甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-基)甲基甲磺酸酯和对甲酚制备。1H NMR(500MHz,CDCl3)δppm7.98(d,1H),7.56(d,1H),7.38(dd,1H),7.08(d,2H),6.74(d,2H),4.08(s,2H),3.91-3.96(m,4H),3.90(s,2H),2.29(s,3H),1.76(br s,1H)。LCMS[M+H]+416,418。
实施例93-化合物93
4-((1-((2,4-二氯苯基)磺酰基)-3-(羟甲基)氮杂环丁烷-3-基)甲氧基)苯甲酰胺以与反应路线24中相似的方式,从(3-(((叔丁基二甲基甲硅烷基)氧基)甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-基)甲基甲磺酸酯和4-羟基苯甲酰胺制备。1H NMR(500MHz,DMSO-d6)δppm 7.97(d,1H),7.94(d,1H),7.78-7.85(m,3H),7.67(dd,1H),7.14-7.18(br s,1H),6.79-6.84(m,2H),5.07-5.14(m,1H),4.00(s,2H),3.78-3.84(m,4H),3.53-3.56(m,2H)。LCMS[M+H]+445,447。
实施例94-化合物94
(3-(((2-氯吡啶-4-基)氧基)甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-基)甲醇以与反应路线24中相似的方式,从(3-(((叔丁基二甲基甲硅烷基)氧基)甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-基)甲基甲磺酸酯和2-氯吡啶-4-醇制备。1H NMR(500MHz,CDCl3)δppm 8.20(d,1H),7.98(d,1H),7.57(d,1H),7.39(dd,1H),6.82(d,1H),6.72(dd,1H),4.16(s,2H),3.93-3.97(m,4H),3.91(d,2H),1.90-1.95(m,1H)。LCMS[M+H]+437,439。
实施例95-化合物95
(1-((2,4-二氯苯基)磺酰基)-3-(((2-甲基吡啶-4-基)氧基)甲基)氮杂环丁烷-3-基)甲醇以与反应路线24中相似的方式,从(3-(((叔丁基二甲基甲硅烷基)氧基)甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-基)甲基甲磺酸酯和2-甲基吡啶-4-醇制备。1HNMR(500MHz,CDCl3)δppm 8.26(d,1H),7.98(d,1H),7.57(d,1H),7.39(dd,1H),6.56-6.64(m,2H),4.13(s,2H),3.91-3.97(m,4H),3.90(s,2H),2.52(s,3H)。LCMS[M+H]+417,419。
实施例96-化合物96
(1-((2,4-二氯苯基)磺酰基)-3-((间甲苯氧基)甲基)氮杂环丁烷-3-基)甲醇以与反应路线24中相似的方式,从(3-(((叔丁基二甲基甲硅烷基)氧基)甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-基)甲基甲磺酸酯和间甲酚制备。1H NMR(500MHz,CDCl3)δppm7.98(d,1H),7.56(d,1H),7.38(dd,1H),7.17(t,1H),6.80(d,1H),6.62-6.68(m,2H),4.08(s,2H),3.92-3.97(m,4H),3.91(s,2H),2.33(s,3H),1.83(br.s,1H)。LCMS[M+H]+416,418。
实施例97-化合物97
(1-((2,4-二氯苯基)磺酰基)-3-((吡啶-3-基氧基)甲基)氮杂环丁烷-3-基)甲醇以与反应路线24中相似的方式,从(3-(((叔丁基二甲基甲硅烷基)氧基)甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-基)甲基甲磺酸酯和3-羟基吡啶制备。1H NMR(500MHz,CDCl3)δppm 8.21-8.29(m,2H),7.98(d,1H),7.57(d,1H),7.39(dd,1H),7.21-7.24(m,1H),7.15-7.18(m,1H),4.16(s,2H),3.94-3.99(m,4H),3.93(s,2H),1.94-2.37(m,1H)。LCMS[M+H]+403,405。
实施例98-化合物98
4-((1-((2,4-二氯苯基)磺酰基)-3-(羟甲基)氮杂环丁烷-3-基)甲氧基)-3-甲氧基苯甲腈以与反应路线24中相似的方式,从(3-(((叔丁基二甲基甲硅烷基)氧基)甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-基)甲基甲磺酸酯和4-羟基-3-甲氧基苯甲腈制备。1H NMR(500MHz,CDCl3)δppm 7.97(d,1H),7.55(d,1H),7.37(dd,1H),7.23-7.29(m,1H),7.08(d,1H),6.92(d,1H),4.23(s,2H),3.90-4.00(m,6H),3.84(s,3H)。
实施例99-化合物99
(3-((4-氰基-3-乙氧基苯氧基)甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-基)甲基4-溴苯甲酸酯按照反应路线25来制备:
试剂:步骤1)4M NaOH水溶液,THF,EtOH;2)BH3·SMe2,THF;3)4-溴苯甲酰氯,Et3N,DCM。
步骤1. 3-((4-氰基-3-乙氧基苯氧基)甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-甲酸。向3-((4-氰基-3-氟苯氧基)甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-甲酸乙酯(1.96g,4.0mmol)在THF(25mL)和EtOH(25mL)中的溶液添加NaOH水溶液(4M,10mL),并将混合物在rt和N2下搅拌16h。将反应混合物真空浓缩以除去大多数THF和EtOH,用1M HCl(100mL)酸化,用水(100mL)稀释,用固体NaCl饱和并用DCM(3×150mL)萃取。将萃取液在Na2SO4上干燥,过滤并真空浓缩,给出3-((4-氰基-3-氟苯氧基)甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-甲酸和标题化合物(1.86g)的混合物。
步骤2. 4-((1-((2,4-二氯苯基)磺酰基)-3-(羟甲基)氮杂环丁烷-3-基)甲氧基)-2-乙氧基苯甲腈。在0℃和N2下向3-((4-氰基-3-氟苯氧基)甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-甲酸和3-((4-氰基-3-乙氧基苯氧基)甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-甲酸(941mg,2.0mmol)在无水THF(20mL)中的混合物逐滴添加BH3·SMe2溶液(0.3mL,3.16mmol)。将混合物升温至rt并搅拌20h。将反应混合物用4M NaOH(50mL)淬灭,倾倒在饱和NaHCO3水溶液(200mL)中并用EtOAc(2×350mL)萃取。将有机相用盐水(250mL)洗涤,在Na2SO4上干燥,过滤并真空浓缩。将残留物通过快速层析进行纯化(己烷/EtOAc),给出作为粘稠无色油状物的4-((1-((2,4-二氯苯基)磺酰基)-3-(羟甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈和标题化合物(703mg)的混合物。
步骤3.(3-((4-氰基-3-乙氧基苯氧基)甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-基)甲基4-溴苯甲酸酯。向4-((1-((2,4-二氯苯基)磺酰基)-3-(羟甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈和4-((1-((2,4-二氯苯基)磺酰基)-3-(羟甲基)氮杂环丁烷-3-基)甲氧基)-2-乙氧基苯甲腈(1.94g,4.4mmol)与Et3N(0.95mL,6.82mmol)的混合物在无水DCM(45mL)中的溶液添加固体4-溴苯甲酰氯(1.15g,5.24mmol),并将混合物在rt和N2下搅拌4h。将反应混合物真空浓缩,并将残留物通过快速层析进行纯化(己烷/EtOAc),给出作为白色固体的标题化合物(103mg)。1H NMR(500MHz,CDCl3)ppm 7.98(d,1H),7.84-7.89(m,2H),7.57-7.63(m,2H),7.53(d,1H),7.48(d,1H),7.38(dd,1H),6.40-6.50(m,2H),4.56(s,2H),4.19(s,2H),4.03-4.14(m,6H),1.48(t,3H)。
实施例100-化合物100
4-((1-((2,4-二氯苯基)磺酰基)-3-(羟甲基)氮杂环丁烷-3-基)甲氧基)-2-乙氧基苯甲腈如下所述来制备。向4-((1-((2,4-二氯苯基)磺酰基)-3-(羟甲基)氮杂环丁烷-3-基)甲氧基)-2-乙氧基苯甲腈(74.6mg,0.11mmol)在THF(0.5mL)和EtOH(0.5mL)中的溶液添加NaOH水溶液(1M,1.15mL),并将混合物在rt搅拌1h。将反应混合物用EtOAc(20mL)稀释并用饱和NaHCO3水溶液(3×15mL)洗涤,在Na2SO4上干燥,过滤并真空浓缩。将残留物通过快速层析进行纯化(己烷/EtOAc),给出作为白色固体的标题化合物(25.2mg)。1H NMR(500MHz,CDCl3)δppm 7.98(d,1H),7.56(d,1H),7.47(d,1H),7.38(dd,1H),6.47(dd,1H),6.43(d,1H),4.14(s,2H),4.08-4.14(m,2H),3.91-4.00(m,4H),3.90(s,2H),1.66-1.72(m,1H),1.48(t,3H)。LCMS[M+H]+471,472。
实施例101-化合物101
4-(((1-((2,4-二氯苯基)磺酰基)-3-(羟甲基)氮杂环丁烷-3-基)甲基)氨基)-2-氟苯甲腈按照反应路线26来制备:
试剂:步骤1)4-氨基-2-氟苯甲腈,LHMDS(1.0M,在THF中),NaI,DMF,70℃;2)TBAF,THF。
步骤1. 4-(((3-(((叔丁基二甲基甲硅烷基)氧基)甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-基)甲基)氨基)-2-氟苯甲腈。在rt和N2下向4-氨基-2-氟苯甲腈(27.8mg,0.20mmol)和NaI(5.6mg,0.037mmol)在无水DMF(0.4mL)中的混合物添加LHMDS溶液(1.0M,在THF中,0.20mL)。在搅拌15min后,逐滴添加(3-(((叔丁基二甲基甲硅烷基)氧基)甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-基)甲基甲磺酸酯(51mg,0.10mmol)在无水DMF(0.8mL)中的溶液,并将混合物在70℃搅拌22h。将反应混合物冷却,用EtOAc(10mL)稀释,用饱和NaHCO3水溶液(10mL)、盐水(2×10mL)洗涤,在Na2SO4上干燥,过滤并真空浓缩。将残留物通过快速层析进行纯化(EtOAc/己烷),给出作为黄色油状物的标题化合物(4.3mg)。1H NMR(500MHz,CDCl3)δppm 7.96(d,1H),7.56(d,1H),7.38(dd,1H),7.32(dd,1H),6.32(dd,1H),6.28(dd,1H),5.19(t,1H),3.82-3.85(m,2H),3.81(s,2H),3.77-3.80(m,2H),3.40(d,2H),0.92(s,9H),0.10(s,6H)。
步骤2. 4-(((1-((2,4-二氯苯基)磺酰基)-3-(羟甲基)氮杂环丁烷-3-基)甲基)氨基)-2-氟苯甲腈。向4-(((3-(((叔丁基二甲基甲硅烷基)氧基)甲基)-1-((2,4-二氯苯基)磺酰基)氮杂环丁烷-3-基)甲基)氨基)-2-氟苯甲腈(4.3mg,0.01mmol)在无水THF(0.5mL)中的溶液逐滴添加TBAF溶液(1.0M,在THF中,40μL),并将混合物在rt搅拌5h。将反应混合物干装在硅胶上,并通过快速层析进行纯化(EtOAc/己烷),给出作为黄色油状物的标题化合物(1.4mg)。1H NMR(500MHz,CDCl3)δppm 7.96(d,1H),7.56(d,1H),7.38(dd,1H),7.33(t,1H),6.37(dd,1H),6.33(dd,1H),5.11(s,1H),3.88-3.94(m,4H),3.82(d,2H),3.44(d,2H),3.35(s,1H)。LCMS[M+H]+443.9,446.1。
实施例102-化合物102
4-((1-((2-溴-4-甲氧基苯基)磺酰基)-3-(羟甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈以与反应路线23中相似的方式,从3-((4-氰基-3-氟苯氧基)甲基)-3-(羟甲基)氮杂环丁烷-1-正离子三氟乙酸盐和2-溴-4-甲氧基苯磺酰氯制备。1H NMR(500MHz,CDCl3)δppm 8.00(d,1H),7.53(dd,1H),7.28(d,1H),6.92(dd,1H),6.76(dd,1H),6.70(dd,1H),4.16(s,2H),3.85-3.94(m,9H),1.68(br.s,1H)。
实施例103-化合物103
4-((1-((2-氰基-4-甲基苯基)磺酰基)-3-(羟甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈以与反应路线23中相似的方式,从3-((4-氰基-3-氟苯氧基)甲基)-3-(羟甲基)氮杂环丁烷-1-正离子三氟乙酸盐和2-氰基-4-甲基苯磺酰氯制备。1H NMR(500MHz,CDCl3)δppm 7.96(d,1H),7.70(s,1H),7.49-7.57(m,2H),6.75(dd,1H),6.66(dd,1H),4.16(s,2H),3.92-4.01(m,4H),3.89(s,2H),2.50(s,3H),1.76(br.s.,1H)。
实施例104-化合物104
4-((1-((2-氰基-4-氟苯基)磺酰基)-3-(羟甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈以与反应路线23中相似的方式,从3-((4-氰基-3-氟苯氧基)甲基)-3-(羟甲基)氮杂环丁烷-1-正离子三氟乙酸盐和2-氰基-4-氟苯磺酰氯制备。1H NMR(500MHz,CDCl3)δppm8.10(dd,1H),7.59(dd,1H),7.54(dd,1H),7.41-7.46(m,1H),6.78(dd,1H),6.73(dd,1H),4.18(s,2H),3.97-4.04(m,4H),3.90(s,2H),1.75(br.s,1H)。
实施例105-化合物105
4-((1-((2-溴-4-(三氟甲氧基)苯基)磺酰基)-3-(羟甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈以与反应路线23中相似的方式,从3-((4-氰基-3-氟苯氧基)甲基)-3-(羟甲基)氮杂环丁烷-1-正离子三氟乙酸盐和2-溴-4-三氟甲氧基苯磺酰氯制备。1H NMR(500MHz,CDCl3)δppm 8.13(d,1H),7.61(d,1H),7.53(dd,1H),7.26-7.32(m,1H),6.77(dd,1H),6.73(dd,1H),4.18(s,2H),3.94-4.02(m,4H),3.92(s,2H),1.74(br.s.,1H)。
实施例106-化合物106
4-((1-((2-氰基-4-甲氧基苯基)磺酰基)-3-(羟甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈以与反应路线23中相似的方式,从3-((4-氰基-3-氟苯氧基)甲基)-3-(羟甲基)氮杂环丁烷-1-正离子三氟乙酸盐和2-氰基-4-甲氧基苯磺酰氯制备。1H NMR(500MHz,CDCl3)δppm 7.99(d,1H),7.52(dd,1H),7.35(d,1H),7.18(dd,1H),6.75(dd,1H),6.67(dd,1H),4.16(s,2H),3.90-3.99(m,7H),3.89(s,2H),1.82(br.s,1H)。
实施例107-化合物107
4-((1-((2-氰基-4-三氟甲氧基苯基)磺酰基)-3-(羟甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈以与反应路线23中相似的方式,从3-((4-氰基-3-氟苯氧基)甲基)-3-(羟甲基)氮杂环丁烷-1-正离子三氟乙酸盐和2-氰基-4-三氟甲氧基苯磺酰氯制备。1H NMR(500MHz,CDCl3)δppm 8.14(d,1H),7.70(d,1H),7.50-7.59(m,2H),6.77(dd,1H),6.73(dd,1H),4.19(s,2H),3.99-4.08(m,4H),3.91(s,2H),1.74(br.s.,1H)。
实施例108-化合物108
4-((1-((2,4-二氯苯基)磺酰基)-3-(羟甲基)氮杂环丁烷-3-基)甲氧基)-2-氟-5-甲氧基苯甲腈以与反应路线23中相似的方式,从3-((4-氰基-5-氟-2-甲氧基苯氧基)甲基)-3-(羟甲基)氮杂环丁烷-1-正离子三氟乙酸盐和2,4-二氯苯磺酰氯制备。1H NMR(500MHz,CDCl3)δppm 7.97(d,1H),7.55(d,1H),7.37(dd,1H),6.95(d,1H),6.73(d,1H),4.21(s,2H),3.96-4.00(m,2H),3.90-3.95(m,4H),3.82(s,3H),2.06-2.13(m,1H)。
实施例109-化合物109
4-((1-((2-氰基苯基)磺酰基)-3-(羟甲基)氮杂环丁烷-3-基)甲氧基)-2-氟-5-甲氧基苯甲腈以与反应路线23中相似的方式,从3-((4-氰基-5-氟-2-甲氧基苯氧基)甲基)-3-(羟甲基)氮杂环丁烷-1-正离子三氟乙酸盐和2-氰基苯磺酰氯制备。1H NMR(500MHz,DMSO-d6)δppm 8.15(dd,1H),8.03(dd,1H),7.91-7.96(m,1H),7.86-7.91(m,1H),7.39(d,1H),7.19(d,1H),4.97(t,1H),4.08(s,2H),3.80(d,2H),3.75(s,3H),3.72(d,2H),3.40(d,2H)。
实施例110–化合物110
4-((1-((2-氰基-4-甲基苯基)磺酰基)-3-(羟甲基)氮杂环丁烷-3-基)甲氧基)-2-氟-5-甲氧基苯甲腈以与反应路线23中相似的方式,从3-((4-氰基-5-氟-2-甲氧基苯氧基)甲基)-3-(羟甲基)氮杂环丁烷-1-正离子三氟乙酸盐和2-氰基-4-甲基苯磺酰氯制备。1H NMR(500MHz,CDCl3)δppm 7.95(d,1H),7.68(s,1H),7.50-7.55(m,1H),6.94(d,1H),6.72(d,1H),4.22(s,2H),3.97-4.01(m,2H),3.93-3.97(m,2H),3.90(s,2H),3.82(s,3H),2.48(s,3H),2.08(br.s.,1H)。
实施例111–化合物111
4-((1-((2-氰基苯基)磺酰基)-3-((氧杂环丁烷-3-基氨基)甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈以与反应路线14中相似的方式,从4-((1-((2-氰基苯基)磺酰基)-3-(羟甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈和氧杂环丁烷-3-胺制备。1H NMR(500MHz,CDCl3)δppm 8.09(dd,1H),7.90(dd,1H),7.74(m,2H),7.54(dd,1H),6.76(dd,1H),6.71(dd,1H),4.80(t,2H),4.37(t,2H),4.16(s,2H),3.98-4.03(m,2H),3.88-3.96(m,3H),2.91(s,2H)。LCMS[M+H]+456.9。
实施例112-化合物112
4-((1-((2-氰基苯基)磺酰基)-3-(((反-4-羟基环己基)氨基)甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈以与反应路线14中相似的方式,从4-((1-((2-氰基苯基)磺酰基)-3-(羟甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈和反-4-氨基环己醇制备。1H NMR(500MHz,CDCl3)δppm 8.08(dd,1H),7.90(dd,1H),7.69-7.79(m,2H),7.52(dd,1H),6.74(dd,1H),6.69(dd,1H),4.12(s,2H),3.94-3.99(m,2H),3.91(d,2H),3.59(tt,1H),2.90-2.96(m,2H),2.38(tt,1H),1.83-1.99(m,4H),1.23-1.33(m,2H),0.99-1.10(m,2H)。
实施例113-化合物113
4-((1-((2-氰基苯基)磺酰基)-3-(((反-3-羟基环丁基)氨基)甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈以与反应路线14中相似的方式,从4-((1-((2-氰基苯基)磺酰基)-3-(羟甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈和反-3-氨基环丁-1-醇制备。1HNMR(500MHz,CDCl3)δppm 8.08(dd,1H),7.90(dd,1H),7.69-7.80(m,2H),7.53(dd,1H),6.75(dd,1H),6.69(dd,1H),4.39-4.46(m,1H),4.11-4.15(m,2H),3.96-4.01(m,2H),3.88-3.93(m,2H),3.36-3.43(m,1H),2.81(s,2H),2.05-2.13(m,2H),1.96-2.04(m,2H)。LCMS[M+H]+470.9。
实施例114-化合物114
3-(((3-((4-氰基-3-氟苯氧基)甲基)-1-((2-氰基苯基)磺酰基)氮杂环丁烷-3-基)甲基)氨基)丙酸乙酯以与反应路线14中相似的方式,从4-((1-((2-氰基苯基)磺酰基)-3-(羟甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈和3-氨基丙酸乙酯制备。1H NMR(500MHz,CDCl3)δppm 8.08(dd,1H),7.90(dd,1H),7.69-7.79(m,2H),7.52(dd,1H),6.75(dd,1H),6.70(dd,1H),4.08-4.15(m,4H),3.95-4.00(m,2H),3.89-3.94(m,2H),2.93(s,2H),2.86(t,2H),2.44(t,2H),1.21-1.25(m,3H)。LCMS[M+H]+501.1。
实施例115-化合物115
4-((1-((2-氰基苯基)磺酰基)-3-(((2,3-二羟基丙基)氨基)甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈以与反应路线14中相似的方式,从4-((1-((2-氰基苯基)磺酰基)-3-(羟甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈和3-氨基丙-1,2-二醇制备。1HNMR(500MHz,CDCl3)δppm 8.05-8.11(m,1H),7.90(dd,1H),7.69-7.80(m,2H),7.49-7.55(m,1H),6.75(dd,1H),6.70(dd,1H),4.12-4.16(m,2H),3.95-4.02(m,4H),3.77(m,1H),3.68-3.73(m,1H),3.56(dd,1H),2.92-3.03(m,2H),2.78-2.84(m,1H),2.73(dd,1H)。LCMS[M+H]+475.1。
实施例116-化合物116
4-((1-((2-氰基苯基)磺酰基)-3-(((四氢-2H-吡喃-4-基)氨基)甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈以与反应路线14中相似的方式,从4-((1-((2-氰基苯基)磺酰基)-3-(羟甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈和4-氨基四氢吡喃制备。1H NMR(500MHz,CDCl3)δppm 8.09(dd,1H),7.90(dd,1H),7.69-7.79(m,2H),7.49-7.55(m,1H),6.75(dd,1H),6.69(dd,1H),4.12-4.16(m,2H),3.89-4.00(m,8H),3.35(m,1H),2.96(s,2H),2.56-2.65(m,1H),1.73-1.82(m,2H),1.30(dd,2H)。LCMS[M+H]+484.5。
实施例117-化合物117
(S)-4-((1-((2-氰基苯基)磺酰基)-3-(((2-羟丙基)氨基)甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈以与反应路线14中相似的方式,从4-((1-((2-氰基苯基)磺酰基)-3-(羟甲基)氮杂环丁烷-3-基)甲氧基)-2-氟苯甲腈和(S)-1-氨基丙-2-醇制备。1H NMR(500MHz,CDCl3)δppm 8.08(dd,1H),7.90(dd,1H),7.69-7.79(m,2H),7.49-7.56(m,1H),6.76(dd,1H),6.70(dd,1H),4.13-4.17(m,2H),3.94-4.02(m,4H),3.74-3.82(m,1H),2.91-3.05(m,2H),2.69-2.75(m,1H),2.46(dd,1H),1.12-1.16(m,3H)。LCMS[M+H]+458.8。
实施例118.生物活性
本公开的TRPV4拮抗剂的生物活性如下进行评估。
在人胚胎肾细胞中评估TRPV4拮抗剂的活性和效力(IC50)
进行基于细胞的Ca2+通量荧光测定法,以在稳定过表达人TRPV4的人胚胎肾293细胞(HEK-293)中评估TRPV4拮抗剂活性并确定效力(IC50值)。所述测定法按照下述文献中描述的方法来进行:Deering-Rice,C.E.,Johansen,M.E.,Roberts,J.K.,Thomas,K.C.,Romero,E.G.,Lee,J.,Yost,G.S.,Veranth,J.M.和Reilly,C.A.(2012),Mol.Pharmacol.81(3),411-419;Shapiro,D.,Deering-Rice,C.E.,Romero,E.G.,Hughen,R.W.,Light,A.R.,Veranth,J.M.和Reilly,C.A.(2013),Chem Res.Toxicol.,26,750-758;以及Deering-Rice,C.E.,Mitchell,V.K.,Romero,E.G.,Abdel Aziz,M.H.和Reilly,C.A.(2014),Pharmacol.Res.&Perspectives.2(5),1-10。
将稳定过表达人TRPV4的HEK-293细胞在2%(w/v)明胶包被的96孔板中,在增补有5%胎牛血清、1×青霉素/链霉素(Invitrogen)和遗传霉素(300μg/mL)的DMEM:F12培养基中生长至合生。
通过用含有Fluo 4-AM、pluronic F-127、丙磺舒和专有猝灭染料的LHC-9和Fluo4-Direct(Invitrogen)试剂的1:1溶液替换生长培养基,制备用于测定的HEK-293细胞。然后将细胞在细胞培养箱中,在37℃温育1h。随后通过用含有1mM水溶性丙磺舒(Invitrogen)、750μM锥虫红(ATT Bioquest)和测试化合物(各种不同的浓度)的LHC-9替换载样溶液来清洗细胞。将细胞在37℃下再温育30分钟,以允许Fluo 4-AM裂解和活化以及测试化合物和Fluo 4两者的平衡。
在LHC9中以3×浓度制备激动剂处理溶液(90nM GSK1016790A,这是一种TRPV4强效激活剂),并将25μL添加到96孔板中细胞上的50μL培养基中,提供30nM的终浓度。使用BMGLabtech NOVOStar荧光读板器在37℃下监测细胞荧光的变化1分钟。将数据量化为荧光强度变化的最大速率(maxΔF/s),针对仅仅培养基的处理(阴性对照)进行校正,并表示为相对于无拮抗剂对照的响应百分率。每种处理条件至少重复三次并使用至少8个浓度,以推导为每种拮抗剂报告的IC50值。在下面的表4中示出的每种拮抗剂的IC50值按照下述文献中描述的方法来计算:Deering-Rice,C.E.,Johansen,M.E.,Roberts,J.K.,Thomas,K.C.,Romero,E.G.,Lee,J.,Yost,G.S.,Veranth,J.M.和Reilly,C.A.(2012),Mol.Pharmacol.81(3),411-419;Shapiro,D.,Deering-Rice,C.E.,Romero,E.G.,Hughen,R.W.,Light,A.R.,Veranth,J.M.和Reilly,C.A.(2013),Chem Res.Toxicol.,26,750-758;以及Deering-Rice,C.E.,Mitchell,V.K.,Romero,E.G.,Abdel Aziz,M.H.和Reilly,C.A.(2014),Pharmacol.Res.&Perspectives.2(5),1-10。
表4
TRPV4选择性
为了确定各种不同测试化合物对TRPV4的选择性,还测试了在基于细胞的Ca2+通量TRPV4荧光测定中具有活性的所选化合物对在HEK-293细胞中稳定过表达的人TRPA1、在HEK-293细胞中稳定过表达的TRPM8、在HEK-293细胞中稳定过表达的TRPV3和在人肺上皮(BEAS-2B)细胞中稳定过表达的TRPV1的抑制作用。所述测定基本上如上对稳定过表达TRPV4的HEK-293细胞所述来进行,尽管对于TRPV1来说将BEAS-2B细胞维持在含有遗传霉素(300μg/mL)的LHC-9培养基中,并在室温下加载Fluo-4AM。TRPA1的激动剂是2,4-二叔丁基苯酚(50μM),TRPM8的激动剂是icilin(50μM),TRPV3的激动剂是香芹酚(300μM),TRPV1的激动剂是香草壬酰胺(5μM)。上述测定的所有其他方面是相同的。对于化合物11来说,对TRPA1、TRPM8、TRPV3和TRPV1的IC50值分别为52.0μM、14.4μM、>100μM和24.3μM。对于化合物52来说,对TRPA1、TRPM8、TRPV3和TRPV1的IC50值分别为89.6μM、35.9μM、>100μM和60.0μM。这些结果显示,化合物11和化合物16对TRPV4的选择性明显更高。对于化合物16来说,对TRPA1、TRPM8、TRPV3和TRPV1的IC50值分别为20.7μM、17.8μM、>100μM和6.0μM。对于化合物17来说,对TRPA1、TRPM8、TRPV3和TRPV1的IC50值分别为>35.5μM、25.4μM、>50μM和5.3μM。
在眼细胞中的体外筛选测定
按照本文和[Ryskamp等,J Neurosci 34(47):15689,2014;Ryskamp等,Sci Rep6:30583,2016和Jo等,Proc Natl Acad Sci U.S.A.113(14):3885,2016]中描述的方法对几种测试化合物进行了基于细胞的Ca2+通量荧光测量,以评估所述测试化合物在人原代小梁网(TM)细胞、Müller细胞和视网膜微血管内皮细胞中的TRPV4拮抗剂活性和效力(IC50值)。
小梁网是眼中的一个组织区域,位于角膜基底周围,靠近睫状体,并负责通过前房从眼中排出房水。TM细胞据信是房水从前眼流出的阻力的主要来源,因此是眼内压(IOP)的主要决定因素,而眼内压据信是青光眼的主要原因。IOP的提高可能通过提高细胞内钙的水平来增加TM细胞的刚度和收缩性。TRPV4拮抗剂可降低TM细胞中压力诱导的钙升高,从而由于抑制它们的收缩反应而降低IOP。从人眼的近小管和角巩膜区域分离出原代TM细胞,并将其在37℃和5%CO2下在小梁网细胞培养基(ScienCell,目录号6591)中生长。
Müller细胞是视网膜中的主要大胶质细胞。Müller细胞作为压力和容量传感器发挥作用,强烈表达TRPV4通道,并据信造成与青光眼神经变性相关的炎症反应并可能造成青光眼神经变性[Ryskamp等,J Neurosci.34(47):15689-700,2014]。TRPV4拮抗剂可以减轻压力诱导的钙依赖性反应性神经胶质增生、神经胶质肿胀/水肿和视网膜中的炎性信号传导。从在含有木瓜蛋白酶(7U/ml;Worthington)的L-15中在室温下消化1小时的小鼠视网膜中解离出Müller神经胶质细胞和视网膜神经节细胞(RGC)。
微血管内皮细胞(MVEC)是血-视网膜屏障的关键组分,调节氧气和代谢物进入视网膜内层并介导功能性充血、光诱导的视网膜血流增加。所述细胞强烈表达TRPV4通道,这些通道可以将它们对剪切流、肿胀和拉伸的反应转导成细胞内钙浓度的变化。TRPV4拮抗剂似乎可以调节视网膜血管张力和功能性充血反应。从人视网膜毛细血管组织分离的原代MVEC购自Cell Systems(ACBRI 181),并将第3-5代的细胞在人内皮生长培养基(EBM-2,Lonza,CC-3156&CC4176)中在37℃和5%CO2下生长。
按照本文和[Ryskamp等,J Neurosci 34(47):15689,2014,和Jo等,J Neurosci35(39):13525,2015]中描述的方法进行基于细胞的Ca2+通量荧光测量,以评估在TM细胞、Müller细胞和MVEC中的TRPV4拮抗剂活性并确定效力(IC50值)。在各种不同浓度的不同测试化合物存在下,确定在用TRPV4选择性激动剂GSK1016790A(对于TM细胞和Müller细胞来说25nM,对于MVEC来说10nM)刺激细胞后的活性。更具体来说,在DMSO中制备10mM的激动剂化合物的等分试样,并将其以测试浓度(10–25nM)溶解在盐水缓冲液中。确定细胞中的钙水平,所述细胞用5μM Fura-2-AM(Life Technologies)钙指示染料在室温加载15-30分钟,并用含有下述成分(以mM为单位)的等渗盐水(pH 7.4)灌注:98.5NaCl,5KCl,3MgCl2,2CaCl2,10HEPES,10D-葡萄糖,93甘露糖醇。使用具有40x(1.3N.A.油和0.8N.A.水)物镜的倒置Nikon Ti显微镜和Nikon Elements软件对钙水平进行落射荧光成像。如[Ryskamp等,JNeurosci 34(47):15689,2014,和Molnar等,J Neurosci 36(11):3184]中所述对数据进行量化。下面的表4中示出的计算IC50值代表了来自于至少三个独立实验的细胞(3-6个载片)的平均值,每种处理条件使用20–100个细胞。
数据显示,由TRPV4通道介导的激动剂(GSK1016790A)和肿胀诱导的钙反应被化合物11抑制,IC50值为~0.01μM至~0.03μM,并被化合物52抑制,IC50值为~0.01μM至~0.04μM。相反,HC067047抑制眼细胞中TRPV4介导的钙反应,IC50值为~0.5至~1.6μM。不同细胞类型的效力差异可能反映了TRPV4通道的不同分子构造(异聚化、磷酸化)。
在高眼压症小鼠模型中评估IOP降低的体内测定法
在局部施用化合物后的几周内,使用眼压测量法测量高眼压症小鼠模型中的IOP变化。
为了制备高眼压症小鼠模型,通过腹膜内(IP)注射氯胺酮/甲苯噻嗪(90mg/10mg/kg体重)将小鼠麻醉。施用0.5%丙美卡因盐酸盐滴眼液和1%托吡卡胺滴眼液(Bausch&Lomb),使小鼠的眼失去感觉并扩张。通过将2μl聚苯乙烯微珠(7.8μm FluoSpheres;BangsLaboratories)用Hamilton注射器在60秒内注射到前房中,提高同侧眼中的IOP。对侧眼用磷酸盐缓冲盐水(PBS)注射。
在局部给药化合物11和52和噻吗洛尔这种用于治疗与高眼压症和青光眼相关的IOP的已知药物后,在注射后1、2、6和10小时使用回弹眼压计测量IOP。根据Ryskamp等,SciRep 6:30583,2016中描述的方案,从10至20个读数的平均值确定IOP。如图1中所示,在高眼压症小鼠模型中化合物11和52以及0.5%噻吗洛尔的局部给药均降低IOP并保护RGC。这证实了TRPV4拮抗剂HC067047的有效性,其在以0.3–1.0mM施用时降低了高眼压小鼠眼中的IOP[Ryskamp等,Sci Rep 6:30583,2016]。
所述体内数据显示,化合物11和52的低浓度[1μM和10μM]单次局部施用在最早的测定时间框(1小时)内有效地降低IOP。所述有效性与0.5%噻吗洛尔的效果相当,后者是当前临床实践中靶向次级(葡萄膜巩膜)流出通路的标准降IOP药物。TRPV4阻断剂促进房水通过常规流出通路排出(Ryskamp等,2016),并可作为噻吗洛尔和/或拉坦前列素(Xalatan)的辅助剂用于降低IOP。鉴于噻吗洛尔的施用伴有显著的副作用包括视力模糊、眼睑下垂、眼烧灼、头痛、嗜睡、麻木、口干、恶心、腹泻、情绪变化、心律不齐和食欲不振,并且前列腺素类似物(Xalatan)在应用于降低IOP时显示出引起视力模糊、眼烧灼/刺痛/发红、头痛、头晕、关节痛、胸痛、虹膜褐变、流泪、睫毛生长和视力改变,因此本公开的TRPV4拮抗剂可以用作噻吗洛尔、Xalatan和目前使用的降低IOP的其他药物的替代品。
在高眼压症狗模型中评估IOP降低的体内测定法
本发明得到了在高眼压狗中化合物52降低IOP这一发现的进一步支持。
具有ADAMTS10基因的常染色体隐性错义突变的纯合比格犬由于房水流出能力的下降而发生显著的IOP升高,导致开角型青光眼,其表现为视神经头形成杯状和视神经病变。碳酸酐酶抑制剂盐酸多佐胺在患有OAG的狗中产生3.8-5.0mm Hg的IOP降低(GelattKN,MacKay EO,Vet Ophthalmol.2001年3月;4(1):61-7),多佐胺和噻吗洛尔的组合实现6.6-8.4mm Hg的IOP降低(Plummer CE,MacKay EO,Gelatt KN,Vet Ophthalmol.2006年7月-8月;9(4):245-9;Scardillo A,Pugliese M,De Majo M,Niutta PP,Pugliese A.,VetTher.201011(3):E1-6),而青光眼狗中的IOP不受Rho抑制剂影响(Leary KA,Lin KT,Steibel JP,Harman CD,Komáromy AM,Vet Ophthalmol.2019年12月24日)。
在7AM将8滴化合物52(200mM,在羟丙基甲基纤维素溶液中,储用物溶解在DMSO中)给药到比格犬1.5小时。对照眼接受载剂(用DMSO适当稀释的羟丙基甲基纤维素滴眼液)。在9:00AM通过眼压计测量局部麻醉下的狗(N=5只OAG,N=5只无症状的狗)中的IOP(每个事件6个读数,平均值)。一般眼科检查通过裂隙灯生物显微镜(Kowa SL-17便携式裂隙灯;Kowa Company,Ltd.)和间接检眼镜检查(Keeler All Pupil II headset;KeelerInstruments;Pan Retinal 2.2D聚光透镜;Volk Optical)来进行,以检测潜在的治疗相关的不良反应。
化合物52被狗(N=10)良好耐受,没有可观察到的眼部不适或结膜充血的迹象。平均基线IOP为45.5mm Hg。化合物52的局部施用显著地将IOP降低到36.6mm Hg的平均水平。
应当理解,上述详细描述和随附的实施例仅仅是说明性的,不应被视为对本发明范围的限制,本发明的范围仅由权利要求书及其等同物限定。
对本领域技术人员来说,对所公开的实施方式的各种不同改变和修改将是显而易见的。此类改变和修改,包括但不限于与本发明的化学结构、取代基、衍生物、中间体、合成、组合物、制剂或使用方法有关的改变和修改,可以在不背离本发明的精神和范围的情况下做出。
Claims (24)
1.一种式(I)的化合物
或其可药用盐,其中:
L1是-C(O)-、-S(O2)-、-S(O)-或C1-C4亚烷基;
X是O或NR1;
m是0、1、2、3或4;
n是0、1、2、3或4;
Ar1和Ar2各自独立地选自5-10元芳基或杂芳基;
Z是CHR2R3、COR4或NHR5;
R1选自氢和C1-C4烷基;
R2、R3、R4和R5各自独立地选自氢、羟基、C1-C6烷基、羟基-C1-C6烷基、C1-C6烷氧基、C1-C6烷氧基-C1-C6烷基、磷酸酯、C1-C6烷基磷酸酯、C4-C8杂环基、NR6R7、-OC(O)R8、-C(O)R9、-S(O)2R10和-OS(O)2R11;
R6、R7、R8、R9、R10和R11各自独立地选自氢、C1-C6烷基、C1-C6杂烷基、C1-C6烷氧基、C4-C8环烷基、C4-C8杂环基、C5-C8芳基、C5-C8杂芳基、C1-C6烷氧基-C1-C6烷基、C5-C8芳基-C1-C6烷基、C5-C8杂芳基-C1-C6烷基、C5-C8杂环基-C1-C6烷基、氨基-C1-C6烷基、羟基-C1-C6烷基、羟基-C3-C8环烷基、氰基-C1-C6烷基、羟基磺酰基-C1-C6烷基、磷酸酯-C1-C6烷基、烷基磷酸酯-C1-C6烷基、-COR12和-CR13R14C(O)R15;
R12选自C1-C6烷基、C1-C6杂烷基、C1-C6烷氧基、氨基-C1-C6烷基、C4-C8杂环基、羟基-C1-C6烷基、氨基-C4-C8杂环基、磷酸酯-C1-C6烷基和C1-C6烷基磷酸酯;
R13和R14各自独立地选自氢、C1-C6烷基和C1-C6杂烷基,或者任选地与它们所连接的原子合在一起形成环;并且
R15是羟基、C1-C6烷氧基或氨基;
其中m和n中的至少一者不是零,并且每个芳基、杂芳基、环烷基或杂环独立地是未取代的,或者被独立地选自氰基、卤素、C1-C6烷基、C1-C6烷氧基、氨基-C1-C6烷基、卤代烷基、磺酰基、-C(O)-C1-C6烷氧基和-C(O)-NH2的一个或多个取代基取代。
2.根据权利要求1所述的化合物或其药用盐,其中L1是-S(O2)-。
3.根据权利要求1-4中的任一项所述的化合物或其药用盐,其中Ar1选自5元芳基、5元杂芳基、6元芳基或6元杂芳基,
其中每个芳基或杂芳基是未取代的,或者被独立地选自氰基、卤素、C1-C6烷基、C1-C6烷氧基、卤代烷基、磺酰基和-C(O)-C1-C6烷氧基的一个或两个取代基取代。
4.根据权利要求3所述的化合物或其药用盐,其中所述卤素是氟或氯。
5.根据权利要求3或4所述的化合物或其药用盐,其中所述卤代烷基是三氟甲基。
8.根据权利要求1-7中的任一项所述的化合物或其药用盐,其中Ar2选自5元芳基、5元杂芳基、6元芳基或6元杂芳基,
其中每个芳基或杂芳基是未取代的,或者被独立地选自氰基、卤素、C1-C6烷基、C1-C6烷氧基、-C(O)-C1-C6烷氧基和-C(O)-NH2的一个或两个取代基取代。
9.根据权利要求8所述的化合物或其药用盐,其中所述卤素是氟或氯。
12.根据权利要求1-11中的任一项所述的化合物或其药用盐,其中
Z是CHR2R3、COR4或NHR5;
R2和R3各自独立地选自氢、羟基、C1-C6烷氧基、C4-C8杂环基、磷酸酯、NR6R7、-OC(O)R8和S(O)2R10;
R4选自羟基、C1-C6烷氧基和NR6R7;
R5选自氢、C1-C6烷基、-C(O)R9和-S(O)2R10;
R6和R7各自独立地选自氢、C1-C6烷基、C1-C6杂烷基、C4-C8杂环基、C1-C6烷氧基-C1-C6烷基、C5-C8杂芳基-C1-C6烷基、C5-C8杂环基-C1-C6烷基、氨基-C1-C6烷基、羟基-C1-C6烷基、羟基-C3-C8环烷基、氰基-C1-C6烷基、羟基磺酰基-C1-C6烷基、烷基磷酸酯-C1-C6烷基、-COR12和-CHR13C(O)R14;
R8是C5-C8芳基或C5-C8杂芳基;
R9选自C1-C6烷基、C1-C6杂烷基、氨基-C1-C6烷基、羟基-C1-C6烷基或-COR12;
R10是氨基-C1-C6烷基;
R12选自C1-C6烷基、C1-C6杂烷基、C1-C6烷氧基、氨基-C1-C6烷基、C4-C8杂环基、氨基-C4-C8杂环基、磷酸酯-C1-C6烷基和C1-C6烷基磷酸酯;
R13和R14各自独立地选自氢和C1-C6烷基;并且
R15选自羟基、C1-C6烷氧基和氨基。
13.根据权利要求1-12中的任一项所述的化合物或其药用盐,其中Z是-CH2OH、-C(O)OH、NH2、-NHC(O)CH2、-CH2NH2、-CH2NHCH3、-CH2NH(CH2)2OH、-CH2NH(CH2)3OH、-CH2NH(C5H9O)、-CH2NH(CH2)2OCH3、-CH2NHCH2(C4H7O)、-CH2NHCH2CH3、-CH2NHCH2CH(OH)CH3、-CH2NH(C3H5O)或-CH2NHCH2(C3H5O)。
14.根据权利要求1-13中的任一项所述的化合物或其药用盐,其中m是1。
15.根据权利要求1-14中的任一项所述的化合物或其药用盐,其中X是O并且n是0。
16.根据权利要求1-13中的任一项所述的化合物或其药用盐,其中X是NR1。
17.根据权利要求16所述的化合物或其药用盐,其中R1是氢。
18.根据权利要求16或权利要求17所述的化合物或其药用盐,其中m是0。
19.根据权利要求16或权利要求17所述的化合物或其药用盐,其中n是0。
21.一种药物组合物,其包含有效量的至少一种根据权利要求1-20中的任一项所述的化合物或其可药用盐,以及可药用载剂。
22.一种用于在对象中治疗与瞬时受体电位阳离子通道亚家族V成员4(“TRPV4”)受体活性相关的障碍的方法,所述方法包括向所述对象给药有效量的根据权利要求1-20中的任一项所述的化合物或其可药用盐或根据权利要求21所述的药物组合物。
23.根据权利要求22所述的方法,其中所述障碍是高眼压症。
24.根据权利要求22所述的方法,其中所述障碍是动脉粥样硬化、与肠水肿、手术后腹部水肿、局部和全身水肿相关的障碍、体液潴留、脓毒症、高血压、炎症、骨相关功能障碍和充血性心力衰竭、肺部障碍、慢性阻塞性肺部障碍、呼吸机引起的肺损伤、高原引起的肺水肿、急性呼吸窘迫综合征、急性肺损伤、肺纤维化、鼻窦炎/鼻炎、哮喘、膀胱过度活动症、疼痛、运动神经元障碍、遗传性功能获得障碍、心血管疾病、肾功能不全、骨关节炎、克罗恩病、结肠炎、腹泻、肠道不规则(高反应性/低反应性)、大便失禁、肠易激综合征(IBS)、便秘、肠痛和痉挛、乳糜泻、乳糖不耐症或肠胃胀气。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962938693P | 2019-11-21 | 2019-11-21 | |
US62/938,693 | 2019-11-21 | ||
PCT/US2020/061587 WO2021102314A1 (en) | 2019-11-21 | 2020-11-20 | Trpv4 receptor ligands |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115052478A true CN115052478A (zh) | 2022-09-13 |
Family
ID=75980874
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202080080479.8A Pending CN115052478A (zh) | 2019-11-21 | 2020-11-20 | Trpv4受体配体 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20230026696A1 (zh) |
EP (1) | EP4061124A4 (zh) |
JP (1) | JP2023503091A (zh) |
CN (1) | CN115052478A (zh) |
AU (1) | AU2020388645A1 (zh) |
CA (1) | CA3157279A1 (zh) |
WO (1) | WO2021102314A1 (zh) |
ZA (1) | ZA202205110B (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130109668A1 (en) * | 2011-11-01 | 2013-05-02 | Hoffmann-La Roche Inc. | Azetidine compounds, compositions and methods of use |
WO2015046193A1 (ja) * | 2013-09-25 | 2015-04-02 | 塩野義製薬株式会社 | Trpv4阻害活性を有する芳香族複素環式アミン誘導体 |
US20190125728A1 (en) * | 2016-03-31 | 2019-05-02 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003514913A (ja) * | 1999-11-24 | 2003-04-22 | マサチューセッツ インスティテュート オブ テクノロジー | 多糖、天然生成物及びコンビナトリアル・ライブラリの合成に有用な保護基 |
TW201825458A (zh) * | 2016-09-20 | 2018-07-16 | 英商葛蘭素史克智慧財產(第二)有限公司 | Trpv4拮抗劑 |
-
2020
- 2020-11-20 JP JP2022529521A patent/JP2023503091A/ja active Pending
- 2020-11-20 US US17/778,584 patent/US20230026696A1/en active Pending
- 2020-11-20 AU AU2020388645A patent/AU2020388645A1/en active Pending
- 2020-11-20 CA CA3157279A patent/CA3157279A1/en active Pending
- 2020-11-20 WO PCT/US2020/061587 patent/WO2021102314A1/en active Search and Examination
- 2020-11-20 CN CN202080080479.8A patent/CN115052478A/zh active Pending
- 2020-11-20 EP EP20890028.2A patent/EP4061124A4/en active Pending
-
2022
- 2022-05-09 ZA ZA2022/05110A patent/ZA202205110B/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130109668A1 (en) * | 2011-11-01 | 2013-05-02 | Hoffmann-La Roche Inc. | Azetidine compounds, compositions and methods of use |
WO2015046193A1 (ja) * | 2013-09-25 | 2015-04-02 | 塩野義製薬株式会社 | Trpv4阻害活性を有する芳香族複素環式アミン誘導体 |
US20190125728A1 (en) * | 2016-03-31 | 2019-05-02 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
Non-Patent Citations (4)
Title |
---|
GUEROT, CARINE等: "Synthesis of Novel Angular Spirocyclic Azetidines", ORGANIC LETTERS, vol. 13, no. 4, pages 780 * |
JOHANNES A. BURKHARD等: "Synthesis and Structural Analysis of a New Class of Azaspiro[3.3]heptanes as Building Blocks for Medicinal Chemistry", ORGANIC LETTERS, vol. 12, no. 9, pages 1944 - 1947, XP055015554, DOI: 10.1021/ol1003302 * |
SARAH E. SKERRATT等: "Identification of false positives in "HTS hits to lead": The application of Bayesian models in HTS triage to rapidly deliver a series of selective TRPV4 antagonists", MED. CHEM. COMMUN., pages 244 - 251 * |
SIVAPRAKASHAM等: "A straightforward synthesis of 3-substituted azetidinic amino acids", ARKIVOC, vol. 2007, pages 71 - 93, XP055830361, DOI: 10.3998/ark.5550190.0008.a08 * |
Also Published As
Publication number | Publication date |
---|---|
JP2023503091A (ja) | 2023-01-26 |
ZA202205110B (en) | 2023-01-25 |
EP4061124A4 (en) | 2023-12-20 |
WO2021102314A1 (en) | 2021-05-27 |
EP4061124A1 (en) | 2022-09-28 |
AU2020388645A1 (en) | 2022-06-02 |
US20230026696A1 (en) | 2023-01-26 |
CA3157279A1 (en) | 2021-05-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111377917B (zh) | 杂环类化合物、中间体、其制备方法及应用 | |
US10442782B2 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
CN108602809B (zh) | 异噁唑烷衍生的受体相互作用蛋白激酶1(ripk 1)的抑制剂 | |
JP6419990B2 (ja) | ブロモドメイン阻害剤としてのベンゾイミダゾール誘導体 | |
CN102348697B (zh) | 磺酰胺衍生物 | |
CN111491920A (zh) | 毒蕈碱性乙酰胆碱受体m4的拮抗剂 | |
CN107108601A (zh) | 糖苷酶抑制剂 | |
CN105228997A (zh) | Carm1抑制剂及其用途 | |
WO2019174577A1 (zh) | 酞嗪异噁唑烷氧基衍生物、其制备方法、药物组合物和用途 | |
TW202003472A (zh) | 鈣蛋白酶(calpain)調節劑及其醫療用途 | |
CN111788182A (zh) | 毒蕈碱性乙酰胆碱受体m4的拮抗剂 | |
WO2019154294A1 (zh) | 吡唑并[1,5-a][1,3,5]三嗪-2-胺类衍生物、其制备方法及其在医药上的应用 | |
CN110981876B (zh) | 8-取代的苯乙烯基黄嘌呤衍生物及其用途 | |
JP2022521453A (ja) | 複素環式の誘導体 | |
US11827640B2 (en) | Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators | |
CN115557913A (zh) | 苯并氮杂环类化合物及其在药物中的应用 | |
CN111018856B (zh) | 8-取代的苯乙烯基黄嘌呤衍生物及其用途 | |
CN115052478A (zh) | Trpv4受体配体 | |
KR20220101666A (ko) | 질소산화물 공여 pde-5 및/또는 pde-6 억제제 화합물 | |
CN107428682A (zh) | 酰胺类衍生物、其制备方法及其在医药上的用途 | |
JP2020529449A (ja) | 高カリウム血症を処置するためのグリチルレチン酸誘導体 | |
CN110922408B (zh) | 3H-[1,2,3]三唑并[4,5-d]嘧啶-5-胺衍生物及其用途 | |
WO2024099403A1 (zh) | 一种具有软药性质的硫醚类化合物、药物组合物及其用途 | |
TW202333663A (zh) | Rxfp1促效劑 | |
CN113227070A (zh) | Ask1抑制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |